DEVELOPMENT OF CONTINUOUS-FLOW PROCESSES FOR REDOX BIOCATALYSIS AND APPLICATION IN THE CHEMO-ENZYMATIC SYNTHESIS OF ACTIVE PHARMACEUTICAL INGREDIENTS by F. Dall&apos
1 
 
UNIVERSITÀ DEGLI STUDI DI MILANO 
 
Dipartimento di Scienze Farmaceutiche 
DOTTORATO DI RICERCA IN CHIMICA 
XXXI CICLO 
 
 
DEVELOPMENT OF CONTINUOUS-FLOW PROCESSES FOR REDOX BIOCATALYSIS 
AND APPLICATION IN THE CHEMO-ENZYMATIC SYNTHESIS OF ACTIVE 
PHARMACEUTICAL INGREDIENTS 
 
 
         Tesi di Dottorato di: 
         Dott.ssa Federica Dall’Oglio 
         Matr. R11264 
 
Tutor: Prof. Andrea Pinto 
Co-tutors: Dott.ssa Lucia Tamborini 
             Dott. Diego Romano 
 
 
 
Coordinatore del corso di Dottorato: 
Prof.ssa Emanuela Licandro 
 
 
 
Anno Accademico: 2017/2018 
2 
 
  INDEX   
Abstract            4 
 
Introduction           6 
Enabling techniques          7 
Green Chemistry          8 
Biocatalysis           11 
 Biocatalysts immobilization        12 
 Immobilization techniques        13 
 Types of support                    15 
 Whole cells VS purified enzymes       16 
Flow reactor technology         18 
 Principles of Flow Chemistry                             20 
 Flow Chemistry: a process intensification technology    23 
Biocatalysis in Flow Reactors        24 
 Biocatalysis in flow reactors: selected examples                                                   27 
 REDOX reactions                                                                                                              27 
           Oxidations                     28 
           Reductions                    28 
           Biocatalyzed redox reactions: an overview of the biocatalysts employed in the  
           present thesis                                                                                                            29 
 
Aim of the thesis          30 
 
Biocatalyzed regio- and stereo-selective oxidation reaction of a cheap commercially available 
prochiral diols to chiral mono carboxylic acids: application in the continuous flow synthesis of 
Captopril           32 
Introduction           33 
Results and discussion         35 
          First step: biocatalyzed oxidation       36 
           Second step: chlorination reaction        44 
          Third step: amide coupling        46 
           Two sequential steps: second and third steps in continuous    48 
           Fourth step: nucleophilic substitution      49  
3 
 
          Continuous flow-synthesis of Captopril      51 
Conclusions           51 
Material and methods          53 
 
 
Stereoselective reduction of ketones using a pre-mixed bed of ketoreductase and 
glucodehydrogenase          58 
Introduction           59 
Results and discussion         60 
Conclusions           66 
Material and methods          67 
 
Biocatalyzed stereo- and regioselective reduction of 2,2-disubstituted-1,3-cyclopenta- and 1,3-
cyclohexanediones          69 
Introduction           70 
 Steroids synthesis: chemical and biochemical processes    72 
 Hydroxylated steroids        73 
Results and discussion         75 
 Synthesis of 2,2-disubtituted-1,3-cyclopenta- and 1,3 cyclohexanediones  75 
 Biotransformations with recombinant whole cells expressing KRED1-Pglu 78 
 Biotransformations with wild type whole cells of E.coli BL21   83 
 Biotransformations with purified free KRED1-Pglu    86 
Conclusions           90 
Material and methods          91 
 
Transamination reactions with transaminase from Halomonas elongata in a  
flow reactor           98 
Introduction           99 
Results and discussion         101 
Conclusions           109 
Material and methods          110  
  
General conclusions and perspectives       113 
References           114 
4 
 
ABSTRACT 
 
The present thesis has the aim of develop and find new and more environmental friendly synthetic 
routes for the synthesis of active pharmaceutical ingredients (APIs) and pharmaceutically 
interesting intermediates, exploiting the advantages of the combination between flow chemistry and 
biocatalysis. Indeed, biocatalytic processes in continuous flow reactors have attracted attention in 
recent years for carrying out continuous manufacturing systems with high level of intensification. 
Flow processing has the potential to accelerate heterogeneous biotransformations due to biocatalyst 
high local concentration and enhanced mass transfer, making large-scale production more 
economically feasible in significantly smaller equipment with a substantial decrease in reaction 
time, from hours to a few minutes, and improvement in space–time yield, with increases of up to 
650-fold as compared to batch processes. Moreover, biocatalyst stability is enhanced by working in 
an environment where harsh mixing is avoided. Overall, these features result in reduced inventory, 
waste and energy requirements of the flow biocatalytic process, as compared to the conventional 
batch mode. 
In particular, I focused my attention on redox reactions, since for these the traditional chemical 
procedures and reagents are far from being sustainable and environmental friendly. For example, 
for oxidative reactions the most used chemical reactives are Chromium VI (a well known 
cancerogenic agent), Dess-Martin periodinane (a potential explosive reagent) and the Swern 
reagent, a thiol based compound that produces dimethyl sulphide as co-product. Moreover, the 
traditional chemical methods are not able to reach the selectivity and specificity that is possible to 
achieve with biocatalytical systems.  
Briefly, the projects I was involved in during my PhD and that are present in the thesis are:  
1. Development of a new synthetic route to obtain Captopril, using both chemical and 
biocatalyzed reactions and exploiting the advantages of flow chemistry, that allows to 
perform continuous synthesis; 
2. Development of a flow based biocatalyzed oxidation with immobilized whole cells of 
Acetobacter aceti in order to obtain enantiomerically pure mono-carboxylic acids, starting 
from the corresponding diols; 
3. Stereoselective reduction of ketones and di-ketones, in order to obtain enantiomerically pure 
mono-alcohol products, using together two enzymes (ketoreductase from Pichia glucozyma 
and a glucodehydrogenase from Bacillus megaterium) in a Flow Chemistry pcked bed 
reactor; 
4. Stereoselective reduction of 2,2-disubstituted 1,3-cyclopenta- and 1,3 cyclohexanediones 
using both whole cells and a purified ketoreductase from Pichia glucozyma, to obtain 
enantiomerically pure mono-alcohols products, that can be important intermediates in the 
synthesis of various steroids. 
5. Use of an immobilized transaminase from Halomonas elongata able to perform 
transaminations in both directions (from amine to aldehydes, and from aldehydes to amine) 
with the Flow Reactor technology; 
 
To reach the goal, I both used whole cells and purified enzymes as biocatalysts, either in a free or 
immobilized form, and I exploited many advantages of continuous flow technology, as for example 
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downstream processes (i.e., in-line acidifications, extractions and purifications) that allowed me to 
in-line purify the products, thus avoiding the traditional work-up procedures, reducing the 
operational times and the amount of organic solvents used.  
In almost all cases, important results were achieved, as faster kinetics, cleaner procedures that 
required less purification steps, complete stereo- and regioselectivity, higher conversions and 
productivities compared to batch procedures, increased stability of the biocatalyst, that could be 
used for several cycles, thus reducing the waste. 
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INTRODUCTION 
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Enabling techniques 
 
In the next years, the entire world will face environmental, social and economic challenges. The 
demand of new healthy products will increase all over the world. Indeed, poor countries will need 
more and more drugs to win mortal diseases, the entire population will increase and the 
sustainability of our resources will be under danger. Consequently, many efforts are currently 
directed to the development of innovative, solid and, in view of an industrial application, easily 
scalable routes to produce commodities, high-value chemicals and active pharmaceutical 
ingredients (APIs), in a safer, more economic and more sustainable way. For these reasons, 
synthetic chemists are asked to find different and innovative solutions that can be positive answers 
to these problems. In particular, pharmaceutical chemists are trying to find different synthetic ways 
that can be interesting for the industries, easily scalable and environmentally friendly to produce 
and deliver active pharmaceutical ingredients in a faster way
1
. In this context, an answer to these 
problems has been the introduction of enabling techniques to speed up reactions and to simplify 
work-up and purification procedures. Enabling techniques include various traditional but also new 
techniques, as: 
 Catalysis – is a technique, not always considered an enabling one, which modifies the rate of 
a reaction, usually accelerating it, by the addition of a substance not consumed during the 
reaction itself. Since the catalyst is not consumed, each catalyst induces the transformation 
of many molecules of reactant. There are several types of catalysis, such as biocatalysis (that 
is already an established field in terms of industrial applications and I will particularly focus 
on it later), organocatalysis, in both cases also in the form of solid supported catalysis. 
Solid-supported biocatalysts can be used for asymmetric and stereoselective transformations 
and the product can be easily separated from the catalyst by simple filtration.  
 Solid phase assisted synthesis – is commonly used for automated peptide synthesis and 
greatly simplifies purification procedures. An alternative is the solid-phase assisted solution-
phase synthesis using immobilized reagents or catalysts that allow, in addition to the simple 
purification, to drive the solution-phase reactions to completion thanks to the use of 
immobilized reagents in excess.  
 New solvent systems – for example ionic liquids, have been created to separate the reagent 
from the catalyst, so that the reagent stays in a solvent, and the catalyst in another one. This 
can allow multiphase reactions, with the possibility to easily isolate and recover the used 
catalysts. There are also indications that switching from a normal organic solvent to an ionic 
liquid can lead to novel and unusual chemical reactivity.  
 Microwave assisted organic synthesis – generally, provides a considerable increase of the 
reaction rates, promoted by focused heating, associated with higher yields and purities.  
 New reactor systems such as flow reactor technology (which will be deeply discussed later). 
It is possible to combine two or more enabling techniques to get advantages by both. Anyway, each 
reaction has its best combination, which must be determined and optimized
2
 (Figure 1).  
8 
 
 
Figure 1. Enabling techniques and some proposed combinations (adapted from ref. 2) 
 
Green chemistry  
 
Chemistry has a great impact on earth and human’s health. Chemists should keep in mind that row 
materials are not unlimited: more than 98% of the organic chemicals currently used are derived 
from petroleum. In addition, it was estimated that between 25 to 100 kg of waste result from every 
kilogram of pharmaceutical synthesized.
3
 It is not possible for the chemical industry to ignore the 
devastating impact on the environment that is caused by the traditional organic synthesis. In this 
context, in the recent years, the concept of “green chemistry” has been introduced. Green chemistry 
consists in the design of chemical products and processes that reduce or eliminate the generation of 
hazardous and polluting substances. The introduction of this revolutionary and diverse discipline 
will lead to significant environmental benefits, innovation and a strengthened economy
3
. Developed 
by Paul Anastas and John Warner
4
, the following list (Figure 2) outlines an early conception of 
what would make a greener chemical, process, or product 
 
Figure 2. The twelve principles of green chemistry. 
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In the last fifteen years the concept of green chemistry has been widely embraced in both industrial 
and academic circles. The essence of the green chemistry concept can be summarized in this 
sentence: “Green chemistry efficiently utilises (preferably renewable) raw materials, eliminates 
waste and avoids the use of toxic and/or hazardous reagents and solvents in the manufacture and 
application of chemical products”.5 It is important to underline that there is no absolute greenness, 
one process is greener than another process, but appropriate green metrics are a prerequisite for a 
meaningful comparison of greenness. The most widely accepted measures of the environmental 
impact of chemical processes are the two most simple metrics: the E factor, defined as the mass 
ratio of waste to desired product
5
, and the atom economy, defined as the molecular weight of the 
desired product divided by the sum of the molecular weights of all substances produced in the 
stoichiometric equation, expressed as a percentage.
5
 So, a knowledge of the stoichiometric equation 
allows one to predict, without performing any experiments, the theoretical amount of waste that can 
be expected. Atom economy (AE), introduced by Trost in 1991 has become the widely accepted 
terminology and it is a theoretical number that is based on a chemical yield of 100% of theoretical 
and assumes that reactants are used in exactly stoichiometric amounts. It disregards substances, 
such as solvent and acids or bases used in work-up, which do not appear in the stoichiometric 
equation. The E factor, in contrast, is the actual amount of waste produced in the process, defined as 
everything but the desired product. It takes the chemical yield into account and includes all 
reagents, solvents losses, all process aids and, in principle, even the energy required as this 
generates waste in the form of carbon dioxide. A higher E factor means more waste and, 
consequently, greater negative environmental impact. The ideal E factor is zero. It can be easily 
calculated from a knowledge of the number of tons of raw materials purchased and the number of 
tons of product sold, for a particular product or a production site or even a whole company (Figure 
3). 
5
 
         
          
       
 
 
Figure 3. Equation of E-factor: it is the ratio of the mass of waste per mass of product.
5
 
 
It is clear that the E factor increases substantially on-going downstream from bulk chemicals to fine 
chemicals and pharmaceuticals. In fact, firstly there is a more widespread use of stoichiometric 
reagents in these industry segments, and secondly it is a consequence of the fact that the target 
pharmaceuticals, for example, are more complicated molecules compared to bulk chemicals and, 
hence, their production involves multi-step syntheses which can be expected to generate more 
waste. 
Until this point, only the amount of the waste has been taken into account. However, the 
environmental impact of waste is not only determined by its amount but also by its nature. In order 
to consider this issue, the term environmental quotient, EQ, was introduced by Sheldon et al, and it 
is obtained by multiplying the E factor with an arbitrarily assigned value, Q, called environmental 
hazardous quotient.
5
 For example, one could arbitrarily assign a Q value of 1 to NaCl and, say, 
100–1000 to a heavy metal salt, such as chromium, depending on its toxicity, ease of recycling, etc. 
The magnitude of Q is obviously debatable and difficult to quantify but, importantly, ‘quantitative 
assessment’ of the environmental impact of chemical processes is, in principle, possible. Also, the 
Q value of a particular waste should take into account the ease of disposal or recycling a certain 
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waste. Ironically, the waste generated in the manufacture of organic compounds consists primarily 
of inorganic salts. This is a direct consequence of the use of stoichiometric inorganic reagents in 
organic synthesis, particularly in fine chemicals and pharmaceuticals manufacture.
5 
 
Another major source of waste is solvent losses, which end up in the atmosphere or in ground 
water. Indeed, solvent losses are a major contributor to the high E factors of pharmaceutical 
manufacturing processes. Furthermore, health and/or safety issues associated with many traditional 
organic solvents have led to their use being severely curtailed. Solvents are divided into four 
classes
5
: 
- Class 1: solvents should not be used in the manufacture of drug substances because of their 
unacceptable toxicity or deleterious environmental effects. They include benzene and 
various chlorinated hydrocarbons. 
- Class 2: solvents should be used only sparingly in pharmaceutical processes because of 
inherent toxicity and include acetonitrile, dimethyl formamide, methanol and 
dichloromethane. 
- Class 3: solvents may be regarded as less toxic and of lower risk to human health. They 
include many lower alcohols, esters, ethers and ketones. 
- Class 4: solvents, for which no adequate data are available, include di-isopropyl ether, 
methyl tetrahydrofuran and isooctane. 
Many pharmaceutical companies are focusing their attention on minimizing solvent use and on 
replacing many traditional organic solvents, such as chlorinated and aromatic hydrocarbons, by 
more environmentally friendly alternatives such as lower alcohols, esters and some ethers such as 
methyl tert butyl ether (MTBE).
5
 Pfizer scientists, for example, have produced a solvent selection 
guide for medicinal chemists, dividing solvents into three categories: undesirable (red), usable 
(yellow) and preferred (green) as shown in Fig. 4.
6
 
 
 
 
Figure 4. List of undesirable, usable and preferred solvents made by Pfizer scientists (adapted from 
reference 6).  
 
Since the major sources of waste in chemicals manufacture are clearly stoichiometric reagents and 
solvent losses, the solution to the waste problem is evident: catalytic reactions in alternative 
11 
 
reaction media. With regard to the latter, the best solvent is no solvent but if a solvent is needed it 
should be safe to use and there should be provisions for its efficient separation from the product and 
reuse. The use of water and supercritical carbon dioxide as reaction media fits well with the current 
trend towards the use of renewable, biomass-based raw materials, which are ultimately derived 
from carbon dioxide and water. 
 
Biocatalysis 
 
One of the principles of Green Chemistry involves reaction catalysis, and this is also one of the 
enabling techniques mentioned above (Figure 5). 
 
Figure 5: Differences between biocatalytic and chemical process (adapted from reference 7a). 
 
In a biocatalytic process occurs a biotransformation, i.e., a chemical reaction, catalyzed by 
biological catalysts, mostly enzymes. Biocatalysts can be used as isolated proteins, crude cell 
extract or as whole cell, free or immobilized on a solid support. The substrates could be different 
molecules, often synthetic but also natural compounds. 
A general scheme for the enzymatic mechanism of catalysis is showed in Figure 6: 
 
Figure 6: Enzymatic mechanism of catalysis and effect on Activation energy during reaction 
process. 
 
Biocatalysis posseses some unique features:
7b,8
  
• Selectivity 
o Chemo-specificity: it means that an enzyme acts on a single type of functional group, 
whereas other sensitive functionalities, which would normally react to a certain extent 
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under chemical catalysis, survive. As a result, biocatalytic reactions tend to be cleaner 
and laborious purifications of product(s) from impurities emerging through side-
reactions are not required anymore; 
o Regio-specificity: considering their complex three-dimensional structure, enzymes can 
distinguish between functional groups which are situated in different regions of the 
substrate; 
o Stereo-specificity: since almost all enzymes are made from L-aminoacids, enzymes are 
chiral catalysts. Consequently, any type of chirality present in the substrate molecule is 
recognized upon the formation of the enzyme-substrate complex. Thus, the two 
enantiomers of a racemic substrate may react at different rates (kinetic resolution); 
moreover, a prochiral substrate can be transformed into an optically active product due 
to a stereospecific interaction with the reaction intermediate; 
• Mild reaction conditions; 
• High reaction rates, enzymes can be very efficient. 
 
Other advantages of biocatalyzed reactions involve less production costs and less process passages, 
with consequent less waste of time, solvents and substrates. In addition, biotransformations 
represent a more sustainable alternative to chemical synthesis, with less use of toxic reagents and 
metals. With enzymes, chemistry becomes greener, with less impact on the environment, also 
because they can be easily re-used. 
Even if biocatalysis has gained importance in the latter half of the 20
th 
century, enzymes as catalysts 
however suffer from some limitations:  
• Many enzymes are not accessible in enough large quantities for practical applications  
• Enzyme stability is affected by several factors such as temperature, pH, surfactants, etc. 
• Some enzymes show a narrow substrate scope. 
 
The recombinant DNA technology has solved some problems and the number of enzyme is now 
virtually infinite thanks to techniques as high throughput microbial screening, genomic and 
metagenomic screening.
9
 The enzyme stability, on the other hand, has been improved with different 
approaches: selecting new stable enzymes from peculiar natural habitats, using protein engineering 
or immobilization. This technique limits heat and mass transfer and minimizes access of 
destabilizing agents to the enzyme. Moreover, immobilization onto a surface introduces additional 
interactions that stabilize the tertiary structure of the enzyme. In batch operations, immobilized 
enzymes could be recovered and reused.
10 
 
Biocatalysts immobilization  
 
In the first Enzyme Engineering Conference that was held at Henniker, NH, USA, in 1971, it was 
defined that immobilized biocatalysts, enzymes, or cells, are physically fixed in a defined region in 
order to catalyze a specific reaction. The desiderable aim of immobilization should be the lower loss 
of catalytic activity of the immobilized biocatalyst, and so the possibility to re-use it several times. 
To face up the necessity of increasing productivity, reducing time and the total cost of the whole 
process at once, immobilization became one of the most promising technique. The recovery of the 
biocatalysts during downstream processes and the improvement of the operational stabilities are the 
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greatest problems working with biocatalysts. Immobilization allows to overcome most of the 
process limitations (Figure 7) as: 
• recovery of biocatalysts for reuse 
• stability, activity and selectivity 
• resistance against inhibition 
• separation and purification steps. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Advantages and disadvantages of biocatalysts immobilization (adapted from reference 
11) 
 
Immobilized biocatalysts are employed in various industries such as food processing, biomedical 
production, wastewater treatment, textile, detergent industry, and even biodiesel production. 
The immobilization consists in confining a biocatalyst, cell or isolated enzyme, on the surface or 
within a solid or semi-solid support to preserve its activity but also to prevent its mobility. It is 
essential for an immobilized enzyme that two functions are comprised: 
1. The non-catalytic functions, which provide an easier separation and a consequent re-use of 
the catalyst;  
2. The catalytic functions, which are fundamental to convert the substrates into the product.  
However, immobilization of an enzyme can modify its chemical and physical properties.
11
  
 
Immobilization techniques 
 
The interaction between the enzyme and the support could be by a strong chemical bond, but 
generally, the linkages are not covalent. In Figure 8, some methods of immobilization are shown. 
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Figure 8: Immobilization techniques (adapted from reference 12a) 
 
1 Physical adsorption: it is a simple method of immobilization. The enzyme is adsorbed on the 
external surface of the support. This type of immobilization requires no permanent bonds, but only 
weak bonds such as ionic interactions, hydrogen bonds, Van der Waals forces. Its main advantage is 
the minimal distortion to the protein that can avoid enzyme denaturation. However, its efficiency 
and its lifetime are low compared to the covalent technique. Some of the materials used for the 
adsorption immobilization are, for example, coconut fibers, cellulose, kaolin and micro and 
mesoporous materials;
12b
 
2 Encapsulation: in this method, the enzyme is put into a capsule. The capsule has a semi-
permeable membrane. In this case, the enzyme activity depends on its stability inside the capsule. 
This is a cheap method, however, the main limitation is the difficulty for the substrate to overcome 
membrane. 
3 Entrapment: it consists of trapping the biocatalyst into a caged network with covalent and 
no-covalent interactions with the immobilization support. The supports that can be used for this 
technique can be, for example, alginate–gelatin hybrids, nano-materials such as nanowires, 
chitosan, mesoporous silica, calix[n]arene polymers, and k-carrageenan.
12b
 It is a fast method of 
immobilization, but it has pore diffusion limitation. 
4 Crosslinking method: it is also called copolymerization. Enzymes are directly linked by 
covalent bond, there is not support or matrix in this method. This method is simple and cheap, but 
there is the risk that enzymes can lose their activity because of covalent bond between them. 
5 Covalent binding: it involves the formation of covalent bonds between a surface-exposed 
reactive group of the enzyme or cell and a reactive group of the support or carrier. Generally, 
surface-exposed functional groups include guanidines, carboxylic acids, imidazoles, indoles, 
phenols, hydroxyl groups, and thiols. Immobilization surfaces used for covalent immobilization 
include peptide-modified surfaces for high specific activity and controlled protein orientation, 
cyanogens bromine-infused agarose and sepharose, glutaraldehyde-modified glass surfaces, silica, 
chitosan, epoxides, and nanowires amongst others. This technique is able to improve catalyst 
lifetime due to decreased leaching.  
In Table 1 are summarized the advantages and disadvantages of each technique. 
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Table 1: Advantages and disadvantages of most commonly known immobilization techniques 
(adapted from reference 11). 
 
Type of supports 
 
The choice of the most suitable support material is a very important issue. The ideal support 
material should have the following properties: large surface area, sufficient functional groups for 
attachment, hydrophilic character, water insolubility, chemical and thermal stability, mechanical 
strength, high rigidity, resistance to microbial degradation, and ease of regeneration. Ideally, resins 
will also be non-toxic, and have a low price.
12b
 In reality, many immobilization supports have 
several of these qualities, but not all. There are a lot of support material, each one made of a 
compound that must or has been approved for food and pharmaceutical applications and, depending 
on the circumstance, the best one is chosen. Some of them are: 
• Collagen: is the main protein of the connective tissues of the animal bodies. In fact, tendon, 
skin, bone and cartilage are generous sources for its isolation and, therefore, collagen is naturally 
available. This polymer is largely used because of its biocompatibility and ability to attach cells. 
The main issue is the expensive purification process.  
• Alginate: is a polysaccharide which contains L-glucuronic acid and D-mannuronic acid. It is 
soluble in water as a sodium salt, and it becomes a gel in presence of bi- or tri-valent cations, like 
calcium. The size of the internal pore depends on the proportions of the two acids.
13
  
• K-Carrageenan: sometimes this polysaccharide is used as an alternative to alginate, thanks to 
its stronger resistance to chelating agents. The rigidity of the carrageenan is related to high 
potassium concentration. 
16 
 
• Chitosan: is a polysaccharide obtained by deacetylation of chitin, a structural component 
found in crustacean, shells, fungi, insects, and mollusks. Chitosan can form hydrogels by ionic or 
chemical crosslinking with glutaraldehyde and can be hydrolyzed enzymatically. Conversely, 
chitosan has weak mechanical properties compared to other support materials.
11
  
• Agar and Agarose: agar is extracted from the cell walls of some red seaweeds, belonging to 
Rhodophyceae class, widespread all along the world (including Japan, Korea, Spain, Portugal, some 
African countries, Mexico, Chile, and India). Agar is formed by two components: agaropectine and 
agarose. Agarose-based beads are highly porous, mechanically resistant, chemically and physically 
inert, and sharply hydrophilic (Figure 9).
14
 Agarose gel contains pentagonal pores with proportional 
size to allow diffusional access of many proteins. On the other hand, agarose gel does not have a 
strong mechanical structure.
11
 
 
 
Figure 9: Agarose as support material. 
 
Whole cells versus isolated enzymes 
 
Whole-cell biocatalysis employs recombinant or native enzymes produced by cellular metabolism 
to perform interesting reactions. Generally, it is necessary to consider the type of reaction, the 
cofactor recycling and the biotransformation scale to decide what to employ as catalysts, if whole 
cells or purified enzymes. In fact, using isolated enzymes allows to obtain high specific activity and 
high selectivity, but it is necessary to supply specific cofactors (especially in redox reactions), it is 
expensive and there could be problems in the recovery of the biocatalyst. On the other hand, whole 
cells are less expensive, easily recoverable and own cofactors and systems for their regeneration. 
However, they could show competing enzymatic activities, low specific activity and require 
facilities for fermentations. 
Table 2 and 3 summarize some advantages and disadvantages of these two different approaches. 
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Table 2: Advantages and disadvantages of isolated enzymes. 
 
WHOLE CELLS 
FORM ADVANTAGES DISADVANTAGES 
Growing cultures or resting 
cells 
• No cofactor recycling 
necessary 
• High activity 
• Simple workup 
• Fewer by-products 
• Expensive equipment 
• Tedious workup 
• Low productivity 
• Low substrate concentration 
tolerance 
• Low organic solvents 
tolerance 
• Uncontrolled side reactions 
Immobilized cells 
• Possible cell re-use 
• Use in continuous flow 
reactors 
• Loss of activity during 
immobilization 
Table 3: Advantages and disadvantages of whole cells. 
 
 
 
 
 
 
ISOLATED ENZYMES 
FORM  ADVANTAGES DISADVANTAGES 
Dissolved in water • Simple apparatus 
• Simple work-up 
• Better productivity 
• High substrate 
concentration tolerance 
• High catalytic activity 
• Cofactor recycling 
necessary 
• Side reaction possible 
• Lipophilic substrates 
insoluble 
• Workup requires 
extraction 
 
Suspended in organic 
solvents 
• Easy to perform 
• Simple workup 
• Lipophilic substrates 
soluble 
• Easy enzyme recovery 
• Reduced catalytic activity 
Immobilized • Easy enzyme recovery 
• Enzymatic recycling  
• Possibility to use 
continuous flow reactors 
• Loss of activity during 
immobilization 
18 
 
Flow reactor technology 
 
One of the enabling techniques introduced in the recent years is flow chemistry. This technology 
has been developed in order to overcome some problems related to the traditional batch synthesis 
and to provide a more sustainable and environmental friendly chemistry. A flow chemistry reactor 
is composed by two or more pumps that move fluids into small channels and where the channels 
join each other, the fluids meet each other. If these fluids are reactive, a reaction takes place in a 
reactor, which can be of different types, for example a glass column packed with immobilized 
reagents (catalysts and biocatalysts) for heterogenous reactions solid/liquid or a coil for 
homogenous reactions liquid/liquid (Figure 10). 
 
 
Figure 10. Different types of reactors. 
 
After the reactor, the product can be collected and directly analyzed, if systems like UV or infrared 
detectors are linked to the flow device. This would provide a rapid optimization of the reaction 
parameters (e.g., stoichiometry, concentration, residence time and temperature). The product can be 
also directly purified-in line with solid resins or scavengers, avoiding in this way traditional work-
up or purification procedures (Scheme 1).
15
 
 
 
 
Scheme 1. Schematic representation of a flow reactor configuration. 
 
As shown in the scheme above, in some reactors is possible to have two injection loops after the 
pumps, that can be used to bypass the pumps if corrosive reagents are used.  
Flow reactors have been classified depending on reactor dimensions in micro-, meso- and macro 
reactors. Microchannels have diameters between 10 and 1000 µg and can produce until hundred 
19 
 
milligrams of product. They are divided into microfluidic (i.d: 10-500 µm) and minifluidic reactors 
(i.d: 500 µm-several mm). They both have advantages and disadvantages depending on their 
dimensions (Table 1). Meso reactors have channels with diameters from 1 to 100 mm and they can 
produce from few grams to ten grams of product. Macro or large scale reactors can produce more 
than 100 mega tones each year. They are used in industrial plants, while micro and meso ones are 
commonly used in research laboratories. Channels are generally made of polymers (e.g., PFE, 
PTFE), glass, stainless steel or silicon (Figure 11).
1,16a 
 
 
 
Figure 11: Flow reactors for homogeneous liquid synthesis (adapted from reference 16b). 
 
A scientific debate is currently open on which, between micro or mini reactors, are better (Table 4). 
As it is possible to note in table 3, the major advantage of microfluidic reactors is the high heat 
transfer, due to the high ratio surface/volume. On the other hand, this peculiarity could create high 
pressure drops that could limit flow capacity and block the whole system.
16a
 
 
 Advantages Disadvantages 
Microfluidic 
reactor (10-
500 μm i.d) 
• high heat transfer surface to product 
volume ratios; 
• good heat transfer capabilities ideally 
suited for optimizing reactions 
conditions; 
• efficient mixing. 
• micro channels suffer 
from restricted flow 
capacity; 
• high pressure drop; 
• tendency to block. 
Minifluidic 
reactor (500 
μm - several 
mm i.d) 
• improved flow capacity; 
• lower pressure drop; 
• no blocking of channels; 
• preparation of multigram to 
multikilogram quantities; 
• possibility to work with packed bed 
reactors. 
• lower heat transfer 
surface; 
• poorer heat transfer 
capabilities. 
 
Table 4. Advantages and disadvantages of microfluidic and minifluidic reactors. 
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Flow chemistry has demonstrated to be perfectly in line with the principles of green chemistry, 
because it results in high yields, increased safety, possibility for automation, less usage of solvent, 
re-use of supported reagents or catalyst (which is connected with less waste), more efficient 
reactions.
7
 Also, flow reactor technology allows another way to achieve atom economy, i.e., 
reaction telescoping. It means that one-pot synthesis is conducted in a continuous reactor, in which 
reagents are added one at a time and work up is not necessary.
3
 
 
Principles of Flow Chemistry 
 
As mentioned above, organic chemistry is a changing world: nowadays, chemists need more time to 
design and discover new drugs and, consequently, they have less time to apply standard procedures 
and recipes. For these reasons, a common think now is that a machine-assisted approach can help 
chemists in their researches. It is possible to state that traditional chemistry follows the concept of 
“quick and dirty chemistry”, for which HPLC systems have been invented. The main goal of flow 
reactor technology is to achieve a clearer and faster chemistry, allowing a dramatic reduction of 
waste.
17,18
 
In a batch reaction, stoichiometry is determined by the concentration of reagents and their 
volumetric ratio, whereas in flow it is dependent on concentration of reagents and/or the ratio of 
their flow rates. Flow rate and reactor volume determine the residence time, which is the time 
during whom the reagents stay in contact in the reactor. Reaction time corresponds or is lower than 
the residence time.  
Other parameters that must be considered are temperature and pressure. Heat transfer in flow 
systems is better than in batch: in fact, the small dimensions of the channels determine a high 
contact surface for heat exchange. The result is that reagents are homogeneously heated and the 
temperature can be precisely controlled. This is a very important issue because a non-homogeneous 
heating, as in batch systems, can cause reagent and product degradation or the formation of 
secondary products. A consequence is obviously the need of performing extensive purifications 
(e.g., aqueous work-ups, column chromatography, crystallizations) by which ensue increased costs 
in terms of time, manpower and environment impact (resources, also manufacturing ones). The 
reagent degradation could be also due to their high reactivity that leads to degradation. Also, the 
high surface/volume ratio allows to perform exothermic reactions, that are very hazardous in batch, 
in a safer and more controlled way. The increased safety is an important advance of flow chemistry 
that can have an important impact in industry. The safer conditions depend on the fact that the used 
volumes are smaller than batch ones, and this allows to have a better control on reactions and to use 
hazardous reagents and solvents. Some examples are the fluorination reaction using DAST and the 
nitration reaction. This peculiarity can be also exploited for photochemical reactions, in which it is 
important to well control the energy. These reactions are currently receiving increased attention
16
. 
In flow reactors, there is not only a better heat transfer, but also a better mass transfer, that can 
result in a better mixing (if compared with batch), short reaction times, and improved safety
19
. In 
fact, in batch, mass transfer is made by convection, which results in chaotic and turbulence mixing. 
Only a minimal portion of materials is indeed efficiently mixed. These idle portions lead to poor 
heat-transfer, concentrate reagents, and to the formation of “heat spots”; so, in this way, reactions 
are often inefficient. In flow, microchannels have a volume/surface ratio of about 30.000 m
2
/m
3
. 
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This peculiarity and the continuous flow allow complete and homogeneous mixing, that is achieved 
in milliseconds, usually in T o Y piece mixer (Figure 12).
3 
 
 
Figure 12: Types of mixing in flow reactors (adapted from reference 3) 
 
As mentioned above, reaction parameters, such as stoichiometry, residence time, pressure and 
temperature, can be easily changed and optimized. The optimization can be quick and precise, and 
allows flow reactor technology to be used for high-throughput screening, and, so, for preparing 
libraries of candidates. This is also due to the small volumes of reagent and solvent that are used 
which can result in time and cost reductions. The easier in-line monitoring of the reactions allows 
more control and
19
 safer conditions, also for handling hazardous reagents
3
. This is a very important 
issue because, at present, a lot of time is spent for optimization and manipulation of reactions, and 
too much energies and economic resources are involved in these activities. Figure 13 sums up 
briefly the advantages of using continuous flow reactors
20
.  
 
 
Figure 13: How the characteristics of a continuous flow reactor can affect the process parameters 
 
Another important issue concerns multistep reactions. This type of reactions is an interesting 
strategy to reduce solvent waste, especially if it is possible to re-use it. In batch, every intermediate 
of each step has to be isolated and purified to perform the following synthetic step. In a flow 
reactor, this is not necessary, if the chemist is able to build a continuous system where an 
intermediate is the reagent of the next reaction. It is also possible to converge two different 
synthetic flows into one flow device, which allows to produce products with complex structure
16
. 
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The biggest problem in multistep reactions is the necessity of switching the solvent. In fact, in flow 
reactors, it is fundamental that the reagents and products are in solution; otherwise, there could be 
the formation of a precipitate with a blockage and a consequent increment of pressure. For this 
reason, it is necessary that each step is conducted with the appropriate solvent. Therefore, the 
solvent should be the same in all the synthetic steps, in order to make a continuous process, or it has 
to be available a mechanism to switch solvents in continuous
18
. To overcome this issue, a prototype 
in-line evaporation system (Figure 14) has been developed by Ley’s group at the University of 
Cambridge. It was constructed using a glass column and Swagelok fittings, common equipment in 
flow chemistry laboratories; the device acts as a spray drier for an incoming liquid stream. A fine 
dispersion of solution is nebulized by a gas, usually N2, at high temperature. In this way, the solvent 
is partially evaporated and the solution is concentrated. The exhausted gas passes through a 
condenser to recover and recycle solvent. Using this prototype, it was possible to switch solvent in 
continuous, by taking advantage of the differences in their volatilities
17
. 
 
 
Figure 14. In-line evaporation system. 
 
Flow can be also combined with immobilized reagents or catalysts. As opposed to what happens in 
batch conditions, in flow, supported reagents or catalysts can permanently remain in the reactor and 
can be easily recovered and re-use. Reaction and filtrations are simultaneous. As mentioned above, 
catalysis offers many advantages, such as selectivity and, in the case of immobilized catalysts, the 
possibility to well separate products from reagents, in order to make the work up easier. The choice 
of the support is decisive in determining the reaction set-up and in dictating the recovery and the 
recycle techniques. In addition, in a flow reactor, the immobilized reagent or catalyst is packed into 
a glass column (Figure 15 and 16) and, therefore, there is not mechanical stirring or agitation. 
Consequently, supported materials do not degrade, and this can extend the material lifetimes
19
. 
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Figure 15: Glass columns for continuous flow. 
 
 
Figure 16: 1. A starting material; B product; C immobilized reagent. 2. The picture shows the case 
of an immobilized catalyst (adapted from reference 18). 
 
Today, also continuous purification systems have been developed, and they can be linked in-line in 
continuous flow systems, to reduce times and chemist manual work (for examples, HPLC, 
electrophoresis, etc). 
 
Flow chemistry: a process intensification technology 
 
Flow chemistry is the result of a combination between process intensification and process 
optimization, and, so, it is fundamental to have chemical and engineering knowledge (Figure 17)
18
. 
It also requires an adjustment in how the chemists plan and conduct the chemical development. In 
general, process intensification has four main goals: i) to maximize the effectiveness of intra- and 
inter-molecular events, ii) to provide the same processing experience for each molecule, iii) to 
optimize the driving forces and maximize specific interfacial areas, and iv) to maximize the 
synergistic effects of partial processes. So, it aims at reducing waste, energy consumption, costs, 
time and material usage. The main goal is to “produce much more with much less”. 
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Figure 17. Process intensification and process optimization in flow chemistry. 
 
In flow, it is possible to work on three parameters to increase the production: more channels or 
more devices that work in parallel, longer operational times and higher flow rates
21
. It is easy to 
understand that also scale up in flow is simplified. In fact, optimized reaction parameters on a small 
scale can be used unchanged also in a larger scale
16
. Clearly, flow chemistry has much to offer to 
pharmaceutical industry, for the easy scale up, easy optimization and process intensification. Most 
of all, a peculiarity is the ability of producing large quantities of product in a short time, and this is 
possible when the synthetic pathway is clean, simple, efficient, safe, reliable and reproducible. 
There is a continuous balance between speed and optimization, and flow reactor technology has all 
the qualities to be inserted in these transitions. All the industrial departments can benefit from flow 
chemistry. 
 
Biocatalysis in flow reactors 
 
In response to the challenges of the pharmaceutical industry and medicinal chemistry, biocatalytic 
flow reactors have been increasingly developed. The use of biocatalysts (both whole cells and 
isolated enzymes) in flow reactors allows to further improve the productivity of the process, without 
forgetting the green aspect of the synthetic chemistry. Flow processing has the potential to 
accelerate biotransformations due to enhanced mass transfer, making large-scale production more 
economically feasible in significantly smaller equipment with a substantial decrease in reaction time 
(from hours to few minutes), and improvement in space-time yield.
10
 As mentioned above, flow 
reactors could be of different dimensions, materials and shapes and they could be used for 
heterogeneous or homogeneous reactions. The whole system can be coupled to in-line monitoring 
systems in addition to mixing and heating devices. In-line monitoring is desirable to quickly react to 
fluctuations of the key parameters together with tracking the reaction’s progress.  
Another important issue of flow processes concerns their application on a large scale. For batch 
reactions, the scale has implications on the mass and heat transfer within the system, so the process 
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conditions must often be reoptimized. Although scaling up microreactors for produc-ing compounds 
at least at the gram scale seems simple on paper, the cost of individual microchip type reactors and 
the challenge of pumping liquid throughout the microreactors limit this approach. Larger 
mesoreactors can overcome these limitations, ultimately allowing for throughputs from g/h to 
tons/year. They may consist of scaled-up versions of the planar chip-type microreactor, single 
tubular reactors or parallel capillary reactors. The amount of product generated is determined by the 
duration over which the entire flow regime is operated, once flow rates and reactor volumes are 
defined.
10 
 
All these features combined with biocatalysts are shown in Scheme 2. Among biocatalytic flow 
reactors the mesoreactors and minireactors are mostly used. Two types of microfluidic chemical 
reactors were reported to date, the first one is chamber type and the second one is the continuous 
flow type. The micro chamber type has the static reagent in the micro chamber and the continuous 
flow type has the continuous flow of reagent through the overall microchannel
22
. The micro 
chamber type can be problematic when is necessary to increase the production up to gram scale. In 
fact, even if is a modular system, this device has a great impact on the cost of the process.  
 
Scheme 2: Schematic representations of main components of biocatalytic flow reactors: A pumps; 
B reaction loops; C T-piece; D coil reactor; E column reactor; F back pressure regulator; G 
downstream unit; H syringe pumps; I microfluidic reactor (adapted from reference 10). 
 
Both cell-free enzymes and whole cells could be used ad biocatalysts. Immobilized enzyme reactors 
and free enzyme reactors are the most common because cell-free systems offer advantages versus 
the whole cell approach, such as
10
:  
 Generally faster flow 
 Less barriers between the substrate and the catalyst 
 No need to maintain the cell wall integrity 
 Less side reactions. 
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Figure 18 shows different configurations of biocatalytic flow reactors, both for free and 
immobilized enzymes.  
 
Figure 18: 1 Free biocatalyst; 2 immobilized biocatalyst in a packed bed reactor; 3 biocatalyst 
immobilized on the inner surface of the channel; 4 biocatalyst immobilized on a monolith; 5 
biocatalyst immobilized on a membrane; 6/7 free biocatalyst/immobilized biocatalyst in a l/l 
biphasic parallel flow stream; 8 immobilized biocatalyst in a g/l biphasic flow stream; 9 free 
biocatalyst in a tube-in-tube reactor
 
(adapted from reference 10). 
 
However, the stability of th biocatalyst can be a challenge in flow chemistry, which has to be 
studied very deeply. Enzyme stability is typically affected by several factors, such as temperature, 
pH, surfactants, etc., which can disrupt the catalyst structural interactions. Immobilization is often 
used to enhance enzyme stability: it limits heat and mass transfer, minimizing access of 
destabilizing agents to the enzyme; moreover, immobilization onto a surface introduces additional 
interactions that stabilize the tertiary structure of the enzyme; and loss of quaternary structure can 
be minimized by crosslinking unbound subunits to those already bound to the support. This is not, 
unfortunately, true for all the examples: in some cases, immobilization can be a problem, for both 
activity and stability, if not correct domains are touched. Indeed, in these cases, a deep study must 
be done concerning the best immolization technique to be used. Also, in flow a particular attention 
must be paied for the flowstream that passes through the column with the immobilized reagents: 
indeed, if the stability is not great, the biocatalyst can be flowed away from the support, and 
therefore a release in the exiting flowstream will be observed, concerning the nature of the solvent 
used.
10
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Biocatalysis in flow reactors: selected examples 
 
The following list shall include some examples from the recent literature of biocatalysis in flow 
reactors: 
 
1 Hydrolases: catalyze the hydrolysis of many functional groups as esters, amides, glycosides, 
nitriles and epoxydes. Hydrolyses do not require organic coenzyme. There are many examples in 
literature, mainly lipase, such as the dynamic kinetic resolution of a protected amino acid derivative 
(N-Boc-phenylalanine thioethyl estert) in continuous flow mediated by an alcalase.
10
 
  
2 Transferases: catalyze the transfer of a functional group from a molecule to another. In this 
group are included transaminases, which are really relevant in the pharmaceutical industry but 
require cofactors, tranketolases and purine nucleoside phosphorylase (PNP). One example is PNP 
from Aeromonas hydrophyla (AhPNP) immobilized in a packed stainless steel column and used for 
bioconversion on analytical scale coupled with product purification (Scheme 3)
23
.  
 
 
Scheme 3: PNP catalysed reaction. 
 
3 Lyases: add or remove a chemical group with a different mechanism from hydrolases or 
oxidoreductases. As much as they would be a powerful instrument in the synthesis of non-natural 
amino acid, there are limitations due to the immobilization of the free enzyme. 
 
REDOX reactions 
 
A reduction-oxidation reaction is a chemical reaction in which the oxidation states of atoms are 
changed. Any such reaction involves both a reduction process and a complementary oxidation 
process, two key concepts involved with electron transfer processes. Redox reactions include all 
chemical reactions in which atoms have their oxidation state changed; in general, redox reactions 
involve the transfer of electrons between chemical species. The chemical species from which the 
electron is stripped is said to have been oxidized, while the chemical species to which the electron is 
added is said to have been reduced. The processes of oxidation and reduction occur simultaneously 
and cannot happen independently of one another. The oxidation alone and the reduction alone are 
each called a half-reaction, because two half-reactions always occur together to form a whole 
reaction. Familiar examples of redox reactions are, for example: 
 Combustion reactions: oxidation-reduction reactions that occur when oxygen oxidizes 
another material and are accompanied by the release of heat and sometimes flames; 
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 Corrosion reactions: limited to the oxidation of metals and usually occur when moisture is 
present. They occur most rapidly when metals are strained and bent; the metals rapidly 
oxidize in the strained regions; 
 Respiration: this is one of the key ways a cell releases chemical energy to fuel cellular 
activity, where large molecules (i.e, sugars, amino acids, fatty acids) are broken into smaller 
ones. The formed chemical energy is stored in ATP molecules, that can be used in processes 
requiring energy. Cellular respiration is considered an exothermic redox reaction which 
releases heat. The overall reaction occurs in a series of biochemical steps, most of which are 
redox reactions themselves.  
Moreover, redox reactions are the foundation of the electrochemical cells, which can generate 
electricity from chemical energy. 
In organic chemistry oxidations and reductions are different from ordinary redox reactions because 
many reactions carry the name but do not actually involve electron transfer in the electrochemical 
sense of the word. Instead the relevant criterion for organic oxidation is gain of oxygen and/or loss 
of hydrogen. Classical reductions include alkene or alkyne reduction to alkanes and classical 
oxidations include oxidation of alcohols to aldehydes/ketones/carboxylic acids. In oxidations 
electrons are removed and the electron density of the organic compound is reduced. In reductions 
electron density increases when electrons are added to the organic compound. 
 
Oxidations 
Oxidation is a key transformation in organic synthesis. Most of oxidative procedures are far from 
being sustainable, because of the generation of copious amounts of toxic waste, and the 
employment of environmentally undesirable solvents, typically chlorinated hydrocarbons. In fact, 
organic oxidations can occur with different mechanisms and different oxidizing agents, for example 
chromium (VI), Dess-Martin periodinane and the Swern reagent. A very useful and interesting 
alternative to convert alcohols into their corresponding carbonyl compounds is to use N-
oxoammonium salts as oxidants that can satisfy the principles of green chemistry. TEMPO (2,2,6,6-
tetramethylpiperidin- 1-yl) oxidanyl) or derivatives, when used in catalytic amounts, exploit cheap 
sodium hypochlorite as a stoichiometric oxidant and generate in situ oxoammonium salt. TEMPO is 
still very expensive, but cheaper derivatives have been introduced recently. 
However, many of the oxidative procedures that nowadays are mostly used are far from being 
sustainable. For example, the use of stoichiometric amounts of carcinogenic chromium (VI) on an 
industrial scale would raise serious issues, while Dess-Martine periodinane is an unstable and 
potentially explosive reagent. The use of the Swern reagent produces dimethyl sulfide as co-
product, which has a very disagreeable odor even at very low concentrations. Both economic and 
environmental critical issues cause an urgent demand for greener, more atom efficient scalable 
oxidation methods that employ clean oxidants, such as molecular oxygen or hydrogen peroxide, and 
a recyclable catalyst for synthetic applications in the fine chemical industry
24
. 
. 
Reductions 
For reductive reactions, the most employed reagents are the one made of heavy metals, as for 
example LiAlH4, NaBH4 or just Na, Mg, Zn or Fe as reductive catalysts. The main problem 
connected with these reagents is their removal, because is really important that no traces of them are 
present in the final product, in particular if it is a pharmaceutical one. This leads to the formation of 
29 
 
big amounts of waste, that must be selectively and carefully disposed of, thus using a lot of 
energies, money and time. Also, classical hydrogenation must be performed in order to reduce 
alkyne or alkene groups into alkanes and it is well known that these reactions are far from being 
safe and clean.  
 
Biocatalyzed redox reactions: an overview of the biocatalysts employed in the present thesis 
 
A possible answer to the demands illustrated before can be biocatalysis, with whom is possible to 
perform greener oxidations and reactions, helping in finding new synthetic routes that can avoid the 
formation of huge amounts of waste, thus reducing costs and saving the operational time, and the 
use of hazardous reagents 
24
. 
In this thesis, the different chapters (one for each project) are organized as articles, therefore each 
one of them has their introduction, discussion and conclusion. In each introduction, an enlarged 
discussion is made for the specific reactions and biocatalysts employed in the correspondent project. 
In this paragraph, I just want to make a briefly overview about them: 
 
 Oxidation of alcohols are among the most important reactions in organic synthesis. 
Biocatalytic oxidations are attractive reactions, since they often occur with high chemo- 
regio- and stereo-selectivity, under mild conditions of temperature, pressure and pH, using 
environmentally benign oxidants (i.e., O2).
26-27 
They are mostly performed by 
dehydrogenases and oxidases, that can be found in different microorganisms, as for example 
Acetobacter. They possess a PQQ-dependent periplasmic alcohol dehydrogenase (ADH III), 
which catalyzes the oxidation into aldehydes, which are not accumulated into the cells but 
further oxidized to carboxylic acids; 
 The use of alcohol dehydrogenases (ADH, named also ketoreductases  -KREDs - or 
carbonyl reductases -CR- ) is a well established method for the enantioselective reduction of 
prochiral ketones into stereo-defined chiral alcohols.
28a)
 The reduction of these substrates 
frequently occurred with activity and enantioselectivity strongly dependent on the conditions 
of growth and biotransformation, suggesting the possible occurrence of different 
ketoreductases acting on aromatic ketones. Enantiomerically pure mono-alcohols can be 
important building blocks in the synthesis of various steroids, employed as hormonal 
contraceptives; 
 Aromatic aldehydes are key intermediates in a number of synthetic processes and have a 
prominent role as flavor and fragrance components. Among other synthetic methods,
28b)
 
they can be obtained from the corresponding primary aromatic amines, which are readily 
available substrates. Transaminases are a family of enzymes with high potential in 
biotechnological applications, that can be used to obtain aromatic aldehydes. They can 
displayed high stability, high turnover rate, broad substrate specificity and no requirement 
for external cofactors 
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AIM OF THE THESIS 
 
Nowadays scientists and industries talk a lot about sustainability, reduction of waste and processes 
with a lower impact on the environment, even if, in practice, we are far from the so-called “Green 
Chemistry”. There is an urgency in finding different methods, resources and, also, different ways of 
thinking, to be able to change direction now.  
In this context, in the present thesis I worked on the combination between flow chemistry and 
biocatalysis to develop innovative, robust and versatile protocols for performing biocatalyzed redox 
reactions using a combination of biocatalysis and flow-reactor technology for the obtainment of 
high value chemicals of pharmaceutical interest. The focus on redox reactions was chosen since 
traditional chemical redox processes are polluting and toxic, and they are usually not selective. On 
the other hands, biocatalyzed redox reactions often suffer of low productivities and scalability 
issues. 
The thesis is divided into different chapters, and all them have the intent to perform traditional 
reactions in a new and more sustainable way to synthesize active pharmaceutical ingredients or 
pharmaceutically interesting intermediates.  
The projects presented in this thesis are summarized below: 
 
1. Biocatalyzed regio- and stereo-selective oxidation reaction of a cheap commercially 
available prochiral diols to chiral mono carboxylic acids: application in the continuous flow 
synthesis of Captopril: this project had the aim to synthesize important building blocks for 
the synthesis of various pharmaceutical ingredients by using an innovative biocatalyzed 
oxidation performed in a flow chemistry reactor. Also, one of these reactions was used in 
order to obtain Captopril, with a completely continuous-flow synthesis. I woul like to thank 
Fondazione Cariplo for the fundings of this project; 
 
2. Stereoselective reduction of ketones and di-ketones, in order to obtain the corresponding 
enantiomerically pure mono-alcohols, using an immobilized ketoreductase from Pichia 
glucozyma and a glucodehydrogenase from Bacillus megaterium mixed bed reactor: the 
project had the aim to obtain stereo-and regioselective mono-alcohols, some of them 
important intermediates in the synthesis of various hormonal contraceptives, with an 
innovative flow-biocatalyzed approach, using two different purified and immobilized 
enzymes (a ketoreductase from Pichia glucozyma and a glucodehydrogenase from Bacillus 
megaterium). The flow approach was chosen in order to enhance productivity, reduce time 
reactions and increase stability, compared to the batch reactions. 
 
3. Stereoselective reduction of 2,2-disubstituted 1,3-cyclopenta- and 1,3 cyclohexanediones 
using both whole cells and a purified ketoreductase from Pichia glucozyma, to obtain 
enantiomerically pure mono-alcohol products, that can be important intermediates in the 
synthesis of various steroids: the project, made in collaboration with the group of Prof. 
Dörte Rother of the Forschungszentrum Jülich (Germany), had the aim to synthesize 
enantiomerically pure mono-alcohols starting from cyclic diones. These can be important 
building block in the synthesis of various steroids. The batch reactions were deeply studied 
with different biocatalysts in order to understand the differences between them; 
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4. Oxidation of amines to aldehydes using an immobilized form of pure transaminase from 
Halomonas elongata: the project was made in collaboration with the group of Prof. 
Francesca Paradisi, of the University of Nottingham. The aim was to use an immobilized 
transaminase from Halomonas elongate in a flow reactor to enhance productivity, reduce 
time reactions and increase stability, compared to the batch reactions. The produced 
aldehydes are flavours and fragrances used in food, beverage, cosmetics and pharmaceutical. 
The project followed a study in which the same enzyme was used to perform the opposite 
reaction, demonstrating the versatility of the process. 
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Biocatalyzed regio- and stereo-selective oxidation reaction of a 
cheap commercially available prochiral diols to chiral mono 
carboxylic acids: application in the continuous flow synthesis 
of Captopril. 
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Introduction 
 
Oxidation of alcohols are among the most important reactions in organic synthesis. Primary and 
secondary alcohols can be oxidized to their corresponding aldehydes or carboxylic acids and 
ketones, respectively. The oxidation occurs through the transfer of two-hydrogens, and can be 
achieved chemically using metal oxides, as Ag-, Mn-, or Cr oxides (e.g. Jones, Sarett, Collins, and 
Cornforth reagents). However, these reactions have some potential disadvantages in terms of their 
environmental impact (i.e. energy use, toxic byproducts, etc.) and are still often poorly 
stereoselective.  
Biocatalytic oxidations are attractive reactions, since they often occur with high chemo- regio- and 
stereo-selectivity, under mild conditions of temperature, pressure and pH, using environmentally 
benign oxidants (i.e., O2).
26-27
 The impact of enzyme-mediated oxidations in organic chemistry has 
been reviewed recently.
28c)
  
Alcohol oxidations are mostly performed by dehydrogenases and oxidases, which mediate the 
dehydrogenation of the substrate, although, chloroperoxidases, laccases and monooxygenases are 
also known to catalyze these reactions. The most frequently used cofactors are nicotinamide 
adenine dinucleotide (NAD
+
, NADP
+
), flavin adenine dinucleotide (FAD) and pyrroloquinoline 
quinone (PQQ) and they are necessary to perform the reaction. Their regeneration is a key point 
because it is necessary to make the reaction proceeding. Surely, the relative amount of 
reduced/oxidized cofactor plays a crucial role for the equilibrium of the reaction and, in addition, 
their use in stoichiometric amounts is too expensive.
26
  
The use of whole cells (either wild type or engineered) from aerobic microorganisms allows to use 
their respiratory metabolism as co-factor regeneration system. This guarantees the continuous 
regeneration of cofactors and shifts the equilibrium towards oxidation.  
Different aerobic bacteria (including Actinomycetes), molds and yeasts have been used as sources of 
oxidative enzymes, but their use as whole cells is hampered by degradative reactions that can 
further metabolize the carbonyl compounds. Metabolic engineering allows for the selective knock-
out of enzymes involved in further metabolization of the desired products. Thus, whole cells can be 
used as efficient systems. Examples are the selective inactivation of alcohol dehydrogenases for 
accumulating aldehydes or of CoA-synthases for accumulating carboxylic acids.
26
  
A well known exception to this are acetic acid bacteria. These microorganisms have a respiratory 
mechanism with incomplete oxidation where partially oxidized organic compounds are excreted as 
final products. So, these compounds are not further metabolized and the accumulation of, for 
example, carboxylic acids and ketones occurs. The group of Adachi showed most of the mechanism 
of the oxidative enzymes in acetic acid bacteria, as Acetobacter and Gluconobacter.
29
 Both of them 
possess a PQQ-dependent periplasmic alcohol dehydrogenase (ADH III), which performs a rapid 
oxidation that is very useful in industrial applications. Indeed, the main application of these bacteria 
is the production of vinegar. In addition, they are important for the production of several sugar 
derivatives, such as D-xylulose, L-ribulose and D-fructose.
29
 ADH III catalyzes the oxidation into 
aldehydes, which are not accumulated into the cells but further oxidized to carboxylic acids. Acetic 
acid bacteria have an incomplete oxidative metabolism and, therefore, can efficiently perform 
chemo-, regio- and stereo-selective oxidations, affording good yields of the corresponding 
carboxylic acids
26
. Dehydrogenases of acetic acid bacteria are versatile enzymes for alcohol 
oxidation.
30-26
 Production of structurally diverse aldehydes,
26-31
 aldoximes,
32
 lactones,
33
 and 
34 
 
carboxylic acids
34-36
 has been achieved using whole cells of acetic acid bacteria, often with high 
enantioselectivity.
37-38 
Different strategies can be exploited to improve the productivity and selectivity of a 
biotransformation carried out with whole cells. For example, they can be immobilized for 
enhancing stability and easy recovery;
39
 moreover, immobilization may dramatically change 
substrate and product diffusion, thus affecting reaction rates and inhibition effects.
40
 Importantly, 
immobilized cells can be used in packed bed flow micro- and meso-reactors, which ensure high 
surface-to-volume ratios, thus providing high heat and mass transfer rates. Flow packed bed 
reactors generally ensure that the substrate stream flows at the same speed through all the reactor 
volume without orbital shaking or stirring.
41-10
 
 
Gas transfer (air or pure O2-enriched air) to the liquid phase is often the factor limiting the 
efficiency of liquid phase bio-oxidations.
42-44 
A solution to increase the reaction rate is to facilitate 
mass transfer by increasing the interfacial area by applying a segmented gas-liquid flow regime.
45 
It 
is characterized by gas bubbles alternating with short liquid slugs and recirculation occurs within 
segments of the two-phase segmented flow, providing an efficient mass transfer between the 
gaseous and the liquid phase.
 41
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Results and discussion 
 
Chiral 3-hydroxy acids are interesting building blocks for the synthesis of a number of active 
pharmaceutical ingredients, such as Captopril, Scopolamine (a tropane alkaloid drug) and the 
antidiarrheal drug Racecadotril.
46
 Therefore, in this part of the project, I focused my attention to the 
development of a versatile biocatalyzed protocol for the obtainment of differently 2-substituted 
chiral hydroxy acid in flow. Among them, 1,3-propane diol 1 (Scheme 2) can be used as starting 
material for the obtainment of the antihypertensive drug Captopril [i.e., (S)-1-((S)-3-mercapto-2-
methylpropanoyl) pyrrolidine-2-carboxylic acid 5], using a chemo-enzymatic approach in 
continuous flow. Captopril is an angiotensin-converting enzyme (ACE) inhibitor used for the 
treatment of hypertension and heart failure, discovered at E. R. Squibb & Sons Pharmaceuticals in 
the 1970s. It was the first ACE inhibitor developed, followed by other drugs of this class, that were 
developed in order to overcome some problems of Captopril, such as the short half-life and the 
adverse effects. The short half-life necessitates two/three times dosing per day, which can decrease 
the patient compliance. Moreover, Captopril has some side effects as rash and taste which are not 
characteristic of others ACE inhibitors. However, it is still a widely used drug for the hypertension. 
Captopril has been synthesized in different ways. A first possible synthetic pathway was described 
by Ondetti at al. in the 1977
47
 (Scheme 1). 
 
 
Scheme 1. Synthetic pathway reported by Ondetti et al.
47 
 
As reported in Scheme 1, the first step of this synthesis is the formation of compound c starting 
from proline tert-butyl ester a and (S)-3-acetylthio-2-methylpropionic acid b with DCC in 
dichloromethane. Then, after removal of the tert-butyl ester group and the acetyl group, compound 
e (Captopril) was obtained in 50% yiled. (S)-3-Acetylthio-2-methylproprionic acid b was prepared 
following a procedure reported by Holmberg at al.
48
 in which the preparation of this intermediate 
started from the addition of thiolacetic acid to the substituted acrylic acid. Enantiomerically pure b 
was obtained with a resolution using a chiral amine, such as 1,2-diphenylethylamine or 2-amino-1-
butanol.  
A second possible chemical synthesis is the one reported by Shimazaki et al.
49
 This synthetic 
pathway is the one I decided to developed under flow conditions, and, therefore, a detailed 
description will be reported in the next pages. The flow protocol I developed is made of 4 steps and 
it is represented in Scheme 2. Shimazaki et al started from the microbiologically derived 
enantiomerically pure carboxylic acid 2, but they didn’t specify how exactly it was obtained. 
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Scheme 2. Four-step chemoenzymatic flow synthesis of enantiomerically pure Captopril. 
 
Carboxylic acid 2 can be obtained through a biocatalyzed oxidation reaction from the cheap, 
commercially available, prochiral diol. Importantly, using whole cells of A. aceti, just one hydroxyl 
group can be oxidized to carboxylic acid and just one of the two possible enantiomers can be 
obtained. Compound 2 was isolated and then three chemical steps were performed; each step was 
first optimized separately and then the steps were linked together, in order to start from compound 2 
obtaining directly, in a continuous flow way, Captopril as final product. In particular, the second 
step, as represented in Scheme 2, is a chlorination reaction on both the 3-hydroxyl group and on the 
carboxylic acid. The next step is an amide coupling using L-proline, while the last reaction is a 
nucleophilic substitution of the chlorine in position 3 with a thiol group. 
 
First step: biocatalyzed oxidation 
 
The first step is, as mentioned above, the biocalyzed oxidation reaction shown in Scheme 3: 
 
 
 
Scheme 3. Schematic representation of the first step in the synthesis of Captopril. 
 
This oxidative reaction is challenging using traditional oxidative methods that are toxic and 
polluting agents and are not able to oxidize the substrate in a regio and stereoselective way. This 
skill is typical of biocatalysts, either whole cells and enzymes.  
In this case, I performed the oxidative reaction using whole cells of Acetobacter aceti MIM 
2000/28, a strain that belongs to the University of Milan. This microorganism was chosen among 
others (i.e., Asaia bogorensis SF2.1 and Gluconobacter oxydans DSM 2343) by previous batch 
studies performed by the group of Dr. Diego Romano. They tested different achiral 2-substituted 
1,3 diols 1, 1a-1c with crude extract of Acetobacter aceti (Scheme 4).
50 
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Scheme 4. Oxidation of achiral diols 1,1a-1c to obtain the corresponding enantiomerically pure 
mono-carboxylic acids (2, 2a-2c). 
Results are reported in Table 1: 
 
Entry Substrate Conversion
a
 (%) ee
b
 (%) 
1 1 95 94 (R) 
2 1a 33 54 (R) 
3 1b 88 80 (S) 
4 1c 98 88 (S) 
 
Table 1. Oxidation of achiral 2-substituted 1,3-diols 1,1a–1c (12 mM) with free cells of 
Acetobacter aceti 2000/28 in conventional shaken flasks (batch mode). 
[a]
Conversions calculated by 
chiral GC or HPLC. 
[b]
Enantiomeric excesses measured by chiral GC or HPLC analysis after 
treatment with CH2N2. 
 
Under these conditions, quantitative conversions were obtained with diols 1 (95%, entry 1) and 1c 
(98%, entry 4), having a methyl and a n-pentyl substituent in position 2, respectively, while the 
ethyl-substituted diol 1a afforded the lowest conversion value (33%, entry 2). It was also observed 
the formation of reaction by-products, i.e., α-methylenic alkanoic acid and α-methyl alkanoic acid, 
in different ratio depending by the substrate. For example, for compound 1a, a 20% formation of 
the corresponding α-methylenic alkanoic acid and 47% of the corresponding α-methyl alkanoic acid 
were obtained.
50
 
For what concern the enantiomeric excess, it was observed that the (R)-enantiomer of compounds 2 
and 2a were obtained with decreasing ee values as the length of the alkyl chain at position 2 
increased from methyl to ethyl (entries 1 and 2, Table 1). An inversion of stereoselectivity was 
probably promoted by the reduced flexibility of the three-carbon chain of the 2-alkyl derivatives 1b 
and 1c, affording (S) ee values (80 and 88 %, entries 3 and 4, respectively). A possible explanation 
of the different enantioselectivity was reported
50
: since the reaction is known to occur according to 
a two-step sequence with an intermediate aldehyde, the enantioselectivity is controlled by the PPQ-
ADH acting during the first step. A tentative explanation for the observed inversion of 
enantioselectivity can be proposed by comparing the steric hindrance of the alkyl substituent R in 
position 2 and that of the CH2OH, which is left unreacted. If R is small (i.e., Me and Et), the (R)-
enantiomer of compound 2 and 2a is favoured. When the bulkiness of R increases (i.e., nBu and n-
Pent), a switch to (S) selectivity is observed.
50
 
R Sub 
Me 1 
Et 1a 
n-Bu 1b 
n-Pent 1c 
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Starting from these results with free cells of Acetobacter aceti, I investigated this oxidative reaction 
using immobilized whole cells firstly in a batch mode and then in a continuous flow environment. 
To this aim, I chose as immobilization form dried alginates beads, which are cheap, easy to prepare 
and easy to use, also in a flow bioreactor. This immobilization technique was previously used by 
our group for the flow preparation of fructooligosaccharides (FOS)
35
 and they are an example of 
immobilization based on physics entrapment of the whole cells. They showed excellent stability 
under continuous work. Details of the procedure are reported in the Experimental section of this 
chapter.  
2-Methyl-1,3-propandiol (1) was used as substrate for optimizing the biotransformation, since it is 
also the starting material for the synthesis of Captopril. Substrate concentration, buffer pH, and 
immobilized cells concentration were used as control parameters and optimization was carried out 
using a Multisimplex approach;
51
 conversion and enantiomeric excess of the product were the 
response variables. Optimized batch conditions (substrate 12 mM in acetate buffer 20 mM pH 6.0, 
40 mg/mL of alginate beads containing 10 mgdry weight of cells) gave (R)-3-hydroxy-2-
methylpropanoic acid 2 with >95% molar conversion and ee = 94% after 120 minutes. The analysis, 
carried out with chiral GC after derivatization with diazomethane, showed traces of the intermediate 
aldehyde 6, before being completely oxidized to the corresponding carboxylic acid 2 (Scheme 5). 
 
 
Scheme 5. Oxidation of the prochiral diols to carboxylic acid through formation of the aldehyde 
intermediate 6, 6a-6c. 
 
Considering the good results obtained with diol 1, I used the immobilized alginate beads of 
Acetobacter aceti also on the other compounds (1a-1c) under previously optimized conditions. 
Obtained results are shown in Table 2.  
 
Entry Substrate R 6,6a-6c 
(%)
[a]
 
2-2c (%)
[a]
 ee (2,2a-2c) 
(%)
[b]
 
Time (h) 
1 1 Me 5 86 94 (R) 1 
2 1 Me - > 97 94 (R) 2 
3 1a Et 8 56 59 (R) 3 
4 1a Et - > 97 59 (R) 5 
5 1b n-Bu - > 97 80 (S) 5 
6 1c n-Pent 12 45 88 (S) 3 
7 1c n-Pent - > 97 88 (S) 6 
 
Table 2. Oxidation of achiral 2-substituted 1,3-diols 1–1c (12 mM) with immobilized cells of 
Acetobacter aceti 2000/28 in conventional shaken flasks (batch mode). 
[a]
Conversions calculated by 
chiral GC or HPLC and confirmed after work-up by 
1
H-NMR of the crude mixture after the 
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indicated reaction time. 
[b]
Enantiomeric excesses measured by chiral GC or HPLC analysis after 
treatment with CH2N2. 
 
All the tested substrates gave the desired chiral 2-hydroxymethyl alkanoic acid as major product 
and only small amounts of the intermediate aldehydes (6, 6a-6c) were observed during the reaction; 
enantioselectivity was not affected by immobilization.
50
 Reaction rates show a strong dependence 
on the steric hindrance at C2 position; interestingly, dried immobilized cells were much more 
selective than free cells.
50
 The lack of side reactions can be justified considering that cells 
entrapment alters substrate and product diffusion through the solid support, as already observed in 
literature using similar systems.
49, 40
 
With the batch results in hands, I then transferred the reaction in flow. As well as before, I 
optimized the reaction using compound 1. 
At the beginning, I used growing free cells in a tubular coil flow reactor to perform the oxidation, in 
order to evaluate if the oxygen dissolved in the aqueous flow stream was enough to make the 
reaction running. One flow stream was made by the free whole cells in acetate buffer (20 mM pH 
6), while the other one was a 1 gr/L solution of substrate 1 in the same buffer. The two flow streams 
were mixed in a T-piece and directed in a 10 mL coil maintained at 28 °C (Scheme 6). 
 
 
Scheme 6. Schematic representation of flow configuration with Acetobacter aceti free cells. 
 
Despite different reactions times were tested, no product was observed under this condition. This is 
probably due to the lack of oxygen that is required by the biocatalyst. In fact, as reported in the 
Introduction (pag. 33), A. aceti is characterized by different membrane dehydrogenases which are 
associated to pyrroloquinoline quinone (PQQ) that during the reaction is reduced. So, it must be re-
oxidized to let the reaction proceeding, and this happens in presence of oxygen. Probably, with the 
set-up explained above, the oxygen present in the system was not enough for the reaction. 
Therefore, I used in flow the immobilized dried alginate beads, in order to exploit the advantages of 
the immobilized biocatalysts, and I developed a suitable system to guarantee the oxygen supply.  
To this aim, a segmented gas-liquid flow stream was used, in which the gas was compressed air 
(Figure 1). 
 
Figure 1. Air-liquid segmented flow stream. 
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The internal circulation in both phase A and phase B segments allows the passage of components 
between the two parts, and therefore oxygen can pass from the air stream to the liquid one (buffer), 
in this way getting in touch with the cell beads that have been packed into a reactor column. 
 
Figure 2. Segmented gas-liquid flow stream. 
 
For the reaction, I first tried the simplest possible set-up (Scheme 7). One HPLC pump pumped 1 
g/L 2-methyl 1,3 propandiol 1 solution in sodium acetate buffer (20 mM pH 6) and at a T-junction 
it met a pressurized air flow stream. Then the segmented stream entered an Omnifit glass column 
(i.d. 15 mm) packed with 400 mg of alginates (containing 100 mg of whole cells). The alginate 
beads were swelled before starting the reaction by flowing acetate buffer (20 mM pH 6) for 60 
minutes at a flow rate of 400 µL/min. After this time, the alginates triplicated their volume and 
reached a packed volume of 5.3 mL. Importantly, no catalyst release was observed in the exiting 
flow stream. Temperature was kept at 28 °C. 
 
 
Scheme 7. Representation of the flow set-up with segmented flow stream. 
 
With this flow set-up, the segmented flow stream was not stable. Indeed, it was not possible to 
ensure a constant flow stream and this led to a very small conversion. 
To obtain a constant flow of air, I used a mass flow regulator, that guarantees a constant flow rate 
once the parameters are set (Scheme 8). It was then connected to the T junction and it merged with 
the buffer solution of compound 1. After the column with alginates, a backpressure of 5 PSI was 
applied to the system in order to stabilize the exiting flow stream. 
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Scheme 8. Biocatalyzed heterogeneous oxidation of prochiral 2-methyl-1,3-propandiol 1. 
 
With this configuration, I tried different residence times and different concentrations of compound 
1, keeping constant the other parameters (as reported above). Flow outcomes were analyzed by 
chiral GC after derivatization with diazomethane and then confirmed by 
1
H-NMR. For each 
condition, I also calculated the specific reaction rate according to equation 1. In this thesis, the flow 
specific reaction rate will be always calculated according to the Eq.1. 
 
        
      
  
             
 
Eq. 1. rflow: [P] (μmol/mL) concentration of the formed product, f: flow rate of the liquid phase 
(mL/min), mE: mass of the biocatalyst expressed as dry weight of the cells employed (g dry weight). 
 
Results are reported in the table below (Table 3): 
 
Entry [1] (mM) Flow rate 
(mL/min) 
rflow
[a] 
(mol/min 
gdry cells) 
Molar 
conversion 
(%)
[b]
 
1 12 0.015 1.80 > 97 
2 12 0.030 3.60 > 97 
3 12 0.060 4.68 65 
4 24 0.015 3.60 > 97 
5 24 0.030 7.20 >97 
6 24 0.060 7.34 51 
7 48 0.015 4,32 60 
8 48 0.030 5.09 41 
9 48 0.060 8.07 28 
 
Table 3. Results obtained with different residence times and different concentrations of compound 
1 at 28 °C. 
[a]
 Specific reaction rates were calculated according to Eq.1. 
[b]
 Conversions were 
determined by chiral GC or HPLC and confirmed with 
1
H-NMR.  
 
As it is possible to see from the Table 2, total conversion was obtained with substrate concentration 
of 12/24 mM (entries 2 and 5) with both flow rates 15 and 30 μL/min, whereas at higher substrate 
concentrations and lower flow rates (entry 7) the conversion was far from being complete. The best 
results were the ones obtained with 12 mM and 24 mM concentration of 1 at the flow rate of 30 
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µL/min. With this flow rate, the residence time inside the column was 10 minutes. For all the 
entries, one enantiomer ((R)-3-hydroxy-2-methylpropanoic acid 2) was detected by chiral GC with 
an excellent ee = 97%.  
This set-up was then tried on the other achiral 2-subtituted 1,3 diols (1a-1c), under optimized 
conditions found with compound 1, in order to demonstrate the versatility of the flow protocol, 
using the diols already tested under batch conditions (Table 4). 
 
Entry Substrate Conv. (%) ee (%) 
1 1 > 97 94 (R) 
2 1° > 97 59 (R) 
3 1b > 97 80 (S) 
4 1c > 97 88 (S) 
 
Table 4. Oxidation of achiral 2-substituted 1,3-diols 1, 1a-1c (24 mM) with immobilized 
Acetobacter aceti MIM 2000/28 in flow reactor. Liquid flow stream: 30 µL/min. 
 
The continuous flow biotransformation of diols 1a-c occurred with high rates and total conversion 
of the substrate into the desired chiral hydroxy acid, proving that the experimental protocol 
optimized in this work could be generally applied. The enantioselectivity remained the same 
obtained in batch. 
I then tested the stability of the system and of the bioreactor under continuous work, using 
compound 1 as reference compound. Therefore, using the last shown set-up, I flowed 50 mL of 
1g/L solution of compound 1 in acetate buffer through a glass column packed with 400 mg of 
alginates. The conditions in which I tested the stability were the ones reported in table 1, entry 2. 
Here below a graphic summarizes the stability results (Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Stability of flow packed bed reactor with 400 mg of alginate beads under continuous 
work (1 g/L solution of compound 1) in 10 minutes of residence time. 
 
As it is possible to see from the graphic, the flow outcome was constant under 12h of continuous 
monitoring. Also the enantiomeric excess of product 2 was constant (97%). 
Then I performed, after the reaction, the purification and isolation of product 2. Firstly, I tried an in-
line acidification and extraction with ethyl acetate, in order to obtain the desired product in the 
organic phase. So, one HPLC pump pumped the acidified exiting flow stream containing 2, while 
the other pump pumped ethyl acetate. I tried different ratios between the two flow rates, trying to 
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force the extraction of the carboxylic acid, maintaining the pH of the aqueous solution around 1, 
but, unfortunately, all the attempts were not successful due to the high hydrophilicity of the product. 
Indeed, 10/12 extractions were required during normal work up in order to completely obtain 2 in 
the organic phase. Therefore, I used a catch and release strategy in order to isolate it from the water 
phase and to purify it from the any unreacted diol 1. In order to do so, I inserted another Omnifit 
glass column packed with a strong basic resin, Ambersep 900 OH, at the exiting of the bioreactor in 
which the oxidation takes place, (Scheme 9). 
 
 
 
 
 
 
 
 
 
Scheme 9. Representation of the final flow set-up including the catch and release column. 
 
Different resins, as for example Ambersep 400 OH and Cl, or Ambersep 900 Cl, have been first 
tested in batch for the ability to trap the carboxylic acid, and, finally, 900 OH resulted to be the only 
one which was able to completely catch the carboxylic acid and to leave the diol in the buffer 
stream. Scheme 10 shows the used catch and release strategy. 
 
  
 
Scheme 10. Catch and release of carboxylic acid 2 using Ambersep 900 OH. 
 
After trapping the acid through the formation of an ionic interaction with the positively charged 
quaternary amine reactive group of the resin, the release was achieved using 1N HCl  to recover the 
desired product 2, in an aqueous solution. After lyophilization, product 2 was obtained as a pale 
yellow oil in 91% yield. 
I also applied the same catch and release strategy on the others carboxylic acids synthesized (2a-
2c). 
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Second step: chlorination reaction 
 
The isolated mono carboxylic acid was then submitted to chemical reactions to synthesize 
Captopril. The second step of the protocol is the chlorination reaction using thionyl chloride 
reported in Figure 4. 
 
Figure 4. Second step of synthesis protocol. 
 
This reaction meant to insert a chlorine atom in position 3 and to transform carboxylic acid into an 
acyl chloride. As mentioned above, to perform this reaction I considered the protocol developed by 
Shimazaki et al.
49
 In this work, the chlorination reaction is performed using 2.5 equivalents of 
thionyl chloride in CH2Cl2 containing imidazole in a catalytic amount. Thionyl chloride was added 
dropwise at a temperature between 0 and 15 °C over a period of 30 minutes. Then, the reaction was 
stirred at 85 °C for about 2 h. 
I first repeated this reaction in batch and I obtained, after removal of the solvent, compound 3 in a 
yield of 50 %. Remarkably, compound 3 was unstable and particular attention is required to handle 
it. 
I then performed the reaction in flow, using the configuration reported in Scheme 11. 
 
 
 
 
 
 
 
 
 
Scheme 11. Flow configuration of chlorination reaction. 
 
A HPLC pump pumped a 1 M solution of compound 2 containing a catalytic amount of imidazole. 
Different solvents have been tested to prepare the initial solution. The second flow stream was made 
of a solution of SOCl2. The equivalents of SOCl2 have been considered during reaction 
optimization. The two flow streams met each other in a T-junction and entered a 10 mL coil heated 
at different temperatures. A 250 PSI backpressure regulator (BPR) was applied to the system to 
avoid the evaporation of the solvent at elevated temperatures. Using this set-up, I changed and 
optimized different parameters. Firstly, I selected the organic solvent to use. I tried dichloromethane 
(as in the batch procedure), THF and toluene. All the solvents were freshly distilled or dry. In all the 
cases, an addition of 15% v/v of DMF was required to better solubilize compound 2 and the 
imidazole. In fact, in flow, using HPLC pumps, it is really important to work with clear solutions, in 
order to avoid precipitates that can damage the pumps and block the entire system. Also, DMF 
acted as second catalyst, accelerating the reaction, because it forms the Vilsmeier reagent with a 
chloride atom coming from thionyl chloride. Among the solvents tried, dichloromethane was the 
Imidazole cat. 
10 mL coil 
250 PSI 
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worst one for flow applications. In addition, according to what reported by Alfonsi et al.,
6 it is one 
of the most polluted and toxic solvents (it was also inserted in the Group 2A by the World Health 
Organization as probable carcinogenic to humans). For all these reasons, I decided to avoid its use. 
THF and toluene are both solvents which were considered as “usable”.6 The best between them was 
toluene because it allowed us to obtain a cleaner reaction profile and better results.  
Secondly, I optimized the equivalents of thionyl chloride. I started with the same of the batch 
procedure (2.5 eq) and I then increased them up to 3.5 eq. This last amount was the necessary one, 
in order to have the chlorination in both the desired positions. In fact, the main problem of this 
reaction is not the formation of the acyl chloride (which is rapidly formed) but the substitution of 
the hydroxyl group with the chloride atom. It is important to underline that, exploiting the 
advantages of flow chemistry, the potential danger of this exothermic reaction and gas (HCl) 
releasing was mitigated in continuous, because each time only a small amount of thionyl chloride 
passes through the channels and reacts with a solution of compound 2. Indeed, no refrigeration 
neither slow addition of SOCl2 were required in flow, as necessary in batch procedure. So, even if a 
higher use of thionyl chloride is required in flow, this does not represent a problem in terms of 
safety. 
I also tried different temperatures and different reaction times. The results are reported in Table 5. 
 
Entry T [°C] tr [min] Conversion 3
[a]
 
[%] 
1 85 60 80 
2 100 60 100 
3 110 30 100 
4 125 15 70 
5 150 15 70 
6 150 20 80 
7
[b]
 100 30 100 
8
[b]
 100 15 85 
 
Table 5. Results of the chlorination reaction in flow changing temperatures and residence times. 
Conditions (entries 1-6): flow stream A: 1M solution of compound 2 in anhydrous toluene with a 
catalytic amount of imidazole and 15% DMF v/v; flow stream B: 3.5 eq of SOCl2 in anhydrous 
toluene
. [a]
 Conversions were determined by 
1
H NMR after removal of the solvent. 
[b]
 For these two 
entries, 1M solution of compound 2 and 1% imidazole were used in DMF; flow stream B was neat 
SOCl2. 
 
As it is possible to see from the Table 4, a total conversion was achieved in two cases (entries 2 and 
3) if anhydrous toluene was used as organic solvent to prepare the solutions. A 100% conversion 
was also reached if DMF was used to prepare solution of compound 2 and neat thionyl chloride 
acted as second flow stream (entry 7). Due to the easier product recovery, toluene was chosen as the 
reaction solvent. 
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After removal of the solvent, the pure product was collected (purity > 95% determined by 
1
H NMR) 
as an oil with an 80% isolated yield. Importantly, the (R) configuration of the methyl group in 
position 2 was maintained, in batch as well as in flow. 
 
Third step: amide coupling 
 
The next step of the synthesis is an amide bond formation represented in Scheme 12. 
 
 
 
Scheme 12. Schematic representation of amide coupling step. 
 
Following the procedure reported in the article of Shimazaki et al
49
, I first performed the reaction in 
batch, where a solution of L-proline was prepared in NaOH 2N and compound 3 (1 eq) was added 
at 0 °C; the mixture was stirred for 1h at this temperature. Then, the reaction was stirred for another 
hour at room temperature. After acidification and extraction with ethyl acetate, the solvent was 
removed, a chromatographic column was made and compound 4 was obtained in 50% yield. 
Then, I moved the reaction to flow (Scheme 13). 
 
 
 
Scheme 13. Schematic representation of flow configuration for amide coupling. 
 
In view of a continuous flow protocol, I decided to prepare the solution of compound 3 in toluene in 
a 1M concentration. Therefore, a biphasic liquid-liquid system made by water (a solution of L-
proline in aqueous NaOH) and toluene was formed. One HPLC pump pumped a 1M solution of 
compound 3 in toluene, while the second pump pumped a water solution at different concentrations 
of L-proline and different concentrations of NaOH. The two solutions entered a 2 mL coil 
maintained at room temperature. Again in view of a continuous protocol, a 250 PSI backpressure 
was applied to the system.  
For this reaction, I focused the attention mostly on the concentration of L-proline and NaOH and 
the residence time. Therefore, first I tried with the same equivalents used in the batch procedure (1 
eq. of L-proline and 2 eq. of NaOH), but unfortunately I did not obtain full conversion. So, I 
decided to push the reaction by using 2 equivalents of L-proline and 3 equivalents of NaOH. Again, 
the advantages of flow chemistry allowed us to better and safer handling these reagents, even at 
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higher concentrations. Remarkably, there was no need of cooling the system when the two flow 
streams met at the T-junction, as happened for the batch procedure. The increase of equivalents was 
successful. Two equivalents of sodium hydroxide were necessary to deprotonated the L-proline, 
while the left equivalent was necessary to neutralize the HCl formed during the reaction.  
For what concerns the residence time, using the optimized equivalents, I first tried 30 minutes. I 
observed that the reaction was complete and, consequently, I decreased the residence time. The 
reaction turned out to be complete in only 1 minute. 
In order to separate in line the water phase (containing the desired product 4, which is de-protonated 
for the basic pH of the water solution) from the organic phase (Scheme 6), I used a continuous 
Zaiput liquid-liquid separator (Figure 13). 
 
 
Figure 13. Zaiput liquid-liquid separator. 
 
This separator is commercially available and it works thanks to a hydrophobic membrane inside the 
device. The reaction flow stream can enter the separator, and, here, the organic phase passes 
through the hydrophobic membrane, while the aqueous one is retained. In this way, the two phases 
can be separated and collected in two different flasks.  
So, I obtained the desired product 4 in the water phase. I then tried to perform an in-line 
acidification and extraction with ethyl acetate of compound 4 (Scheme 14). 
 
 
 
Scheme 14. In-line acidification and extraction with ethyl acetate of compound 4. 
 
In this way, it was possible to avoid the traditional work-up procedures that normally require more 
solvents and produce more waste. Therefore, I inserted an inlet of HCl 6N to the water phase line 
and this acidified flow stream met at a T junction an ethyl acetate flow. The mixture entered a 2 mL 
coil and then the two phases were separated again using a Zaiput liquid-liquid separator. In the end, 
I completely collected product 4 in the acetate phase, and, after removal of the solvent, I obtained it 
in a yield of 80%. Remarkably, no chromatographic column was required to purify compound 4. 
The configuration at position 2 was retained. 
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Two sequential steps: second and third steps in continuous 
 
After the optimization of the first two steps, I afforded to link them together, starting from 
compound 2 and obtaining in a continuous way compound 4 (Scheme 15). 
 
 
 
Scheme 15. Schematic representation of the first two sequential steps. 
 
For the chlorination reaction, I used the conditions reported in Table 5 entry 3 (100 % conversion in 
30 minutes at 110 °C), because, compared to entry 4, the residence time was lower and compound 3 
was equally pure, even if the temperature was higher. In order to link the steps together, some 
modifications were required. Indeed, in a continuous way, everything has to be designed so that the 
excess of reagents and reaction byproducts from each reaction are compatible with the downstream 
reactions. Therefore: 
 The T-junction between the first and the second step was maintained at 0 °C; this was 
necessary in order to be completely safe, since at this point thionyl chloride meets water, 
and in this way the uncontrolled exothermic neutralization and the release of large 
quantities of HCl vapors were easily controlled. Of course, this adverse situation was also 
mitigated thank to the advantages of flow chemistry, as discussed above; 
 A modification of the equivalents of NaOH was required. Indeed, sodium hydroxide was 
necessary in order not only to de-protonate L-proline and to neutralize the formed HCl, but 
now it must neutralize also the un-reacted SOCl2. If the pH of the water solution is acid, no 
coupling reaction can occur. If it was neutral or slightly basic, the reaction runs very well. 
So, after many attempts, I found that 7 equivalents were the minimum amount of NaOH 
that must be used; 
 The residence time of the second step increased from 1 to 3 minutes. This was an 
automatically modification considering the flow rate coming from the first step. 
 
After the chlorination step, compound 3 met directly, without any isolation or purification, the flow 
stream composed by L-proline and NaOH in water (Scheme 8). In the end, the liquid-liquid 
separator was used again in order to separate toluene from the water phase, and for the acidification 
and extraction with ethyl acetate. In this way, product 4 was collected in the organic phase and 
separated from all the impurities and neutralized reagents coming from the two steps, that are in 
water phase. A 250 PSI backpressure regulator was applied to the entire system. After removal of 
ethyl acetate, compound 4 was obtained as a pale yellow oil in a yield of 70%. Again, no 
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chromatographic column was required to purify the desired product. A very important and 
interesting thing to underline is that, with this protocol, no isolation of the unstable intermediate 3 
was required, and, therefore, the yield was increase, since it was not manipulated and it was retained 
inside system and directly reacted in the next coupling step. Despite the required modifications, the 
absolute configuration of the two stereocenters was retained, since optical rotation values remained 
the same as before. 
 
Fourth step: nucleophilic substitution 
 
The last reaction for the obtainment of Captopril is the nucleophilic substitution of the chlorine with 
a thiol group (Scheme 16). 
 
Scheme 16. Representation of the nucleophilic substitution reaction. 
 
Following the reported procedure,
49
 the batch reaction was performed preparing a DMF solution of 
compound 4 and 3 equivalent of NaHS. The mixture was stirred for 4 h at 50 °C under nitrogen, and 
after a work-up and a chromatographic column, Captopril was obtained as a white solid in 40% 
yield. The main impurities that were detected during this reaction were the possible oxidative 
products, obtained through the formation of a disulfide bond or a thiolether. These dimers were 
formed due to the presence of the free thiol group (Figure 14). 
 
 
Figure 14. By-products formed during the nucleophilic substitution.
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Then, I transferred the reaction in flow (Scheme 17). 
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Scheme 17. Schematic representation of the flow configuration used for the nucleophilic 
substitution with NaHS. 
 
A HPLC pump pumped a 1M solution of compound 4 in ethyl acetate. I decided to try first this 
solvent because, in view of a continuous protocol, compound 4 would be in an ethyl acetate 
solution. The second flow stream is composed by a solution of 3 equivalents of NaHS in degassed 
water, therefore, a biphasic liquid-liquid system was formed. Water was degassed in order to limit 
the presence of oxygen in the solution and therefore to avoid the formation of the oxidative by-
products observed in batch. After mixing in a T-piece, the two flow streams entered a 10 mL coil 
reactor. In view of a continuous protocol, a 250 PSI backpressure regulator was applied to the 
system. Different temperatures and residence times were tested in order to achieve total conversion 
(Table 6). 
 
Entry T [°C] Tr (min) 5
[a]
 (%) 
1 50 60 70 
2 80 60 90 
3 100 60 93 
4 125 30 100 
5 125 15 75 
 
Table 6. Reported conversions obtained for compound 5 (Captopril) with different temperatures 
and residence times.
[a]
 Conversions were determined by 
1
H-NMR. 
 
As it is possible to see from Table 6, a complete conversion was achieved in 30 minutes at 125 °C 
(entry 4). 
 
For this reaction as well, I decided to perform an in-line acidification and extraction of Captopril 
using the Zaiput liquid-liquid separator (Scheme 17). So, the flow outcome was acidified with HCl 
2N in order to protonate the carboxylic acid and to extract Captopril from the water phase. The 
organic phase was ethyl acetate, since it was already the solvent used for the reaction. The 
extraction was successful and the desired product was completely collected in the organic phase, 
while some of the other impurities remained in the water phase. After removal of the solvent, a 
chromatographic column was necessary at this point to completely purify the product (in fact, some 
oxidative by-products have been formed during the reaction). After the column and the 
crystallization, Captopril was obtained as a white solid with a yield of 80%. 
1
H NMR and the 
optical rotation values match the ones reported in literature.
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Continuous flow-synthesis of Captopril 
 
Finally, I linked the last reaction (nucleophilic substitution with NaSH) to the continuous process. 
In the Scheme 18, it is possible to see the entire synthesis developed. 
 
 
Scheme 18. Schematic representation of the continuous flow synthesis of Captopril.  
 
In the continuous protocol, after the amide coupling reaction and its acidification and extraction 
with in-line liquid-liquid separator, compound 4 in acetate acted as feed reservoir and it was used 
without handling or modification for the next and last step. A backpressure regulator of 250 PSI 
was applied to the system. The optical rotation confirmed that the absolute configuration of the two 
stereocenters was retained along all the steps. In the end of the protocol, after crystallization, 
Captopril was obtained with an overall yield of 55-60% over 2h of work. As said before, only one 
final chromatographic column was required to obtain the pure product. This continuous flow 
protocol was robust and could run for multiple hours without interruption. Indeed, I was able to 
scale-up the system until the gram scale (1-2 grams of product was recovered by running the system 
for 1-3 days). 
 
Conclusions 
 
The multistep flow synthesis presented here enabled Captopril to be obtained in an overall yield of 
55-60% after crystallization in an overall time of about 2h, while with the batch procedure an 
overall yield of 45% was achieved after 3 days of work, which include 2 work-ups and two 
chromatographic columns. In contrast, by exploiting the flow protocol, only one final purification 
column was necessary to obtain pure Captopril. This underlines some of the most important 
advantages of flow chemistry, which are the possibility to perform in line quenching and work ups 
to obtain cleaner synthesis and cleaner products, thus reducing solvents and time spent in the 
purification procedures. Simultaneously, yields are higher, compared to traditional protocols. The 
biocatalytic oxidation allowed the conversion of a prochiral substrate into a chiral intermediate with 
high enantiomeric excess. Three chemical transformations were performed without isolation of the 
intermediates. The separation of co-products, by-products, and excess reagents was achieved in-
line. In this way, compared to the traditional strategies, it was possible to reduce solvent waste and 
time consuming. These results clearly highlight the benefits of performing multistep chemical 
synthesis in a flow environment. As a further advantage, our synthetic protocol benefits from the 
use of an environmentally friendly biocatalytic oxidation, avoiding the use of toxic chemical 
oxidants. In this context, desymmetrisation of achiral 1,3-diols with Acetobater aceti was studied 
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and developed in a flow chemistry reactor, taking advantage of the previous batch results that 
showed an efficient procedure for the preparation of enantiomerically enriched hydroxymethyl 
alkanoic acids.
50
 Batch reaction with free cells carried out in conventional shake flasks showed also 
formation of the corresponding α-methylenic alkanoic and α-methyl alkanoic acids. Immobilization 
in Ca-alginate, beyond the advantages of easier work up and potential catalyst reusability, was 
found to be an excellent tool for improving the selectivity of the reactions with respect to the use of 
cell free systems. As further improvement, the oxidation of diols 1, 1a-1c was tested under 
continuous-flow conditions, exploiting the application of alginate beads in a packed-bed reactor. A 
segmented air-water flow regime (which ensured high mass transfer between the gaseous and the 
liquid phase) was applied allowing for high rates.  
The bioprocess might be further linked to the chemical transformations by optimizing the extraction 
of acid 2 with organic solvents, for example, using specific organic-acid-complexing carriers.
53
 In 
view of a future scale-up, whereas none of the chemical steps have foreseen limitations, further 
efforts should be directed toward increasing the productivity of the first biocatalyzed step, which at 
present represents a bottleneck in the process. The new proposed protocol for the synthesis of 
Captopril represents a powerful integration of biocatalysis and flow-chemistry technology. 
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Material and methods 
 
General 
 
All reagents and solvents were purchased from Sigma–Aldrich. The continuous flow reactions were 
performed using a commercial R2C/R4 flow reactor (Vapourtec, Bury St. Edmunds, Suffolk, UK) 
equipped with Omnifit glass columns (15 mm i.d. V 100 mm length) and PFA reactor coils (2 and 
10 mL, respectively). The R2C unit is the pumping unit that contains two adapted Knauer pumps, 
which are able to pump highly concentrated and corrosive acids. R4 is the heating unit with four 
heating positions. The additional HPLC pumps necessary to perform the overall synthesis were 
provided by another R2+/R4 flow reactor (Vapourtec) and by two external pumps (ThalesNano). 
The temperature sensor sits on the wall of the PFA tubing. The pressure was controlled by using 
two 100 psi BPRs. In-line liquid–liquid extractions were performed using a Zaiput separator. 1H 
NMR and 
13
C NMR spectra were recorded with a Varian Mercury 300 (300 MHz) spectrometer. 
Chemical shifts (d) are expressed in ppm, and coupling constants (J) are expressed in Hz. The molar 
conversion of the biotransformation was determined by HPLC analysis using a Luna NH2 100 Ä 
column (250 mmV4.6 mm, particle size 5 µm, Phenomenex, Aschaffenburg, Germany) and a 
Biorad refractor index detector with an acidic aqueous KH2PO4 buffer (20 mM, pH 2.7) as the 
mobile phase (flow rate 0.2 mLmin
-1
). The samples (40 mL) were injected as soon as collected and 
without further treatment. The enantiomeric composition of 2 was determined by gas 
chromatographic analysis of the corresponding methyl ester [methyl (R)-3- hydroxy-2-
methylpropionate: tr=3.6 min], obtained after treatment with diazomethane, using a chiral capillary 
column (diameter 0.25 mm, length 25 m, DMePeBeta-CDX-PS086, MEGA, Legnano, Italy). 
Optical rotation determinations were performed using a Jasco P-1010 spectropolarimeter coupled 
with a Haake N3-B thermostat. MS analyses were performed on a Varian 320-MS triple quadrupole 
mass spectrometer with an electrospray ionization (ESI) source. Microanalyses (C, H, N) were 
within: 0.4% of theoretical values. 
 
Strain preparation 
 
The A. aceti MIM 2000/28 strain was routinely maintained on GYC agar plates [glucose (50 gL
-1
), 
yeast extract (10 gL
-1
), CaCO3 (30 gL
-1
), agar (15 gL
-1
), pH 6.3] at 28 °C. Strain was inoculated 
into 100 mL Erlenmeyer baffled flask containing GLY medium [yeast extract (10 gL
-1
) and glycerol 
(25 gL
-1
), pH 5; 20 mL]. After growth for 24 h (shaking at 150 rpm, 28 °C), the liquid culture was 
entirely used to inoculate a 1 L Erlenmeyer baffled flask containing GLY medium (150 mL). Flasks 
were grown for 24 h at 28 °C, with shaking at 150 rpm. 
 
Preparation of Dry Alginate Beads 
 
Gel beads were prepared by ionotropic gelation, by following a protocol previously developed by 
us
10
: a 4% (w/v) sodium alginate solution was prepared in distilled water and stirred until a 
homogeneous clear solution was formed. The solution was allowed to settle for 2 h in order to 
eliminate the air bubbles. The alginate solution was then gently mixed in a 1:1 (w/w) ratio with a 
suspension of A. aceti cells (40 ODmL
-1
) in sodium acetate buffer (20 mm, pH 6). The resulting 
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mixture was then pumped dropwise into a slightly agitated CaCl2 solution (0.2m). Calcium alginate 
beads were agitated for 20 min, then filtered, washed with deionized water and dried at 25 °C for 16 
h. 
 
General batch procedure for the preparation of mono-carboxylic acids (2,2a-2c) 
 
A 12 mM solution of compounds 1-1c was prepared in acetate buffer pH 6.0. A concentration of 40 
mg/mL of alginates was used (containing 10 mg of whole cells). The reaction was maintained at 28 
°C. The reaction was followed by HPLC. After 120 minutes, the mixture was acidified until pH 2 
and it was extracted with ethyl acetate (10/12 times). The organic phase was dried on Na2SO4 and 
the solvent was evaporated under reduced pressure. Enantiomeric excesses were detected by chiral 
GC after derivatization with diazomethane or by chiral HPLC. 
 
General flow procedure for the preparation of mono-carboxylic acids (2,2a-2c) 
 
Dry alginate beads (400 mg, containing 100 mgdry weight of cells of Acetobacter aceti ) were packed 
into a glass column (i.d. 15 mm X 100 mm lenght) and swelled until their volume tripled by 
flowing acetate buffer (20 mm, pH 6) through the column (flow rate: 400 mLmin
-1
, 60 min). The 
final volume of the bed was 5.1 mL. Air was delivered at 17 psi; its flow was measured and 
controlled thank to a mass flow controller device, that inlet into the system a continuous air flow 
stream at 6 mL/min. A buffer solution of 1-1c (24 mM in acetate buffer 20 mM pH 6.0) was 
pumped at 30 mLmin
-1
, joining the airflow at the T-junction, before entering the column in which 
the oxidation occurs in approximately 10 min. A BPR (5 psi) ensured a constant and controlled 
biphasic air-liquid flow. The exiting flow stream was directed into a column filled with Ambersep 
900 OH resin (2 g) and, after washing the column with water (20 mL, 0.5 mLmin
-1
), the trapped 
acid was released by flowing HCl (1N, 5 mL). Reactions were followed by HPLC and ee were 
calcualated with chiral GC after derivatization with diazomethane or with chiral HPLC. 
 
(R)-(Hydroxymethyl) propanoic acid (2): [α]D
20
 = -11.55 (c=1.00 in EtOH); ee=94%; 
1
H NMR 
(300 MHz, CDCl3): δ = 1.22 (d, J=7.4 Hz, 3H), 2.10 (s, 1H), 2.68–2.80 (m, 1H), 3.75 (d, J=6.0 Hz, 
2H), 5.70 ppm (br s, 1H); 
13C NMR (75 MHz, CDCl3): δ = 13.2, 41.6, 64.0, 180.1 ppm.54 HPLC 
analysis: 1, tr=22 min; 2, tr=18 min. 
(R)-2-(Hydroxymethyl) butanoic acid (2a): [α]D
20=−2.8 (c=0.50, CHCl3), ee=54%; 1H NMR (300 
MHz, CDCl3): δ=3.90–3.70 (2H, m, CH2OH), 2.56 (1H, m, CHCOOH), 1.80–1.55 (2H, m, 
CHCH2), 1.00 ppm (3H, t, J=7.6 Hz, CH2CH3); 13C NMR (75 MHz, CDCl3): δ=180.4, 62.7, 49.0, 
21.6, 11.8 ppm.
55
   
(S)-2-(Hydroxymethyl) hexanoic acid (2b): [α]D
20=−5.1 (c=0.75, CH3OH), ee=81%; 
1
H NMR 
(300 MHz, CDCl3): δ=3.85–3.75 (2H, m, CH2OH), 2.61 (1H, quint., J=5.9 Hz, CHCOOH), 1.75–
1.65 (1H, m, CHCHHCH2), 1.60–1.45 (1H, m, CHCHHCH2), 1.40–1.28 (4H, m, CHCH2(CH2)2), 
0.91 ppm (3H, t, J=6.4 Hz, CH2CH3); 
13
C NMR (75 MHz, CDCl3): δ=180.1, 63.2, 47.9, 29.8, 28.4, 
22.7, 14.0 ppm.
56
 Chiral GC: DAcTBSil BetaCDX, 60 °C/0.8 °C min
−1
/90 °C/30 °C min
−1
/220 °C 
(2 min), tR (R)-2b=29.9 min, tR (S)-2b=30.6 min. 
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(S)-2-(Hydroxymethyl) heptanoic acid (2c): [α]D
20
= -2.1 (c=2.3, CHCl3), ee=92%; 
1
H NMR 
(CDCl3, 300 MHz): δ=3.85–3.70 (2H, m, CH2OH), 2.59 (1H, quint, J=5.9 Hz, CHCOOH), 1.70–
1.57 (1H, m, CHCHHCH2), 1.55–1.42 (1H, m, CHCHHCH2), 1.40–1.20 (6H, m, CHCH2(CH2)3), 
0.88 ppm (3H, t, J=6.5 Hz, CH2CH3); 
13
C NMR (CDCl3, 75.0 MHz): δ=179.6, 63.2, 47.9, 31.8, 
28.4, 26.9, 22.5, 14.0 ppm. 
 
Synthesis of (R)-3-Chloro-2-methylpropanoyl Chloride (3) 
 
Batch procedure
49
  
Thionyl chloride (1.42 gr, 12 mmol) was added dropwise to a solution of 2 (500 mg, 4.80 mmol) in 
CH2Cl2 (480 µL) containing imidazole (25 mg, 0.37 mmol) as a catalyst with stirring at 0-15 °C 
over a period of 30 minutes. The reaction mixture was then warmed to 80 °C. Stirring was 
continued until gaseous evolution of hydrogen chloride and sulfur dioxide subsided. The reaction 
was followed by TLC (1:1 CHX/EA; Rf of 3 = 0.86). After removal of the solvent and excess of 
thionyl chloride on a rotary rotavapor at 40 °C, (R) 3-Chloro-2-methylpropanoyl Chloride 3 was 
obtained as a pale yellow oil. Yield=50%; [α]20D= - 5.63 (c=2.0, CH2Cl2) 
1
H NMR (300 MHz, 
CDCl3): δ=1.42 (d, 3H), 3.20–3.31 (m, 1H), 3.66–3.80 ppm (m, 2H). 
 
Flow procedure 
A solution of 2 (52 mg, 0.5 mmol) was prepared in anhydrous toluene (410 mL). Imidazole (3.5 
mg, 0.1 equiv) and DMF (50 mL) were added to the solution. A second solution of thionyl chloride 
(125 mL, 3.5 equiv) was prepared in anhydrous toluene (375 mL). The two solutions were mixed 
into a T-piece and flowed through a 10 mL reactor coil according to the conditions reported in 
Table 2. Reactions were followed by TLC (1:1 CHX/EA, Rf of 3 = 0.86). A 250 psi backpressure 
regulator was applied to the system. The exiting solution was collected, the solvent was evaporated 
under reduced pressure to yield 3 as a crude oil, which was analyzed by 
1
H NMR spectroscopy. 
Yield=50%; [α]20D= - 5.63 (c=2.0, CH2Cl2); 
1H NMR (300 MHz, CDCl3): δ= 1.42 (d, 3H), 3.20–
3.31 (m, 1H), 3.66–3.80 ppm (m, 2H). 
 
Synthesis of (S)-1-[(S)-3-Chloro-2-methylpropanoyl] pyrrolidine-2-carboxylic Acid (4) 
 
Batch procedure
49 
Compound 3 (350 mg, 2.48 mmol) was added in one portion to a cold solution of L-proline (285.5 
mg, 2.48 mmol) in 2N NaOH (2.5 mL) at 0 °C, and the resulting mixture was stirring at the same 
temperature for 1h, then allowed to room temperature for another hour. A TLC was made to follow 
the reaction (95:5 DCM/MeOH + 4 drops of acetic acid; Rf of 4 = 0.43). The reaction mixture was 
adjusted to pH 1 with HCl 6N, extracted with ethyl acetate (3 times) and dried over anhydrous 
Na2SO4. The solvent was reduced under vacuum at 40 °C and a chromatographic column was made 
in order to yield compound 4 as a crude solid (99:1 DCM/MeOH). Yield= 50%; [α]20D = -103.6 
(c=1 in EtOH); 
1
H NMR (300 MHz, CDCl3): δ=1.24 (d, 3H, J=7.0), 2.02–2.18 (m, 4H), 2.96–3.08 
(m, 1H), 3.44–3.51 (m, 1H), 3.57–3.72 (m, 2H), 3.81 (t, 1H, J=10.4), 4.62–4.69 (m, 1H), 11.30 (br 
s, 1H); 
13
C NMR (75 MHz, CDCl3): δ=15.8, 24.9, 27.7, 41.3, 45.8, 47.7, 59.6, 173, 175 ppm; MS 
(ESI): m/z: 217.9 [M–H]-; elemental analysis calcd (%) for C9H14ClNO3: C 49.21, H 6.42, N 6.38; 
found: C 49.00, H 6.31, N 6.50.  
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Flow procedure 
A solution of compound 3 (70 mg, 0.5 mmol) in toluene (0.5 mL) was prepared. A second solution 
of L-proline (115 mg, 2 equiv) and NaOH (60 mg, 3 equiv) was prepared in water (0.5 mL). The 
two solutions were flowed at a total rate of 2 mLmin
-1
 through a 2 mL reactor coil, that had been 
washed with a mixture of toluene and water, at room temperature. The aqueous phase was acidified 
to pH 2 by introducing a flow of HCl (6N, 1 mLmin
-1
) and the resulting biphasic system was mixed 
using a T-junction into an ethyl acetate stream (1 mLmin
-1
) to perform in-line extraction. The two 
phases were separated in-line using a Zaiput liquid–liquid separator. A 250 psi backpressure was 
applied to the system. The organic solvent was dried over anhydrous Na2SO4 and evaporated under 
reduced pressure to yield 4 as a crude solid, which was analyzed by 
1
H NMR spectroscopy. 
Reactions were followed with TCL (95:5 DCM/MeOH + 4 drops of acetic acid; Rf of 4 = 0.43) 
Yield=80% [α]20D = -103.6 (c=1 in EtOH); 
1
H NMR (300 MHz, CDCl3): δ=1.24 (d, 3H, J=7.0), 
2.02–2.18 (m, 4H), 2.96–3.08 (m, 1H), 3.44–3.51 (m, 1H), 3.57–3.72 (m, 2H), 3.81 (t, 1H, J=10.4), 
4.62–4.69 (m, 1H), 11.30 (br s, 1H); 13C NMR (75 MHz, CDCl3): δ=15.8, 24.9, 27.7, 41.3, 45.8, 
47.7, 59.6, 173, 175 ppm; MS (ESI): m/z: 217.9 [M–H]-; elemental analysis calcd (%) for 
C9H14ClNO3: C 49.21, H 6.42, N 6.38; found: C 49.00, H 6.31, N 6.50. 
 
Synthesis of (S)-1-[(S)-3-Chloro-2-methylpropanoyl] pyrrolidine-2-carboxylic Acid (Captopril, 5) 
 
Batch procedure
49
 
A mixture of 4 (130 mg, 0.59 mmol) and NaHS (134 mg, 1.77 mmol) in DMF (1.2 mL) was stirred 
for 4 h at 50 °C under nitrogen. The reaction was followed by TLC (9:1 DCM/MeOH + 4 drops of 
acetic acid, Rf of 5 = 0.69). The reaction was then cooled and acidified with HCl 6N until pH 1 and 
the desired product was then extracted with ethyl acetate (3 times). The organic phase was then 
dried over anhydrous Na2SO4 and evaporated under vacuum at 40 °C. After a chromatographic 
column (98:2 DCM/MeOH), compound 5 was obtained as a white solid with a yield of 40%. [α]20D 
= -128.5 (c=1 in EtOH); lit= - 129.4 (c=1.35 in EtOH at 22 °C)
[12]
 
1
H NMR (300 MHz, CDCl3): 
δ=1.24 (d, J=7.0 Hz, 3H), 1.58 (t, J=9.2 Hz, 1H), 2.02–2.18 (m, 4H), 2.43–2.51 (m, 1H), 2.79–2.90 
(m, 2H), 3.55–3.71 (m, 2H), 4.62–4.69 (m, 1H), 11.30 ppm (br s, 1H); 13C NMR (75 MHz, CDCl3): 
δ=17.0, 20.8, 24.7, 27.4, 42.5, 47.4, 59.2, 173.0, 175.0 ppm; MS (ESI): m/z: 215.9 [M–H]-; 
elemental analysis calcd (%) for C9H15NO3S: C 49.75, H 6.96, N 6.45; found: C 49.60, H 6.89, N 
6.52. 
 
Flow procedure 
A solution of compound 4 (22 mg, 0.1 mmol) in toluene (0.1 mL) was prepared. A second solution 
of NaSH (21 mg, 3 equiv) was prepared using degassed water (0.1 mL). The two solutions were 
flowed through a 10 mL reactor coil. A 250 psi backpressure was applied to the system. Reaction 
time and temperature were optimized, as reported in Table A. Reactions were followed by TLC (9:1 
DCM/MeOH + 4 drops of acetic acid, Rf of 5 = 0.69). The aqueous phase was acidified at pH 2 by 
introducing a flow of HCl (2N) and the resulting biphasic system was mixed using a T-junction into 
an EtOAc stream to perform in-line extraction. The two phases were separated in-line using a 
Zaiput liquid–liquid separator. The organic solvent was dried over anhydrous Na2SO4 and 
evaporated under reduced pressure. After a chromatographic column (98:2 DCM/MeOH), 5 was 
obtained as a white solid, which was analyzed by 
1H NMR spectroscopy. Yield=80%; [α]20D = -
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128.5 (c=1 in EtOH); lit= - 129.4 (c=1.35 in EtOH at 22 °C)
[12]
 
1
H NMR (300 MHz, CDCl3): 
δ=1.24 (d, J=7.0 Hz, 3H), 1.58 (t, J=9.2 Hz, 1H), 2.02–2.18 (m, 4H), 2.43–2.51 (m, 1H), 2.79–2.90 
(m, 2H), 3.55–3.71 (m, 2H), 4.62–4.69 (m, 1H), 11.30 ppm (br s, 1H); 13C NMR (75 MHz, CDCl3): 
δ=17.0, 20.8, 24.7, 27.4, 42.5, 47.4, 59.2, 173.0, 175.0 ppm; MS (ESI): m/z: 215.9 [M–H]-; 
elemental analysis calcd (%) for C9H15NO3S: C 49.75, H 6.96, N 6.45; found: C 49.60, H 6.89, N 
6.52. 
 
Three-Step Continuous-Flow Synthesis of Captopril (5) 
 
A solution of 2 (156 mg, 1.5 mmol) in anhydrous toluene (1.23 mL) was prepared. Imidazole (10.5 
mg, 0.1 equiv) and DMF (150 mL) were added to the solution. A second solution of thionyl 
chloride (375 mL, 3.5 equiv) was prepared using anhydrous toluene (1.12 mL). The two solutions 
were flowed through a 10 mL coil reactor that was maintained at 110 °C, with a residence time of 
30 min (total flow rate 0.33 mLmin
-1
). Then, the exiting flow was merged at a T-junction with an 
aqueous solution (1.5 mL) of L-proline (2 equiv) and NaOH (7 equiv). This then entered a 2 mL 
reactor coil, maintained at room temperature with a residence time of 3 min (total flow rate 0.66 
mLmin
-1
). The aqueous phase was acidified to pH 2 by adding a flow stream of HCl (6N, 0.33 
mLmin
-1
) and the resulting biphasic system was mixed using a T-junction into an EtOAc stream 
(0.33 mLmin
-1
) to perform an in-line extraction. The two phases were separated in-line using a 
Zaiput liquid–liquid separator. The organic phase was collected in a vial acting as a substrate 
reservoir for the final nucleophilic substitution reaction. The organic phase was pumped and mixed 
with a solution of NaSH (c=1.5 M, 3 equiv) in degassed water, and entered a 10 mL coil reactor 
maintained at 125 °C for 30 min (total flow rate 0.66 mLmin
-1
). A 250 psi backpressure was added 
to the whole system. The exiting flow was then acidified to pH 1 with HCl (2N) and a continuous 
extraction with the Zaiput liquid–liquid separator was performed. The organic solvent was dried 
over anhydrous Na2SO4 and evaporated under reduced pressure to yield a crude material that was 
purified by column chromatography (dichloromethane/methanol 98:2) to yield Captopril, which 
was crystallized from ethyl acetate/hexane (1:1, total volume 1 mL; 160 mg, 50%). 
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Introduction 
 
The use of alcohol dehydrogenases (ADH, named also ketoreductases  -KREDs - or carbonyl 
reductases -CR- ) is a well established method for the enantioselective reduction of prochiral 
ketones into stereo-defined chiral alcohols.
57
 Reduction of aromatic ketones has been studied with 
different reductases, with particular focus on the reduction of sterically hindered (bulky) substrates, 
not easily recognized by most of the available KREDs
58
. Commercially available or engineered 
KREDs can reduce structurally different ketones and their use has been also scaled-up to industrial 
processes
59
. Other alcohol dehydrogenases, such as the ones from Rhodococcus ruber (ADH-A
60
), 
Ralstonia sp. (RasADH
58
), and Lactobacillus brevis (LBADH
61
) have been identified as suitable 
biocatalysts for the reduction of different aromatic bulky substrates. Steric effects of the substrates 
on the activity of LBADH towards aromatic ketones (acetophenone derivatives) were accurately 
studied. In most cases, a tendency for higher activity with smaller substrates could be detected, but 
noticeable deviations from this general trend were observed due to stereoelectronic effects
62
. Whole 
cells of the non-conventional yeast Ogataea glucozyma CBS 5766 have been used for the reductive 
biotransformation of various aromatic ketones and ketoesters (including bulky ones), often showing 
interesting stereoselectivity
63
. The reduction of these substrates frequently occurred with activity 
and enantioselectivity strongly dependent on the conditions of growth and biotransformation, 
suggesting the possible occurrence of different ketoreductases acting on aromatic ketones
64
.  
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Results and discussion 
 
The aim of this project was to develop a biocatalytic flow system in order to reduce in a regio- and 
stereo-selective way ketones and di-ketones, to obtain the corresponding mono-alcohols. To achieve 
this aim, we used a combination of two purified enzymes, the ketoreductase1 from Pichia 
glucozyma and a glucose dehydrogenase from Bacillus megaterium (Scheme 1).  
 
 
Scheme 1. Schematic representation of the reaction mechanism 
 
As it is possible to see in Scheme 1, the enzyme which performs the reductive reaction from ketone 
to alcohol is the ketoreductase KRED1-Pglu, that is able to use only NADPH as cofactor. The 
NADPH regeneration, which allows to use catalytic amounts of cofactor, is assured by a second 
enzyme, glucose dehydrogenase, which oxidize the co-substrate glucose to gluconic acid and 
NADPH. 
This system as free biocatalysts was previously used in the group of Dr. Diego Romano on aromatic 
ketones
64
. Good results were achieved obtaining  mono-alcohols in a stereoselective way. On the 
basis of this preliminary good results, the enzymes were immobilized, in order to exploit them in a 
packed bed reactor, always in collaboration with the group of Dr. Diego Romano, at the University 
of Milan. This strategy could lead to some advantages, for example higher and longer stability of 
the biocatalysts, re-usability (with consequent less waste), higher enzyme-substrate ratio. 
Ketoreductase from Pichia glucozyma (KRED1-Pglu) and glucose dehydrogenase from Bacillus 
megaterium (BmGDH) were prepared as previously reported
64
.  
Different supports were taken into account for the immobilization of the enzymes. The enzymes 
were immobilized separately. The first support tried was the commercially available epoxy-
activated Relizyme 403/S. Although KRED1-Pglu was completely bound to the support, the 
resulting biocatalyst was poorly active (4% of recovered activity). Moreover, on the same support 
only 2% of the offered BmGDH was bound to the matrix. The second support we tried was 
aldehyde activated agarose, that is a suitable support for the immobilization/stabilization of several 
enzymes
65
. Immobilization on aldehyde agarose relies on the reaction between not protonated ε-
amino groups of surface lysines and aldehyde groups on the support. Since alkaline conditions (pH 
≥ 10) are required to ensure that the ε-amino groups are not protonated, stability studies of both 
soluble enzymes were carried out at this pH. BmGDH lost more than 50% of the initial activity after 
1 h of incubation at pH 10.0 both at 25 °C and 4 °C. The addition of stabilizing agents (glycerol or 
PEG600) allowed to maintain 100% and 70% of the initial activity after 3 h of incubation at pH 10. 
For what concerns KRED1-Pglu, it retained 100% of its initial activity over 3 h at pH 10.0 under all 
the conditions tested (25 °C or 4 °C with 20% glycerol as additive). On the basis of these stability 
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tests, different conditions were tried for the immobilization, changing loading, temperature and the 
presence of additive:  
 For KRED1-Pglu, the best results were obtained at 4 °C without additives and they were 
independent from the protein loading; 
 For BmGDH an addition of 20% of glycerol allowed to retain 32% and 28% of activity upon 
immobilization at 25 °C, while the addition of PEG600 was not beneficial to the 
immobilization outcome. 
 
In order to understand if, in this case, there was, through immobilization, an increase of the stability 
of the enzymes, I decided to compare the stability between free and immobilized enzymes in the 
presence of DMSO, which is an organic solvent (water miscible) widely used to solubilize 
hydrophobic substrates. Immobilization remarkably improved the enzymatic stability towards 
DMSO: 60–65% residual activity was found for immobilized KRED1-Pglu after 24 h in the 
presence of 5–20% DMSO, and only 4–6% of the original activity was lost in the case of 
immobilized BmGDH. It should be noted that both the free enzymes were mostly inactivated after 6 
h even at the lowest DMSO concentration. 
Next step was to try the immobilized enzymes in batch reactions. A homogenous agarose gel 
system was obtained by mixing the two immobilized enzymes together (1/50 KRED1-
Pglu/BmGDH), and the system shown in Scheme 1 was employed for the co-factor regeneration 
system, adding NADP
+
 (0.1 mM) and glucose (4 eq x eq of substrate). 4-nitroacetophenone 1 was 
used as a “model” substrate, which was reduced to the corresponding (S)-1-(4-nitrophenyl) ethanol 
(2) (Scheme 2). 
 
 
 
Scheme 2. Schematic representation of the “model” reaction 
 
The system, maintained at 30 °C, was able to convert 1a (3.0 mM) with a conversion between 78-
83% depending on the amount of DMSO used (from 4 to 8%). The enantiomeric excess of 1b was 
always >98%. With free enzymes, the conversions were sluggish with DMSO > 4%. The re-
usability of the immobilized system was investigated in a sequence of reaction cycles performed in 
the presence of 5% DMSO, where the biocatalysts were recovered by filtration after every cycle and 
used for a new batch reaction (Figure 2).  
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Figure 2. Assay of the immobilized KRED1-Pglu/BmGDH system in repeated-batch reductions of 
1a. After each reaction cycle (24 h), the biocatalyst was filtered from the reaction medium, washed 
with fresh buffer and used for a new reaction cycle. 
 
The immobilized biocatalysts lost 20% of the original activity after one cycle and were totally 
inactive after 4 reaction cycles. 
 
I then transferred the same reaction in flow (Scheme 3): 
 
 
 
 
 
 
Scheme 3. Schematic representation of the flow configuration. 
 
One HPLC pump pumped a 3.0 mM solution of compound 1a, containing NADP
+
 (0.1 mM) and 
glucose (4 eq x eq of substrate), in TRIS HCl buffer pH 8.0 (50 mM) through a column (i.d.: 6.6 
mm) packed with the two immobilized enzymes. To this solution I added 5% of DMSO. The 
column was maintained at 30 °C during the reaction. Different ratios between the enzymes and 
residence times were tried in order to obtain the product 1b. The ee was always > 97%.  
 
In Figure 3 are summarized the results of these tests: 
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Figure 3. Summary of the results obtained by changing residence times and enzymatic ratio. 
 
As it is possible to see from the graphic above, three enzymatic ratios (1/10; 1/25; 1/50) were tried 
with different residence times (80 min; 120 min; 180 min; 220 min). All the ratios are KRED1-
Pglu/BmGDH, which means that the ketoreductase was always lower (in terms of mUnits used) 
than the glucodehydrogenase. From the graphic is possible to see that the best results were obtained 
with the ratio 1/25, and this is true for all the residence times tried. With this ratio, a total 
conversion was achieved with a residence time of 220 min and 180 min, while a 90% and an 80% 
of conversion were achieved with 120 min and 80 min, respectively. 
I then studied the stability of the column. I wanted to evaluate if in flow was possible to further 
increase the stability observed with the immobilized enzymes. The Figure 4 here below shows the 
results: 
 
Figure 4. Representation of the stability of the column under 15 days of continuous work. 
 
The column was tested for 15 days under continuous work, flowing through it a 3.0 mM solution of 
compound 1a, with the best condition found (ratio 1/25 and 180 min of residence time). As it is 
possible to see from the graphic, the conversion was constant for 15 days, and the ee of the product 
always remained > 97%. Noteworthy, after 6 months of operation in flow, the reactor only lost 30-
32% of the original activity. The different operational stability shown by the immobilized system in 
the flow reactor and in shaken flasks may be due to the reduced mechanical stress under flow 
conditions. It should be underlined that biotransformations with immobilized enzymes are multi-
phase systems needing continuous agitation in conventional batch reactors; agitation (orbital 
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shaking in our case) can damage or grind the biocatalyst to fine particles. This is an evidence of one 
of the advantages of running biotransformations in a flow reactor. 
The same system was then applied on other three substrates, which were different from 1a since 
they are di-ketones. Indeed, it was nice to see the behavior of the system when two possible ketones 
were present in the molecule. The selected substrates were the following (Figure 5): 
 
 
Figure 5. Di-ketones used and their products. 
 
The reactions were first conducted in batch under the optimized conditions described above for 
compound 1a, using the same co-factor regeneration system. Therefore, a solution of the substrate 
(2a-4a) at different concentrations was prepared in buffer TRIS HCl 50 mM pH 8.0 and 5% DMSO. 
KRED1-Pglu (20 mU/mL) and BmGDH (1U/mL) were added to the solution, with NADP
+
 (0.1 
mM) and glucose (4 eq x eq of substrate). The system was maintained at 30 °C. Here below a table 
is reported with the batch results (Table 1): 
 
Entry Substrate Concentration 
(mM) 
t (min) Conversion 
(%) 
ee (%) 
1 2a 3.0 60 >95% >97% 
2 3a 3.0 1440 60% >97% 
3 4a 6.5 480 65% >97% 
 
Table 1. Reaction conditions and conversions of batch biotransformations with immobilized 
KRED1-Pglu. 
 
Starting from these results, I transferred the reactions in flow (Scheme 4). For all the substrates, a 
solution of the substrate (2a-4a) at different concentrations in buffer TRIS HCl 50 mM pH 8.0 and 
at different percentages of DMSO was prepared. NADP
+
 (0.1 mM) and glucose (4 eq x eq of 
substrate) were added to the solution. This was pumped by one HPLC pump and entered an Omnifit 
glass column packed with the immobilized enzymes (KRED1-Pglu and BmGDH), with the ratio 
found before for compound 1a, which is 1/25 respectively. The exiting flow stream was then 
analyzed by chiral HPLC. 
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Scheme 4. Schematic representation of the flow system used for the reduction of substrates 2a-4a. 
 
The results are summarized below: 
 1-Phenylpropane-1,2-dione (2a): I decided to perform this reaction with the same 
concentration used in batch, but, in order to completely solubilize the substrate, 10% of 
DMSO was necessary. Remarkably, even if a much higher amount of DMSO was employed, 
the enzymes were able to work very well in the same way. I investigated different reaction 
times: I started with 120 minutes of residence time, and, once I noticed that the reaction was 
complete after this time, I decreased it. I finally stopped at 7 minutes, which was the lowest 
residence time that gave a total conversion of enantiomerically pure product 2b; 
 1-Phenylbutane-1,3-dione (3a): even for this compound I decided to run the reaction with 
the same concentration used in batch (3 mM), but to do so it was necessary to add 10% of 
DMSO in order to completely solubilize the substrate. Again, I investigated different 
residence times in order to find the lowest reaction time with the maximum conversion. In 
this case, a full conversion was achieved in 120 minutes. Product 3b was obtain with a ee 
>97%; 
 ethyl secodione (4a): this substrate is a key intermediate in the synthesis of different 
hormonal contraceptives
66
. Using the same concentration as in batch (8.0 mM), even adding 
DMSO up to 20%, it was not possible to obtain a clear solution. So, I decreased to 3.0 mM 
the concentration of compound 4a. Concentrations between 3.0 mM and 8.0 mM were tried 
with percentages > 20% of DMSO, but the enzymes resulted to be less active and stable. I 
tried different residence times: the lowest residence time which led to the highest conversion 
(65%) was 180 min. An increase in the residence time was no productive. A similar 
conversion was achieved in batch after 480 minutes with free enzymes. Interesting, in this 
case just one enantiomer among the four possible isomers was formed with an ee > 97%. 
The diastereoisomeric composition (% de) was determined by HPLC using a Phenomenex 
LUX Cellulose-2 (n-hexane/i-PrOH 85:15; 0.5 mL/min 254 nm): rt (13S, 17S) 18.9 min, 
(13S, 17R) 20.6 min, (13R, 17S) 23.3 min, (13R, 17R) 24.6 min. In the previous article 
published by us
66
, the absolute configurations of the different possible isomers were 
assigned using Mosher’s methodology. 
For all the substrates, the bioreactor was tested under continuous work for 15 days, at the optimized 
conditions. 
 
A summarizing table is reported below (Table 2): 
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Entry Subst. DMSO 
(%) 
tr 
(min) 
Conversion 
day 1 (%) 
Conversion 
day 15 (%) 
Space 
time 
yield 
(mg·d
-1
) 
Catalyst 
productivity 
(mmol·U
-1
) 
Product 
recovered 
(mg) 
1 2a 10 7 >98 97 81.5 150.1 1199 
2 3a 10 120 96 94 5.0 8.4 67 
3 4a 20 180 65 63 4.4 3.8 60 
 
Table 2. Table reporting the conversions of substrates (2a-4a) under optimized conditions, as 
concentration, % of DMSO, residence time. Conversions after 1 and 15 days of continuous work are 
reported. Space time yield, catalyst productivity and product recovery were calculated for all three 
cases.  
 
As it is possible to see from the table above, after 15 days of continuous work with the same 
bioreactor, no significant changes in the composition of the flow outcome were detected. The 
conversions in all cases after 15 days remained the same even if a 10% or a 20% of DMSO was 
used. This is a very important point because underlines the advantages of flow chemistry, as for 
example the higher stability of the immobilized biocatalyst probably due to the absence of 
mechanical stress. Enzymes were washed before and after each reaction with pure buffer TRIS HCl 
50 mM pH 8.0, in order to remove any trace of DMSO and of the other component of reaction 
solution. The stability of the biocatalysts under these conditions enabled the obtainment of 
millimolar amounts of the desired products in a 0.90 mL reactor, using the same amount of enzyme 
that produced only micromolar quantities in batch reactions.  
I also calculated the space-time yield and the catalyst productivity. The space-time yield allows to 
understand the reactor productivity of a reaction. It is calculated knowing the amount of product 
that is formed during a certain time (mg d
-1
). This value is normalized for the reactor volume and 
for the amount of biocatalyst used during the reaction. As reported in Table 2, the best productivity 
was achieved in the case of substrate 2a (entry 1), because a very short residence time (7 minutes) 
allowed to reach total conversion. For compound 3a (entry 2), a residence time of 120 minutes was 
necessary to obtain its complete conversion. Comparing to the batch procedure, the reaction time 
was lower (in batch was 24 h) and higher conversion was achieved (100% vs 60%) using the same 
substrate concentration. Concerning compound 4a (entry 3), the main problem was the very low 
water solubility that makes me to reduce the concentration in comparison to the batch procedure 
(3.0 mM vs 8.0 mM). The flow reaction proceeded with a similar degree of conversion compared to 
batch with a slightly decrease of the reaction time, from 480 min in batch to 180 min in flow. 
 
Conclusions 
 
In conclusion, an immobilized system composed of a ketoreductase (KRED1-Pglu) and a glucose 
dehydrogenase (BmGDH) was successfully used to perform the continuous stereoselective 
reduction of ketones in a flow reactor for weeks; the prolonged operational stability in the flow 
reactor makes the set-up of the biotransformation attractive for preparative (bio)catalysis. 
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Materials and methods 
 
General 
 
All reagents and solvents were obtained from Sigma-Aldrich-Fluka and used without further 
purification or drying. TLC was performed with Merck silica gel 60 F254 pre-coated plates. 
1
H-
NMR and 
13
C-NMR spectra were recorded with a Varian Mercury 300 (300 MHz) spectrometer. 
Chemical shifts (δ) are expressed in ppm, and coupling constants (J) are expressed in Hz. HPLC 
analyses were performed with a Jasco Pu-980 equipped with a UV-vis detector Jasco UV-975. 
Chiral HPLC columns used: Lux cellulose-3 column (4.6 mm x 150 mm, Phenomenex), Lux 
cellulose-2 column (4.6 mm x 150 mm, Phenomenex), Chiralcel OD-H (250 mm x 4mm, Daicel), 
Chiralcel OD (250 mm x 4mm, Daicel). The continuous flow biotransformations were performed 
using a R2 +/R4 flow reactor commercially available from Vapourtec and equipped with Omnifit 
glass columns (6.6 mm x 100 mm length). 
 
Enzyme immobilization and preparation of the mixed bed system 
Aldehyde agarose (1 g), prepared as previously described
63
, was suspended in 50 mM potassium 
carbonate buffer at pH 10.0. After the addition of the desired amount of protein, the solution (14 
mL) was kept under mechanical stirring for 3 h; 14 mg of NaBH4 (1 mg/mL of suspension) were 
then added. The reduction time was 30 minutes. Finally, the immobilized enzyme was filtered and 
washed with 10 mM potassium phosphate buffer pH 5 and deionized water. Different amounts of 
the two immobilized enzymes were mixed together to form a homogeneous slurry of immobilized 
KRED1-Pglu/BmGDH with different ratios (1/10, 1/25, 1/50). 
 
General procedure for batch biotransformations 
Reactions were carried in 2 mL volume of 50 mM Tris HCl buffer pH 8.0 containing NADP
+
 (0.1 
mM), substrate (0.5 g/L), glucose (4 eq × eq of substrate) at 30 °C. The reaction was started by the 
addition of KRED1-Pglu and BmGDH, maintained under orbital shaking (180 rpm), and was 
monitored by HPLC. 
 
General procedure for flow biotransformations 
Solutions of the substrates at different concentrations were prepared in Tris HCl buffer pH 8.0 
(50mM) with DMSO (variable percentages depending on the substrate, for details see Table 2), 0.1 
mM NADP
+
 and glucose (4 eq × eq of substrate). An Omnifit glass column (6.6 mm i.d. × 100 mm) 
was packed with pre-mixed KRED1-Pglu (540 mg) and BmGDH (540 mg), in order to obtain a 
KRED1-Pglu/BmGDH ratio of 1/25. The volume of the reactor was 0.90 mL. The packed column 
was pre-washed by flowing through it a solution of Tris HCl buffer pH 8.0 (0.050 mL/min for 15 
min) followed by a solution of Tris HCl buffer pH 8.0 with DMSO (0.050 mL/min for 15 min). 
Then, the substrate solution was pumped through the column maintained at 30 °C. The exiting 
solution was collected and analyzed at different times. 
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Product characterization (2a-2d) 
 
(S)-(1-(4-nitrophenyl) ethanol), 2a: 
1
H-NMR (300 MHz, CDCl3): δ 8.18 (d, J = 8.5 Hz, 2H), 7.51 
(d, J = 8.0 Hz, 2H,), 4.95 (q, J = 6.5 Hz, 1H), 1.50 (d, J = 6.5 Hz, 3H) ppm. 
13
C-NMR (75 MHz, 
CDCl3): δ 153.1, 147.1, 126.1, 123.7, 69.4, 25.4 ppm. Conversion was determined by HPLC using a 
Purosphere RP-18e STAR column (Merck) 250 mm x 4.6 mm, 5 µm (H2O/CH3CN 25:75, 1 
mL/min; T= 25 °C; 254 nm): rt: 1a 4-nitroacetophenone, 4.14 min; 2a (S)-(1-(4-nitrophenyl) 
ethanol), 3.42 min. The enantiomeric excess of 2a (% ee) was determined by HPLC using a 
Phenomenex LUX Cellulose-3 column (n-hexane/i-PrOH 90:10, 0.5 mL/min, 254 nm): rt (S)-1-(4-
nitrophenyl) ethanol 23.4 min, rt (R)-1-(4-nitrophenyl) ethanol 24.9 min. 
 
(S)-2-Hydroxy-1-phenylpropan-1-one, 2b: 
1
H-NMR (300 MHz, CDCl3) δ 7.87 (d, J = 8.2 Hz, 
2H), 7.57 (t, J = 7.42 Hz, 1H), 7.46 (t, J = 7.7 Hz, 2H), 5.17 (m, 1H), 3.5 (br s, 1H, OH), 1.45 (d, 
J = 7.0 Hz, 3H) ppm. 13C-NMR (75 MHz, CDCl3) δ 202.3, 133.9, 133.4, 128.7, 128.6, 69.3, 22.2. 
The enantiomeric excess (% ee) of 2b was determined by HPLC using a Chiralcel OD column (n-
hexane/i-PrOH 95:5, 0.4 mL/min, 254 nm): rt (R)-2-hydroxy-1-phenylpropan-1-one 17.2 min, rt 
(S)-2-hydroxy-1-phenylpropan-1-one 21.9 min. 
 
S)-3-Hydroxy-1-phenyl-butan-1-one, 2c: 
1
H-NMR (300 MHz, CDCl3) δ 7.97 (dd, J = 8.5, 2.0 Hz, 
2H), 7.50 (m, 3H), 4.42 (m, 1H), 3.24 (br s, 1H, OH), 3.10 (d, J = 6.0 Hz, 2H) 1.30 (d, J = 6.4 Hz, 
3H) ppm. 
13
C-NMR (75 MHz, CDCl3) δ 200.95, 136.8, 133.6, 128.8, 128.1, 64.1, 46.5, 22.5 ppm. 
The enantiomeric excess (% ee) of 2c was determined by HPLC using Chiralcel OD-H column (n-
hexane/i-PrOH 95:5, 0.8 mL/min, 254 nm): rt (R)-3-hydroxy-1-phenyl-butan-1-one 12.1 min, rt (S)-
3-hydroxy-1-phenyl-butan-1-one 13.6 min. 
 
(13R,17S)-E-13-ethyl-3-methoxy-8,14-secogona-1,3,5(10),9(11)-tetraene-17-ol-14-one, 2d: 
1
H 
NMR (300 MHz, C3D6O): δ 7.46 (d, J = 8.7 Hz, 1H), 6.72 (dd, J= 2.8, 8.7 Hz, 1H), 6.65 (d, J = 2.8 
Hz, 1H), 5.86 (t, J = 7.5 Hz, 1H), 4.32 (q, J = 5.5 Hz, 1H), 4.05 (d, J = 4.4 Hz, 1H; OH ), 3.77 (s, 
3H), 2.73 (t, J = 6.2 Hz, 2H), 2.49 (t, J = 5.6 Hz, 2H), 2.13-2.40 (m, 5H), 1.88-1.97 (m, 1H), 1.78 
(qui, J = 6.3 Hz, 2H), 1.63-1.73 (m, 2H),  0.91 (t, J = 7.5 Hz, 3H) ppm. 
13
C NMR (300 MHz, 
C3D6O): δ 218.8, 159.0, 138.7, 135.9, 129.3, 125.2, 117.1, 113.2, 112.7, 75.2, 56.6, 54.8, 35.0, 30.7, 
30.5, 27.9, 26.7, 23.4, 21.6, 8.0 ppm. The diastereoisomeric composition (% de) was determined by 
HPLC using a Phenomenex LUX Cellulose-2 (n-hexane/i-PrOH 85:15; 0.5 mL/min 254 nm): rt 
(13S, 17S) 18.9 min, (13S, 17R) 20.6 min, (13R, 17S) 23.3 min, (13R, 17R) 24.6 min. 
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Biocatalyzed stereo- and regioselective reduction of 2,2-
disubstituted-1,3-cyclopenta- and 1,3-cyclohexanediones 
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Introduction 
 
Steroids are biologically active compounds characterized by a fixed structure. This structure is 
formed by four rings arranged in a typical molecular configuration, which represents the core of the 
structure (called cyclopentaperhydrophenanthrene or gonane). This is made by seventeen carbons 
that create three cyclohexane rings (A, B and C rings, Figure 1) and one cyclopentane ring (D ring, 
Figure 1). 
 
 
 
 
 
 
 
 
Figure 1. 5-Alpha gonane, core of the steroidal structure. 
 
If a chain made by eight carbons is present at C17 and two methyl groups are in C10 and C18 
positions, the steroid has a cholestane framework (Figure 2). 
 
 
 
 
 
 
 
 
 
Figure 2. Cholestane structure. 
 
A well known compound that has a cholestane structure is cholesterol: this is the precursor of two 
different classes of molecules, which are corticosteroids and sex steroids. These two groups have 
different applications and properties. 
Corticosteroids can be divided into two classes: glucocorticoids and mineralcorticoids. The former 
group controls the metabolism of lipids, carbohydrates and proteins. They can also have anti-
inflammatory properties. On the other hand, the latter group is important for the regulation of blood 
pressure. A general structure of corticosteroids is represented by 5-alpha pregnane reported in 
Figure 3. 
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Figure 3. 5-alpha pregnane: representative structure of corticosteroids. 
 
For what concerns sex steroids, they can be female (progesterone and estrogens) or male 
(androgens). The representative structure of progesterone is again 5-alpha pregnane (Figure 3), 
whereas androgens have as principal structure 5-alpha-androstane (Figure 4) and estrogens has 5-
alpha estrange structure (Figure 5). 
 
 
 
 
 
 
 
 
  
 
The steroids mentioned above are all hormones. They are able to explicit their pharmacological 
action even if they have a very low concentration in the blood. Because of their lipophilic nature, 
they can reach the target cells through protein carriers. Once inside cells, steroids go into nucleus 
and activate receptors that interact with DNA in particular regions called Hormone Response 
Element (HRE). 
 
The manufactured steroid compounds have a wide range of therapeutic purposes; in fact, they have 
been used:  
 as anti-inﬂammatory, immunosuppressive, progestational, diuretic, anabolic and 
contraceptive agents; 
 as anti-fungal agents;  
 as inhibitors of HIV integrase, in the prevention and treatment of infections by HIV and in 
the treatment of declared AIDS cases; 
 in the prevention of coronary heart diseases and as replacement agents in the treatment of 
adrenal insufﬁciencies; 
 as active ingredients in anti-obesity agents; 
 in the treatment of some forms of breast and prostate cancer and osteoporosis67.  
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Steroids synthesis: chemical and biochemical processes 
 
Steroid molecules, because of their complex structure and the precise stereochemistry, require 
complicated and multi-step schemes for the chemical synthesis. The synthesis often involves the 
preparation of intermediate derivatives with protected groups and their subsequent regeneration, 
once the intended reaction has occurred, limiting the overall process yield and making it expensive 
and time consuming. Furthermore, the core structure (basic ring) of some steroid derivatives is 
sensitive to cleavage by a wide variety of chemicals. 
Chemical synthesis also requires the use of some highly-reactive reagents which are hazardous to 
researcher’s health and constitute a serious environmental disposal problem. 
Indeed, biocatalyzed steroid syntheses are performed under mild temperature and pressure 
conditions and can provide an efﬁcient alternative to chemical synthesis, once the limitations often 
encountered of unsatisfactory productivity and/or purity levels of the products are overcome. 
The research efforts in this ﬁeld were triggered around 1950, with the announcement of the 
pharmacological effects of cortisol and progesterone and with the identiﬁcation of the 11-alpha-
hydroxylation activity of a Rhizopus species, a decisive step in the development of the practical 
synthesis of steroids with useful biological activity. Several microbial bioconversions of steroids 
have been reported until now, mainly focusing on steroid hydroxylations, delta-1-dehydrogenation 
and sterol side-chain cleavage. It is important to underline that these modified steroids are currently 
favoured when compared to their natural counterparts due to some therapeutic advantages, such as 
an increased potency, longer half-lives in the blood stream, simpler delivery methods and reduced 
side effects
67
.
 
In Scheme 1, a general view of both chemical and biocatalyzed approaches for the 
synthesis of steroids is showed. 
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Scheme 1. An overview of steroid production, from raw materials to completed products. Full lines 
indicate bioconversions whereas dashed lines indicate chemical transformations.
67
 
Hydroxylated steroids 
 
Hydroxylations are probably the most applied type of steroids functionalization. Compared with 
their less polar non-hydroxylated analogues, steroids with hydroxyl group often show a better 
biological activity, which is convenient for therapeutic applications. Over 1500 species (e.g., 
Mycobacterium, Streptomyces, Aspergillus) have been studied for this specific application.      
11-Alpha-, 11-beta-, 15-alpha and 16-alpha-hydroxylations are currently validated processes in 
steroid industry, mainly for the production of adrenal cortex hormones and their analogues. 16-
Alpha-hydroxylated steroids have increased glucocorticoid activity, in which the oxygen group in 
position C11 is regarded as essential for anti-inﬂammatory action. 11-Alpha-hydroxylation is also 
used in the production of an intermediate in the synthesis of a contraceptive drug (i.e., 
Desogestrel)
67
.  
An example of the utility of hydroxylated steroids was given by Jean-Francois Biellmann who 
studied about enantiomerically pure steroids
68
: he confirmed the fact that the steroid biological 
activity is in general restricted to one enantiomer. Thus, he mentioned some examples, one of them 
was RU-486 (A, Scheme 2): the synthesis of the corresponding enantiomer of RU-486 (B) starts 
from the reduction of diketone (C) to enantiomerically pure hydroxyketone (D).  
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Scheme 2. Reduction of diketone (C) to hydroxyketone (D) to obtain A.
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Results and discussion 
 
The aim of the project was to regio- and stereo-selective reduce different 2,2-disubstituted-1,3-
cyclopentanediones and cyclohexanediones, that are represented in Figure 6, in order to obtain 
mono-alcohols as main products. These compounds represent simplified structures that can be used 
as model compounds to study the biocatalyzed regio- and stereo-selective reduction. 
 
 
Figure 6. 2,2-disubstituted-1,3-cyclopenta- and 1,3-cyclohexanediones used as substrates. 
  
The reductive reaction was performed using a biocatalytical approach, with both whole cells and 
purified enzymes. The whole cells used were empty cells of E.coli BL21 DE3 star and cells of the 
same microorganism that expressed a ketoreductase, specifically the KRED1-Pglu from Pichia 
glucozyma. As last, the same substrates were reduced with the purified free KRED1-Pglu. We 
decided to try different biocatalysts in order to see the differences between the various approaches.  
The main goal was to obtain enantiomerically pure mono-alcohols, that can be important building 
blocks in the synthesis of various steroidal molecules
67,68
. However, this goal is challenging, 
because two stereo-centres are generated after the reduction of the prochiral substrates (3a-8a), thus 
forming four possible isomers. In addition, a reaction by-product can be the diol (3f-8f) (Figure 7). 
 
 
 
 
 
 
Figure 7. Substrates (3a-8a), their four possible mono-alcohol products and the diols. 
 
Synthesis of 2,2-disubstituted 1,3-cyclopenta- and 1,3-cyclohexanediones 
 
I firstly chemically synthesized the 2,2-disubstituted 1,3-cyclopenta- and 1,3-cyclohexanediones 
(3a-8a) starting from their precursors 1 and 2 (Figure 8). 
 
76 
 
 
Figure 8. Precursors used for the synthesis of substrates (3a-8a) 
 
Compounds 4a and 5a were synthesized following a reported procedures
69,70
 starting from 2-
methyl-1,3-cyclopentanedione (1), that can be easily deprotonated in position 2 under basic 
conditions and the resulting anion can afford a nucleophilic substitution on allyl or benzyl bromide 
respectively, thus producing the alkylated desired product. The same protocols were followed for 
compounds 7a and 8a starting from 2-methyl-1,3-cyclohexanedione (2), achieving also in this case 
good results.  
For obtaining derivatives with propyl group as substituent in position 2 (compounds 3a and 6a), I 
reduced the double bond of the alkenes 4a and 7a using the H-cube reactor, a flow reactor able to 
perform hydrogenation reactions in a continuous way (Figure 9). 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. H-cube flow reactor for continuous hydrogenation reactions. 
 
Hydrogenation is a very useful reaction, since can be used for reducing C-C double bonds, imines, 
for de-benzylation reactions or to remove Cbz groups. However, it must be run very carefully 
because hydrogen is a highly flammable gas and also the catalysts (e.g., Pd/C 10%) used for the 
reaction are very hazardous.  
In the H-cube reactor, many safety issues related to hydrogenation reactions have been solved. In 
fact, H2 is generated in situ by electrolysis from water and directly used in the reaction. Moreover, 
the pyrophoric catalysts are stuck in sealed catalyst cartridges and are not in contact with the air.  
Summarizing, the advantages are: 
 Increased safety 
 Easy to use 
 No catalyst filtration 
 Fast reactions. 
The reactions are performed in a continuous flow stream and they can be heated up to 100 °C and 
easily pressurized (up to 100 atm). The steps of the hydrogenation reaction using H-cube are the 
following: 
1. Hydrogen is generated by water electrolysis 
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2. The reaction parameters (temperature, pressure and residence time) are set 
3. The starting material flow stream is passed through the cartridge containing the catalyst, after 
being in contact with the hydrogen   
4. The flow stream containing the product exits from the reactor (again reaction and filtration 
are simultaneous, Figure 10). 
 
 
 
 
 
 
 
 
Figure 10. Schematic representation of a reaction in the H-cube reactor.
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To run the hydrogenation reaction on alkenes 4a and 7a, 5% Pd/C was selected as catalyst (Scheme 
3). The reaction was run in methanol at 30 °C and 1 bar of pressure. The reaction was very fast; it 
was completed with both the substrates using a flow rate of 0.5 mL/min.  
Since the hydrogen is produced from water, it is wet. If the reaction is moisture sensitive, a drying 
cartridge can be added to dry hydrogen. Then, methanol was evaporated under vacuum and the 
aqueous phase was extracted with CH2Cl2. Both the substrates were obtained with total conversion 
and no chromatographic column was required after the work-up procedure. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3. Reaction conditions for the hydrogenation with H-cube: a) MeOH, Pd/C 5%, 30 °C, 1 
bar, 0.5 mL/min. 
 
In order to be able to analyze the biocatalyzed reduction reaction with, I also synthesized the 
standards of the mono-alcohol products for all the substrates. I made this in a chemical way with 
NaBH4, and therefore a mixture of the four possible isomers represented in Figure 7 was obtained. I 
reduced with NaBH4 substrates 4a-5a and 7a-8a, using 0.25 eq of the reducing agent in order to 
obtain a mono reduction. Indeed, sodium borohydride has four available hydrides and it means that 
1 mole reduces 4 moles of ketone. The reaction was performed in methanol, a polar, protic solvent. 
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The mixture was stirred for 15 minutes, since longer reaction times will lead to the formation of the 
diol. Then, water was added to quench the reaction and the pH was adjusted to pH = 2 with 1N HCl.  
To obtain the mono-alcohols of compounds 3a and 6a, I used again the H-cube, starting from the 
corresponding unsaturated mono-alcohols of substrates 4a and 7a. The conditions I applied were the 
same that I used to obtain 3a and 6a. Also in this case, after the hydrogenation, I evaporated 
methanol (the solvent of the reaction) and I extracted the water phase with dichloromethane to 
afford the desired products with an almost complete yield. Importantly, all the substrates 3a-8a and 
their reduced mono-alcohol products must be treated carefully, since they are quite volatile 
compounds and they could evaporate under low reduced pressure.  
 
Biotransformations with whole recombinant cells expressing KRED1-Pglu  
 
A part of this project was developed at the group of Prof. Dörte Rother at the Forschungszentrum 
Jülich, in Germany, where I spent six months. The synthesis of substrates 3a-8a was performed at 
the University of Milan, whereas in Jülich I learnt the biotechological processes in order to cultivate 
cells, produce and isolate enzymes. Then, I tried compounds 3a-8a with both whole cells expressing 
KRED1-Pglu and with purified free KRED1-Pglu. At the Forschungszentrum Jülich, I cultivated 
and grew the whole cells E.coli DE3 expressing the desired protein KRED1-Pglu, with the 
supervision of Prof. Dörte Rother and Dr. Reinhard Oeggl, following the procedure described in the 
Experimental Session of this Chapter. After the production, I then lyophilized the cells and directly 
used them for the biocatalyzed reaction.  
 
I firstly used the whole cells on a model substrate, Acetophenone
64
 in order to both check cells 
activity and to find the best buffer for the reaction. The four buffers tried were: HEPES, TEA, 
K3PO4 and TRIS, at pH 8.0 and at a concentration of 50 mM. Reactions were run with 1 gr/L 
acetophenone, 40 mM glucose, 0.1 mM NADPH as cofactor, a tip of spatula of GDH 
(commercially available with > 200 U/mg) and 50 mg of lyophilized whole cells in 1 mL volume 
reaction. Glucose and GDH were added for the NADPH regeneration system necessary for KRED1-
Pglu (as explained in Figure 11): 
 
Figure 11. Schematic representation of the cofactor regeneration system mechanism used in these 
trials. 
 
The higher conversion was obtained with phosphate buffer (70% after 24h). HEPES buffer was not 
bad, but less performing compared to phosphate one. 
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I then tested the biotransformation on compounds 3a-8a. I decided to firstly evaluate the reaction 
conditions using substrate 3a (2-methyl-2-propyl-1,3-cyclopentanedione). The first two reaction 
parameters I optimized were the amount of whole cells to be employed and if NADPH and its 
cofactor recycling system was actually required. Indeed, it is known that one of the advantages of 
whole cells is generally that no external addition of cofactor and cofactor regeneration system is 
required, because usually everything is already inside the cells. Therefore, I tried 50 mg, 25 mg and 
5 mg of whole cells with and without cofactor. Results are reported in the following Table 1. 
 
Entry Cells amount 
(mg) 
NADPH Time 
(h) 
3a 
(%) 
3b 
(%) 
3c 
(%) 
3d 
(%) 
3e 
(%) 
3f (%) 
1 50 Yes 1 0 14 n.d 41 n.d 45 
2 50 Yes 24 0 20 n.d 45 n.d 35 
3 50 No 1 0 22 n.d 43 n.d 35 
4 50 No 24 0 27 n.d 44 n.d 29 
5 25 Yes 1 0 20 n.d 40 n.d 40 
6 25 Yes 24 0 19 n.d 44 n.d 37 
7 25 No 1 10 36 n.d 41 n.d 13 
8 25 No 24 0 26 n.d 46 n.d 28 
9 5 Yes 1 6 34 n.d 43 n.d 17 
10 5 Yes 24 0 23 n.d 52 n.d 25 
11 5 No 1 86 8 n.d 6 n.d 0 
12 5 No 24 39 32 n.d 25 n.d. 4 
 
Table 1.Results of biotransformations run with a 14 mM solution of compound 3a in a phosphate 
buffer solution (pH 8.0, 50 mM) with 40 mM glucose, 0.1 mM NADPH as cofactor (when added), a 
tip of spatula of GDH (from Pseudomonas sp., commercially available with > 200 U/mg) and 
different amounts of lyophilized whole cells in 1 mL total volume reaction. Different samples were 
taken each hour and analyzed by chiral GC. Here are reported the most important results. 
 
As it is possible to see from Table 1, important information were collected with these reactions. 
First, we observed that always two isomers were formed during the reactions in a significant 
amount, that are isomer 3b (2S, 3S) and 3d (2R, 3S). In the next pages, I will explain how it was 
possible to understand the absolute configurations of these two isomer. In addition, we saw that the 
diol 3f was detected as well. The structure of diol 3f was confirmed by 
1
H NMR after a purification 
column of a reaction performed under the conditions reported in Table 1 entry 9 (5 mg whole cells 
and NADPH). 
For what concerns the two variables investigated so far, the presence of a catalytic amount of 
NADPH (0.1 mM) surely speeded up the reaction. This is largely visible when a small amount of 
whole cells is employed (entries 9-10-11-12), while it has a lower impact with higher amounts of 
cells (50 mg, entries 3 and 4, and 25 mg, entries 6 and 8). In general, the reductive reaction resulted 
to be quite fast. 
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Taking into considerations these results, I decided to use the condition of entries 9 and 10, therefore 
to use 5 mg of whole cells and a catalytic amount of NADPH (0.1 mM), reducing of ten times the 
amount of biocatalyst. 
Then, I modified various reaction conditions in order to find the conditions that allow us to have a 
mono stereoselective reduction, with the formation of only one isomer and without the diol. 
  
Keeping constant the other parameters, I evaluated the pH effect, to see if there was an equilibrium 
between the oxidized part (the substrate, 3a) and the reduced one (mono-alcohols 3b-3e and diol 
3f). The tested pH values were 7, 8 , 9 and 10. pHs 7 and 8 were made with phosphate buffer as 
before, while for pH 9 and 10 I used CAPSO buffer (cyclohexylamine 1-propanesulfonic acid). The 
concentration of the buffers was always 50 mM. Graphics here below show the obtained results 
(Figure 12). 
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Figure 12. Four graphics that show the trend of reactions run changing the pH values. Reaction 
conditions: 14 mM solution of compound 3a in a phosphate buffer solution (pH 7.0/8.0/9.0/10.0, 50 
mM) with 40 mM glucose, 0.1 mM NADPH as cofactor, a tip of spatula of GDH (from 
Pseudomonas sp., commercially available with > 200 U/mg) and 5 mg of lyophilized whole cells in 
1 mL total volume reaction. Samples were analyzed in chiral GC.  
 
From these biotransformations, it was observed that at higher pH values (9 and 10) the oxidized 
form is favorite (and the reaction was slower, at pH 9, or did not proceed, at pH 10), while at lower 
pH the reduced form is favorite, even if at pH 7 less diol 3f is formed compared to pH 8. In general, 
the reaction is faster at pH 8, and it is possible to note that the formation of diol 3f seems to be 
possible because the isomer 3b is used by the biocatalyst. Leaving the reactions run further did not 
change the results. The pH value was not a parameter that allowed us to obtain a stereoselective 
reduction and, simultaneously, to avoid the formation of the diol 3f. Again in these cases, isomers 
3c and 3e were not significantly detected. 
 
I then tried to add different co-solvent in order to reach our aim. Indeed, there are reported in 
literature some cases that present the potentiality of co-solvents and additives in directing 
stereselectivity.
72
 The co-solvents I tried are: DMSO, acetone, chloroform, dichloromethane, MTBE 
(methyl tert-butyl ether) and MIBK (methyl isobutyl ketone). All the co-solvents were added in 1% 
v/v. I also tried in the same set of reactions the one without co-solvent, as standard reference (Table 
2). 
 
 
Entry Co-solvent 3a(%) 3b(%) 3c(%) 3d(%) 3e(%) 3f(%) 
1 DMSO 0 22 n.d 42 n.d 36 
2 Acetone 0 28 n.d 50 n.d 22 
3 DCM 14 49 n.d 33 n.d 4 
4 TCM 22 75 n.d 5 n.d 0 
5 MTBE 0 39 n.d 43 n.d 20 
6 MIBK 40 47 n.d 13 n.d 0 
7 No cosolvent 0 20 n.d 50 n.d 30 
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Table 2. Results of the biotransformations after 72h with different co-solvents. Reaction conditions: 
14 mM solution of compound 3a in a phosphate buffer solution (pH 8.0, 50 mM) with 40 mM 
glucose, 0.1 mM NADPH as cofactor, a tip of spatula of GDH (from Pseudomonas sp., 
commercially available with > 200 U/mg), 5 mg of lyophilized whole cells in 1 mL total volume 
reaction and 1% of various co-solvents. Different samples were taken after 15 minutes, 30 minutes, 
1h, 2h, 3h, 4h, 24h, 48h, 72h and analyzed by chiral GC. Here are reported only the results after 72h 
in order to observe the trend of the different reactions. 
 
Actually, the stereoselectivity seems to be influenced by the co-solvent used: some of them have a 
preference for the mono-alcohol 3d (as DMSO and acetone, entries 1 and 2, respectively) and 
others towards the mono-alcohol 3b (DCM, TCM, MIBK, entries 3, 4 and 6, respectively). MTBE 
(entry 5) does not seem to have an impact on the stereselectivity. The condition without co-solvent 
(entry 7) perfectly reflects the results showed in Table 1, entry 10, showing that, if the reaction is 
run for 24h or more, isomer 3b seems to be used to give diol 3f. As before, products 3c and 3e were 
not detected even under these conditions. 
Among all the results, the best one is obtained using 1% of chloroform (entry 4): indeed, after 72h, 
an almost 60% of conversion was obtained, yielding only isomer 3b, without the presence of the 
diol 3f. This was the best result that was obtained so far. Leaving the reaction run for more time did 
not further increase the conversion. 
 
Since the best obtained result was the one with 1% of chloroform, we decided to investigate this co-
solvent, by changing the amount of it inside the reaction. Therefore, I tried 0.5, 0.75, 1, 1.5 and 2% 
of chloroform. The control reaction without co-solvent was always performed. Results are shown in 
Table 3 (as well as before, only results at 72 h are reported). I just reported results for mono-
alcohols 3b and 3d, since the other two products were never detected during these experiments. Of 
course, I inserted in Table 3 results about the diol product 3f. 
 
Entry TCM (%) 3a(%) 3b(%) 3d(%) 3f(%) 
1 0 0 20 50 30 
2 0.5 0 30 45 25 
3 0.75 9 50 31 10 
4 1 22 75 5 0 
5 1.5 75 20 5 0 
6 2 91 5 4 0 
 
Table 3. Results of the biotransformations after 72h with different % of chloroform (TCM). 
Reaction conditions: 14 mM solution of compound 3a in a phosphate buffer solution (pH 8.0, 50 
mM) with 40 mM glucose, 0.1 mM NADPH as cofactor, a tip of spatula of GDH (from 
Pseudomonas sp., commercially available with > 200 U/mg), 5 mg of lyophilized whole cells in 1 
mL total volume reaction and various % of chloroform. Different samples were taken after 15 
minutes, 30 minutes, 1h, 2h ,3h, 4h, 24h, 48h, 72h and analyzed by chiral GC. Here are reported 
only the results after 72h in order to see the trend of the different reactions. 
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As it is possible to see from Table 3, when the amount of chloroform (TCM) was increased, a 
“shift” in the enantioselectivity was obtained. Without the co-solvent (entry 1), a preference for 
isomer 3d can be observed, but with 0.75% (entry 3) the situation was completely the opposite, with 
a higher conversion to isomer 3b, and this preference remains with 1% of chloroform (entry 4), 
when the stereoselectivity for 3b was almost complete, without the formation of 3f. A further 
increase of chloroform led to an inhibition of the biocatalytical activity (entries 5 and 6).  
 
With these results in hands, I changed other parameters, for example by combining % of TCM or 
MIBK (the two co-solvents that gave the best results, Table 2 entries 4 and 6) and pH values, but no 
better results were achieved, or something that could increase our comprehension on the reaction 
outcome. 
Looking at the results obtained with chloroform and the substantial difference between them and the 
one without co-solvent (Table 3), we thought that maybe, with chloroform, the activity of KRED 
enzyme expressed by the whole cells was reduced, while another innate reducing activity of E.coli 
whole cells remained active. Therefore, back to Milan, I started to investigate the same reaction on 
lyophilized whole cells of E. coli BL21 DE3 star, that will be discussed in the next paragraph. 
 
Biotransformations with wild type whole cells of E.coli BL21 
 
The cultivation and production of the empty whole cells of E. coli was carried on following the 
protocol used for E.coli whole cells expressing the KRED1-Pglu enzyme, in order to obtain cells 
grown up in the same way. Then they were lyophilized and used. 
I first performed three experiments with 5 mg of whole cells: without co-solvent, with 1% of 
DMSO and with 1% of chloroform. Compound 3a was always used for reaction optimization. 
Results are reported in Table 4. 
 
Entry Co-solvent 3a (%) 3b (%) 3c (%) 3d (%) 3e (%) 3f (%) 
1 DMSO 82 18 0 0 0 0 
2 TCM 25 75 0 0 0 0 
3 No-cosolvent 80 20 0 0 0 0 
 
Table 4. Results obtained from reactions conducted with 1% of DMSO or chloroform (TCM) and 
without co-solvent. Reaction conditions: 14 mM solution of compound 3a in phosphate buffer (pH 
8.0, 50 mM) with 40 mM glucose, 0.1 mM NADPH as cofactor, a tip of spatula of GDH (from 
Pseudomonas sp., commercially available with > 200 U/mg), 5 mg of lyophilized whole cells in 1 
mL total volume reaction. Different samples were taken after 15 minutes, 30 minutes, 1h, 2h, 3h, 
4h, 24h, 48h, 72h and analyzed by chiral GC. Here are reported only the results after 72h in order to 
see the trend of the different reactions. 
 
Actually, there was an innate activity in empty whole cells of E.coli BL21, and it is a stereselective 
activity, that does not lead to the formation of diol 3f. Importantly, this activity is enhanced when 
chloroform is used (entry 2), while if DMSO or no co-solvent was employed the conversions were 
much lower (entries 1 and 3). Remarkably, the activity shown in entry 2 with chloroform is 
completely comparable with the one found with whole cells expressing KRED1-Pglu enzyme 
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(Table 2, entry 4), while the one obtained with DMSO or without co-solvent are completely 
different from the ones found with the full microorganism (Table 2, entries 1 and 7). Therefore, the 
KRED1-Pglu enzyme expressed by whole cells of E. coli works very well but it really seems to be 
inactivate with chloroform, and under this condition probably remains the innate activity of the 
empty microorganism. We still do not know why chloroform is able to make this effect on empty 
and full whole cells, again an hypothesis can be correlated with the enhanced permeability of the 
cell membrane, but at present we do not have experimental evidences of the explanation.   
However, I tried to push the reaction with empty cells, using reaction conditions without the 
presence of chloroform, and increasing the amount of cells (5, 25 and 50 mg) or the percentage of 
DMSO (0, 10 and 20%). Results are summarized in Table 5. In this table, I reported the conversions 
to the mono-alcohol 3b, since the other isomers were never detected with the empty cells, neither 
the diol. I repeated, as standard reference, the reaction without co-solvent and with 5 mg of whole 
cells. 
 
Entry Cells amount (mg) DMSO(%) 3a(%) 3b(%) 
1 5 0 80 20 
2 5 10 88 12 
3 5 20 88 12 
4 25 0 75 25 
5 25 10 89 11 
6 25 20 88 12 
7 50 0 72 28 
8 50 10 90 10 
9 50 20 90 10 
 
Table 5. Results conducted with different amounts of cells (5, 25 or 50 mg) and various percentages 
of DMSO (0, 10 and 20%). Reaction conditions: 14 mM solution of compound 3a in a phosphate 
buffer solution (pH 8.0, 50 mM) with 40 mM glucose, 0.1 mM NADPH as cofactor, a tip of spatula 
of GDH (from Pseudomonas sp., commercially available with > 200 U/mg), different amounts of 
lyophilized whole cells in 1 mL total volume reaction and various % of DMSO. Different samples 
were taken after 15 minutes, 30 minutes, 1h, 2h, 3h, 4h, 24h, 48h, 72h and analyzed by chiral GC. 
Here are reported only the results after 72h in order to see the trend of the different reactions. 
 
By changing these parameters, no better results were obtained, and, with higher amounts of DMSO, 
conversions seem to be worse, even when more cells are employed (entries 5, 6, 8 and 9). 
Remarkably, I tried to run the reaction without cofactor (NADP
+
) and without the cofactor 
regeneration system, but, in these cases, I did not see the mono-alcohol formation. I also tried to 
perform the reaction only with GDH, because we thought about a secondary activity of this enzyme 
during the reaction, but again I did not observed any conversion.  
 
With these results, the best one obtained so far was again the one with 1% of chloroform. Therefore, 
as proof of concept, I tried the other substrates (4a-8a) under the optimized conditions. The 
reactions were run for 72h and then acidified with HCl 2N until pH 1 and extracted with ethyl 
acetate (for three times). The organic phase was dried over anhydrous Na2SO4 and evaporated under 
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reduced pressure. After purification by column chromatography, different yields for the various 
substrates (3a-8a) were obtained according to Table 6. 
 
Entry Compound Un-reacted substrate (%) 2S, 3S isomer 3b-8b 
(%) 
1 3° 30 70 
2 4° 65 35 
3 5° 70 30 
4 6° 75 25 
5 7° 30 70 
6 8° 90 10 
 
Table 6. Reaction conditions: 14 mM solution of compounds (3a-8a) in a phosphate buffer solution 
(pH 8.0, 50 mM) and 1% of TCM with 40 mM glucose, 0.1 mM NADPH as cofactor, a tip of 
spatula of GDH (from Pseudomonas sp., commercially available with > 200 U/mg), 5 mg of 
lyophilized whole cells in 1 mL total volume reaction. Reactions were stopped after 72 h, worked-
up and yields were determined by isolation of products and 
1
H NMR.  
 
All the compounds 3a-8a were reduced under the optimized conditions, giving different isolated 
yields (entries 1-6). The reactions were also controlled by chiral GC after different times (1h, 2h, 
3h, 4h, 24h, 48h, 72h, 96h). Conversions did not further increase after 72h. For compounds 5a and 
8a (with benzylic chain in position 2), I had some analytical problems, because these products could 
not be seen so clearly in GC. We also tried the HPLC approach but it did not give good results. For 
this reason, the reactions on these two compounds were stopped at 72h, submitted to work up and 
purification and analyzed by 
1
H NMR. As for the other substrates, only one isomer and the un-
reacted substrate were detected, with conversions reported in Table 6 (entries 3 and 6). Leaving the 
reactions for more time did not further increase their conversions.  
I was able to assign the absolute configurations of mono-alcohols obtained under optimized 
conditions by comparison between the 
1
H NMR spectra and optical rotation values of mono-
alcohols with the ones reported in literature.
73,69,72
 For all, the absolute configuration was 2S, 3S. 
 
To be completely sure of the attribution, I prepared the Mosher ester of compound 3b, obtained 
under optimized conditions, following a reported procedure
69
. To do so, I performed the reaction on 
compound 3a with both (+)-(R)-alpha-methoxy-alpha-(trifluoromethyl) phenylacetic acid (R-
Mosher acid) and (-)-(S)- alpha-methoxy-alpha-(trifluoromethyl) phenylacetic acid (S-Mosher acid) 
(Scheme 4). 
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Scheme 4. Schematic representation of reactions performed on mono-alcohol product 3b with both 
(+)-(R)-Mosher acid and (-)-(S)-Mosher acid. Reaction conditions: 10 mg of 3b in 2 mL of 
dichloromethane, with 2 equivalents of DCC and 0.2 equivalents of DMAP. Reactions were stirred 
overnight and controlled by TLC. 
 
Reactions were run at room temperature for 24h with 2 equivalents of DCC and 0.2 equivalents of 
DMAP. After work-up with dichloromethane and evaporation of the solvent, column 
chromatography was made and the 
1
H NMR spectra of the two purified esters (3g and 3h) were 
obtained. The NMR signal of the methyl and the propyl groups in position 2 of product 3g resulted 
to be more shielded if compared with the same signals of ester 3h. Therefore, I was able to assess 
that the mono-alcohol 3b obtained under optimized conditions (Table 6, entry 1) has the absolute 
configuration (2S,3S). 
 
Biotransformations with purified free KRED1-Pglu 
 
At the Forschungszentrum Jülich, in the group of Prof. Dörte Rother, I also purified the KRED1-
Pglu (ketoreductase from Pichia glucozyma), lyophilized it and started to use it on cyclo-diketones 
3a-8a. As done before with whole cells, I decided to use compound 3a to firstly optimize reaction 
parameters. Contrary to what done before, the purified KRED1-Pglu enzyme should be dissolved in 
TRIS HCl buffer, as already reported in literature
64
, since it is the best buffer for KRED1-Pglu 
enzyme. I decided to start with 5% of DMSO as co-solvent and 2 mg of lyophilized purified 
enzyme. Results are reported in the graphic below (Figure 13). 
 
 
 
Figure 13. Graphic representation of the reaction performed with 14 mM solution of compound 3a 
in buffer TRIS HCl (50mM pH 8.0) containing 5% of DMSO, glucose (40 mM), NADP
+
 (0.1 mM) 
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and a tip of spatula of GDH from Pseudomonas sp (commercially available with > 200 U/mg). 2 
mg of lyophilized KRED1-Pglu were used as biocatalyst. Conversions were detected by chiral GC 
at different times. 
 
Under conditions reported in Figure 3, the reaction was very fast. After 15 minutes the 3a wasn’t 
detected anymore, but only two mono-alcohols (3b and 3d) and the diol (3f). If the reaction was left 
for more time, at 24h just one mono-alcohol (3d) was detected and the diol 3f, while 3b wasn’t 
present anymore. Leaving the reaction for more time didn’t change the composition of the reaction. 
As observed before with whole cells, products 3c and 3e were never detected. Therefore, the 
enzyme seems to perform two reactions: the first one was the reduction from 3a to the two mono-
alcohols (3b and 3d), which was very fast. The second reaction was the reduction of one mono-
alcohol (3b) to the diol (3f), while the mono-alcohol 3d was not further reduced. This was nice 
because only one mono-alcohol was obtained, but of course the presence of the diol was not 
desired. Therefore, we decided to change some reaction parameters to try to get rid of it. 
Firstly, I increased the concentration of 3a in the buffer solution, keeping constant the other 
parameters. I reached a 56 mM concentration, and the results are reported here below (Figure 14). 
 
 
Figure 14. Graphic representation of the reaction performed with 56 mM solution of compound 3a 
in buffer TRIS HCl (50 mM pH 8.0) containing 5% of DMSO, glucose (40 mM), NADP
+
 (0.1 mM) 
and a tip of spatula of GDH from Pseudomonas sp (commercially available with > 200 U/mg). 2 
mg of lyophilized KRED1-Pglu were used as biocatalyst. Conversions were detected by chiral GC 
at different times. 
 
By increasing the concentration of 3a, the reaction wasn’t complete. Therefore, both the mono-
alcohols 3d and 3b were detected. As a result, the diol formation was not seen. Even if higher 
reaction times were tried, the composition remained the same. It seems that, in order to obtain only 
one isomer, the diol formation is necessary. 
Secondly, I tried to reduce the amount of enzyme used in the reaction. I tried 1 mg/mL and 0.2 
mg/mL. With this last amount, the reaction didn’t even start: after 48h it was present almost only 
substrate. With 1 mg/mL, the reaction was quite slower but the same profile of Figure 13 was seen 
(Figure 15). 
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Figure 15. Graphic representation of the reaction performed with 14 mM solution of compound 3a 
in buffer TRIS HCl (50 mM pH 8.0) containing 5% of DMSO, glucose (40 mM), NADP
+
 (0.1 mM) 
and a tip of spatula of GDH from Pseudomonas sp (commercially available with > 200 U/mg). 1 
mg of lyophilized KRED1-Pglu were used as biocatalyst. Conversions were detected by chiral GC 
at different times. 
 
As it’s possible to see in Figure 15, after 1h, 3a was completely used but a mixture of 3b and 3d 
was formed. After 24h, only isomer 3d and the diol 3f were detected with a conversion of 42% of 
the mono-alcohol. Therefore, it seemed that the reaction could just be slowed down, since the same 
ratio between the products was observed.  
We decided to try the same conditions found for the whole cells, therefore to use 1% of chloroform 
instead of 5% of DMSO. Results are reported here below (Figure 16). 
 
 
 
Figure 16. Graphic representation of the reaction performed with 14 mM solution of compound 3a 
in buffer TRIS HCl (50 mM pH 8.0) containing 1% of TCM, glucose (40 mM), NADP
+
 (0.1 mM) 
and a tip of spatula of GDH from Pseudomonas sp (commercially available with > 200 U/mg). 2 
mg of lyophilized KRED1-Pglu were used as biocatalyst. Conversions were detected by chiral GC 
at different times. 
 
Under these conditions, the diol 3f was not formed, but I detected both 3d and 3b with the same 
conversion. So this is a different result if compared with the one obtained with whole cells because 
in this case chloroform didn’t change the reaction outcome, but a similar reaction trend is obtained 
if compared with the one achieved by increasing the substrate (3a) concentration (Figure 14). 
Therefore, it could be a confirmation of a second activity in the whole cells as said before (Pag. 84).   
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I also tried to change the amount of chloroform in the reaction medium, but the profile was always 
the same. If 0.5% or 0.75% chloroform is used, the trend is more similar to the one reported in 
Figure 13. If a higher percentage of TCM is used (1.5% or 2%), the reaction doesn’t proceed. 
Last thing tried was to use a small amount of LiOH to try to stop the reaction before forming the 
diol. Indeed, in some chemical reactions lithium hydroxide is necessary to block the ketone and to 
avoid the reduction of it. Therefore, different concentrations of LiOH were used inside the reaction 
(0.5, 1, 2 mM), but the reaction shows always the same profile with low amounts of LiOH, while 
increasing it the reaction started to block and only the substrate 3a was detected.  
So, the best result that was achieved with the free KRED1-Pglu is the one represented in Figure 15, 
with a 14 mM concentration of 3a and 1 mg/mL concentration of enzyme. We exploited the second 
reaction performed by the enzymes on the mixture of compounds 3b and 3d in order to achieve 
only the mono-alcohol 3d, but, of course, the diol 3f was obtained as well.  
As proof of concept, the reduction of the other substrates was performed (4a-8a) under optimized 
conditions (14 mM solution of compounds 4a-8a in buffer TRIS HCl 50 mM pH 8.0 containing 5% 
of DMSO, glucose (40 mM), NADP
+
 (0.1 mM) and GDH from Pseudomonas sp (tip of spatula: it 
should be in terms of unit five times the unit of KRED1-Pglu). 1 mg of lyophilized KRED1-Pglu 
was used. For each substrate, the reaction profile was the same and samples were taken at different 
times to stop the reaction at the correct point, in order to obtain only one enantiomerically pure 
mono-alcohol product and the corresponding diol. Then the reactions were performed at a higher 
scale, ad after the correct time the buffer solutions were acidified with HCl 1N to pH 1.0 and 
extracted with ethyl acetate (3 times). The organic phases were dried over anhydrous Na2SO4 and 
evaporated under reduced pressure. The mono-alcohol and the diol were separated with a 
chromatographic column and both of them were characterized with 
1
H NMR and optical rotation 
values. In Table 7 are summarized the recovered yields of all the obtained products. 
 
Entry Compound Time (h) 2S, 3S isomer (%) 2R, 3S isomer 
4d-8d (%) 
diol 
(%) 
1 4a 24 0 50 50 
2 5a 36 50 0 50 
3 6a 4 0 40 60 
4 7a 2 0 25 75 
5 8a 36 60 0 40 
 
Table 7. Results of the reactions performed with 14 mM solution of compound 4a-8a in buffer 
TRIS HCl (50 mM pH 8.0) containing 5% of DMSO, glucose (40 mM), NADP
+
 (0.1 mM) and a tip 
of spatula of GDH from Pseudomonas sp (commercially available with > 200 U/mg). 1 mg of 
lyophilized KRED1-Pglu was used as biocatalyst. Yields were obtained after isolation and 
1
H NMR 
of the products. 
 
As it is possible to see from Table 7, the same profile was detected for all the substrates 3a-8a. 
Indeed, in all cases the substrate was completely used, ad after a certain time (different from case to 
case), only one mono-alcohol product and the diol were detected. The faster compound to be reduce 
was 7a, which instead gave the worst conversion and ratio between mono-alcohol and diol (entry 
4). For it, as well as for 3a, 4a and 6a, the produced isomer was 2R,3S, with various conversions 
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(entry 1,2,4 and 5). The results were different for compounds 5a and 8a, the ones which have the 
benzylic chain in position 2. For these, after 36h, the isomer detected was the 2S,3S, differently 
from the one obtained with the other substrates. This can be probably due to the increased steric 
hindrance of compounds 5a and 8a. For these two compounds some analytical problems were 
detected, because these products could not be seen so clearly in GC. Also the HPLC approach was 
tried but it wasn’t better. For this reason, these two compounds were stopped at 36h and, as the 
other substrates, only one isomer and the diol were detected, with conversions reported in Table 7 
(entries 2 and 5). The reaction composition wasn’t modified if a higher reaction time was applied .  
 
In all cases, the absolute configurations were assigned by comparison with 
1
H NMR and optical 
rotation values reported in literature.
25,75 
Since for the whole cells I synthesized the two Mosher 
esters (3g and 3h) to confirm the results found in literature
69
, here we just compared our NMR 
spectra and optical rotation values with the one reported in the same article
69
.  
 
Conclusions 
 
A deep study on 2,2-disubstituted-1,3-cyclopenta- and 1,3-cyclohexanedione was developed with 
the aim to obtain only one enantiomerically pure mono-alcohol product, among the four possible 
isomers that can be obtained with the mono reductive reaction. Whole cells of E.coli expressing 
KRED1-Pglu enzyme, empty whole cells of E.coli and purified free KRED1-Pglu enzyme were 
used as biocatalysts to understand the trend and the potentialities of the reaction. The reaction seems 
very fast with two drawbacks: the formation of two mono-alcohol isomers and the presence of the 
diol. Optimizing the reaction parameters, two different results were achieved: with whole cells, 
probably, a secondary activity of E. coli was exploited, reached using 1% of chloroform in the 
reaction medium, and obtaining only one enantiomerically pure mono-alcohol, without the diol. The 
biotransforations did not go to completion, and the same results were obtained with both 
recombinant and wild type cells. Of course, the same trick wasn’t successful with purified free 
enzyme, because here a possible second activity is not possible. Therefore, with the free enzyme the 
best result we obtained was to run the reaction for more time and to exploit a second activity of the 
biocatalyst, that seems to use only one mono-alcohol to give the diol, while the second mono-
alcohol remains un-touched. In this way, also with the free enzyme only one enantiomerically pure 
product was obtained, but this time also the diol. We solved the absolute configuration by 
comparison of our NMR spectra and optical rotation values with the ones reported in literature.  
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Materials and methods 
 
General 
 
All reagents and solvents were purchased from Sigma–Aldrich. 1H NMR and 13C NMR spectra 
were recorded with a Varian Mercury 300 (300 MHz) spectrometer. Chemical shifts (δ) are 
expressed in ppm, and coupling constants (J) are expressed in Hz. The molar conversion of the 
biotransformation and its enantiomerical purity was determined by GC equipped with a (CP)-
Chirasil-DEX-CB and a FID detector. Different methods were used for the various substrates: 
- 3a-3f  starting from 90 °C for 10 minutes, then increasing the temperature with a rate of 4 
°C/min until 180 °C for 5 minutes; 
- 4a-4f  starting from 80 °C for 10 minutes, then increasing the temperature with a rate of 2 
°C/min until 180 °C for 5 minutes; 
- 5a-5f  starting from 90 °C, then increasing the temperature with a rate of 3 °C/min until 
180 °C for 5 minutes; 
- 6a-6f  starting from 90 °C for 10 minutes, then increasing the temperature with a rate of 2 
°C/min until 180 °C for 5 minutes; 
- 7a-7f  starting from 90 °C for 10 minutes, then increasing the temperature with a rate of 3 
°C/min until 180 °C for 5 minutes; 
- 8a-8f  starting from 90 °C for 10 minutes, then increasing the temperature with a rate of 2 
°C/min until 180 °C for 5 minutes; 
 
Synthesis and characterization of 2-methyl-2-(3-propenyl)-1,3-cyclopentadienone (4a)
69
 
 
To a solution of 1 (673 mg, 6 mmol) in 1M NaOH (6 mL) was added allyl bromide (1.451 gr, 12 
mmol). The reaction was stirred for 24h at room temperature. It was followed by TLC (9:1 
DCM/MeOH). The mixture was extracted with dichloromethane (5 times) and the organic phase 
was dried over Na2SO4, filtered and evaporated. The crude extract was then purified with a 
chromatographic column (9:1 cyclohexane/ethyl acetate) to obtain compound 4a as a pale yellow 
oil with a yield of 50% (470 mg, 3 mmol): bp 65 °C (2 mm); 
1
H NMR (CDCI3, 300 MHz) δ 1.1 
(3H, s, CH3), 2.3 (2 H, d, J = 8 Hz), 2.7 (4 H, br s), 4.8-5.2 (2 H, m), 5.3-5.9 (1 H, m); 
13
C NMR 
(CDCl3, 75 MHz) δ 18.7 (CH3), 35.4 (2CH2), 40.1 (CH2), 56.6 (C), 119.7 (=CH2), 131.7 (CH=), 
215.9 (2 C=O), MS, m/e M
+
 152. Anal. Calcd for C9H1202: C, 71.03; H, 7.95. Found: C, 71.12; H, 
7.83. Chiral GC retention time: 26.179 minutes.   
 
Synthesis and characterization of 2-methyl-2-propyl-1,3-cyclopentanedione (3a)
69
 
 
A solution of compound 4a (700 mg, 4.6 mmol) was prepared in MeOH (140 mL) and it was 
pumped by the HPLC pump of H-cube mini ThalesNano. A CatCart of Pd/C 5% was used, at a 
temperature of 30 °C and a pressure of 1 bar. A flow rate of 0.5 mL/min was used and a DryCart 
was applied to the system, to remove the major part of water formed for the in-situ production of 
H2. The reaction was controlled by TLC (7:3 CHX/EA). The exiting flow was collected and MeOH 
was evaporated. The low amount of water left was extracted with dichloromethane (3 times), the 
organic phase was then dried on Na2SO4 and evaporated. Compound 3a was obtained with a yield 
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of 95% (674 mg, 4.37 mmol): bp 65 °C (2 mm); 
1
H NMR (CDCl3, 300 MHz) δ 0.84 (3 H, t, J = 7 
Hz, CH3), 1.08 (3 H, s, CH3), 1.15-1.75 (4 H, m), 2.73 (4H, br s); 
13
C NMR (CDCl3, 75 MHz) δ 
14.3 (CH3), 18.1 (CH2), 19.1 (CH3), 35.3 (2CH2), 38.2 (CH2), 56.8 (C), 216.6 (2 C=O); MS, m/e M
+
 
154. Anal. Calcd for C9H14O2: C, 70.10; H, 9.15. Found C, 69.95; H, 9.25. Chiral GC retention 
time: 18.105 minutes.   
 
Synthesis and characterization of 2-methyl-2-benzyl-1,3-cyclopentanedione (5a)
70
 
 
To a solution of 1 (650 mg, 5.8 mmol) in 1M NaOH (6.5 mL) was added benzyl bromide (1.978 gr, 
11.57 mmol). The reaction was stirred for 36h at room temperature and it was followed by TLC 
(7:3 CHX/EA). The mixture was then extracted with ethyl acetate (3 times) and the organic phase 
was dried on Na2SO4 and evaporated. The crude extract was purified with a chromatographic 
column (9:1 CHX/EA). Compound 5a was obtained as a white solid with a yield of 50% (587 mg, 
2.9 mmol): mp 50 °C; 
1
H NMR (CDCl3, 300 MHz): δ 1.20 (3H, s), 2.01-2.08 (2H, m), 2.51-2.57 
(2H, m), 2.95 (2H, s), 7.02-7.04 (2H, m), 7.19-7.24 (3H, m); 
13
C NMR (CDCl3, 75 MHz): δ 20.1, 
35.9, 43.2, 58.4, 127.3, 128.7, 129.7, 135.9, 217.9. Chiral GC retention time: 20.065 minutes. 
 
Synthesis and characterization of 2-methyl-2-(3-propenyl)-1,3-cyclohexanedione (7a)
69
 
 
To a solution of 2 (757 mg, 6 mmol) in 1M NaOH (6 mL) was added allyl bromide (1.451 gr, 12 
mmol). The reaction was stirred for 24h at room temperature. It was followed by TLC (9:1 
DCM/MeOH). The mixture was extracted with dichloromethane (3 times) and the organic phase 
was dried over Na2SO4, filtered and evaporated. The crude extract was then purified with a 
chromatographic column (8:2 CHX/EA) to obtain compound 7a as a pale yellow oil with a yield of 
50% (500 mg, 3 mmol): 
1
H NMR (CDCl3, 300 MHz): δ=5.63–5.54 (m, 1H), 5.10–5.05 (m, 2H), 
2.68-2.64 (m, 4H), 2.54 (d, 2H, J=8 Hz), 2.05–1.87 (m, 2H), 1.25 (s, 3H); 13C NMR (CDC13, 75 
MHz) δ 14.0 (CH3), 15.6 (CH2), 30.48 (2CH2), 33.0 (CH2), 51.8 (C), 94.5 (=CH2), 105.2 (CH=), 
209.0 (2 C=O); MS, m/e M
+
 166. Anal. Calcd for C10H1402: C, 72.26; H, 8.49. Found: C, 72.34; H, 
8.29. Chiral GC retention time: 24.698 minutes. 
 
Synthesis and characterization of 2-methyl-2-propyl-1,3-cyclohexanedione (6a)
69
 
 
A solution of compound 7a (700 mg, 4.2 mmol) was prepared in MeOH (140 mL) and it was 
pumped by the HPLC pump of H-cube mini ThalesNano. A CatCart of Pd/C 5% was used, at a 
temperature of 30 °C and a pressure of 1 bar. A flow rate of 0.5 mL/min was used and a DryCart 
was applied to the system, to remove the major part of water formed for the in-situ production of 
H2. The reaction was controlled by TLC (7:3 CHX/EA). The exiting flow was collected and MeOH 
was evaporated. The low amount of water left was extracted with dichloromethane (3 times), the 
organic phase was then dried on Na2SO4 and evaporated. Compound 6a was obtained with a yield 
of 95% (671 mg, 3.9 mmol): 
1
H NMR (CDCl3, 300 MHz) δ 0.9 (3H, t, J = 7 Hz), 1.0-1.3 (2H, m), 
1.2 (3H, s, CH3), 1.7-2.2 (4H, m), 2.6-2.8 (4H, m); 13C NMR (CDCl3, 75 MHz) δ 14.4 (CH3), 17.8 
(CH3), 18.1 (CH2), 18.8 (CH2), 38.0 (2CH2), 40.0 (CH2), 65.9 (C), 210.3 (2C=O); MS, m/e M
+
 168. 
Anal. Calcd for C10H16O2:  C, 71.39; H, 9.59. Found C, 71.42; H, 9.48. Chiral GC retention time: 
27.780 minutes. 
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Synthesis and characterization of 2-methyl-2-benzyl-1,3-cyclohexanedione (8a)
70
 
 
To a solution of 1 (650 mg, 5.2 mmol) in 1M NaOH (6.5 mL) was added benzyl bromide (1.978 gr, 
11.57 mmol). The reaction was stirred for 36h at room temperature and it was followed by TLC 
(7:3 CHX/EA). The mixture was then extracted with ethyl acetate (3 times) and the organic phase 
was dried on Na2SO4 and evaporated. The crude extract was purified with a chromatographic 
column (9:1 CHX/EA). Compound 5a was obtained as a white solid with a yield of 50% (562 mg, 
2.6 mmol): 
1
H NMR (CDCl3, 300 MHz) δ 1.28 (3H, s), 1.55-1.42 (1H, m), 1.80-1.67 (1H, m), 2.35-
2.23 (2H, m), 2.60-2.48 (2H, m), 3.11 (2H, s), 7.04-6.99 (2H, m), 7.28-7.16 (3H, m), 13C NMR 
(CDCl3, 75 MHz,) 17.0, 22.5, 39.7, 44.3, 65.7, 127.4, 128.8, 130.3, 137.1, 211.8. Chiral GC 
retention time: 48.694 minutes. 
 
Preparation of recombinant E. coli BL21 DE3 cells expressing KRED1-Pglu  
 
Cultures of E. coli BL21 (DE3) containing Chaperone III transformed with the plasmid pET26 
KRED1-Pglu were pr-inoculated in 100 mL Erlenmeyer baffled flask containing 20 mL of LB 
medium [yeast extract (5 gL-1), tryptone (10 gL-1) and NaCl (10 gL-1)] supplemented with 25 
μg/mL kanamycin and 25 μg/mL chloramphenicol. After growth for 24h (37 °C at 150 rpm) the OD 
concentration was checked and a calculated volume was picked up, in order to have in the main 
culture a 0.1 OD concentration. The inoculation was made in 200 mL of TB medium [yeast extract 
(24 gL-1), tryptone (12 gL-1), glycerol (4 gL-1)], 10% of buffer phosphate pH 7.0 0.1M, 25 μg/mL 
kanamycin, 25 μg/mL chloramphenicol and 0.5 mg/mL L-arabinose. The shaking flasks were 
leaved at 37 °C and 90 rpm until the culture reached an OD value of 0.5. At this point, cells were 
induced for 72h with isopropyl-β-D-thiogalactopyranoside (IPTG) to a final concentration of 0.5 
mM, at a temperature of 10 °C and a shaking of 90 rpm. Cells were then harvested by centrifugation 
at 8000 rpm and 4 °C for 45 min, washed once with 20 mM phosphate buffer at pH 7.0, lyophilized 
for 24/48h and stored at −20 °C. 
 
Preparation of wild type E. coli BL21 DE3 star cells 
 
The preparation of the wild type cells was performed following perfectly the protocol reported 
above for the E. coli cells expressing KRED1-Pglu enzyme. The only difference is that, in case of 
empty cells, no induction with IPTG was performed. 
 
Expression and purification of KRED1-Pglu enzyme 
 
For the expression of KRED1-Pglu enzyme, the hosting cells of E. coli BL21 DE3 were prepared as 
described above. Cells were suspended in 50 mM phosphate buffer, 300 mM NaCl, pH 8.0. Proteins 
were extracted by sonication (10 cycles of 1 min each, in ice, with 1 min interval) and cell debris 
were harvested by centrifugation at 21000 rpm for 30 min at 4 °C. The enzyme was purified by 
affinity chromatography with HIS-Select® Nickel Affinity Gel using an AKTӒ system. Briefly, the 
column was equilibrated with 50 mM phosphate buffer, 300 mM NaCl, pH 8.0 and the crude extract 
loaded; column was then washed with 50 mM phosphate buffer, 300 mM NaCl, 20 mM imidazole, 
pH 8.0; finally, the adsorbed enzyme was eluted with 50 mM phosphate buffer, 300 mM NaCl, 250 
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mM imidazole, pH 8.0. Pellets, crude extracts and collected fractions were analysed by SDS-PAGE. 
The fractions showing the presence of a band of the expected size (27 kDa) were pooled and stored 
at −20 °C. After 24h, we lyophilized the enzyme for a 24/48h. From 4 g of whole cells we obtained 
600 mg of lyophilized enzyme. 
 
KRED1-Pglu activity test 
 
Activity measurements were performed following a protocol previously reported
74
. It was made 
spectrophotometrically at 340 nm by determining the consumption of NAD(P)H at 25 °C in a half-
microcuvette (total volume 1 mL) for 5 min. One unit (U) of activity is defined as the amount of 
enzyme which catalyses the consumption of 1 μmol of NAD(P)H per minute under reference 
conditions, namely with 0.25 mM NAD(P)H and 0.47mM benzil as substrate (added as 
concentrated DMSO solution; final DMSO concentration in cuvette amounts to 0.1 %), in 50 mM 
Tris–HCl buffer, pH 8.0. 
 
General procedure for the biotransformation with E. coli cells (both recombinant and wild 
type) 
 
A solution of the substrate (3a-8a) (14 mM) was prepared in 20 mL of phosphate buffer 50 mM pH 
8.0 with 1% of TCM. In the same solution were added glucose (40 mM), NADP
+
 (0.1 mM) and a 
tip of spatula of GDH from Pseudomonas sp (commercially available from Sigma Aldrich, > 200 
U/mg). As last, lyophilized wild type E.coli cells BL21 DE3 star were added to the buffer solution 
(5mg/mL). After 72h, the reactions were then acidified, extracted with ethyl acetate (3 times) and 
the organic phase was dried with sodium sulphate. After removal of the solvent, a chromatographic 
column was performed to separate the un-reacted substrate from the products (8:2 
cyclohexane/ethyl acetate). Both the un-reacted substrates and the obtained mono-alcohols were 
confirmed with 
1
H NMR and 
13
C NMR. The absolute configuration of products (3b-8b) were 
assigned by comparison with reported NMR spectra and reported optical rotation values.
73,69,72
  
 
Products characterization (3b-8b): 
 
(2S,3S)-3-hydroxy-2-methyl-2-propylcyclopentan-1-one (3b)
69
: αD
20
= +61.0 ° (c 1.94, CHC13,); 
IR (neat) 3400 (br s), 1720 cm
-1
 (s); 
1
H NMR (CDCl3, 300 MHz) δ 0.94 (3 H, t, J = 7.2 Hz, CH,), 
1.00 (3 H, s, CH,), 1.29 (1 H, m), 1.42 (1 H, m), 1.50 (2 H, m), 1.61 (1 H, br s, OH), 1.95 (1 H, m), 
2.16-2.32 (2 H, m), 2.46 (1 H, m), 4.11 (1 H, t, J = 4.5 Hz); 
13
C NMR (CDCl3, 300 MHz) δ 14.8 
(CH3), 17.1 (CH2), 19.2 (CH3), 27.8 (CH2), 32.3 (CH2), 34.0 (CH2), 53.2 (C), 77.6 (CHOH), 221.0 
(C=O); MS, m/e M
+
 156. Anal. Calcd for C9H1602: C, 69.19; H, 10.32. Found: C, 68.97; H, 10.59. 
Chiral GC retention time: 26.590 minutes.  
 
(2S,3S)-2-allyl-3-hydroxy-2-methylcyclopentan-1-one (4b)
69
: αD
20
= + 54.0 ° (c 0.4, CHCl3); IR 
(neat) 3380 (br s), 3010 (w), 1710 cm
-1
 (s); 
1
H NMR (CDCl3, 300 MHz) δ 1.01 (3 H, s, CH,), 1.78 
(1 H, d, J = 3 Hz), 1.97 (1 H, m), 2.16-2.52 (5 H, m), 4.13 (1 H, dd, J = 4, 3 Hz), 5.16 (2 H, m), 
5.89 (1 H, m); 
13
C NMR (CDCl3, 300 MHz) δ 19.7 (CH3), 27.8 (CH2), 34.0 (CH2), 35.4 (CH2), 
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53.2 (C), 77.2 (CHOH), 118.1 (=CH2), 134.4 (CH=), 220.6 (C=O); MS , m/ e M
+ 
154. Anal. Calcd 
for C9H14O2: C, 70.10; H, 9.15. Found: C, 70.40; H, 9.43.  
 
(2S,3S)-2-benzyl-3-hydroxy-2-methylcyclopentan-1-one (5b)
76
: αD
20
= + 74.88 ° (c 1.0, CHCl3); 
IR (film) 3503, 2975, 2954, 2905, 1725, 1636, 1558, 1458, 1069, 1027, 741, 703 cm-1; 
1
H NMR 
(300 MHz, CDCl3) δ 0.87 (3H, s), 1.93-1.85 (2H, m); 2.18 (1H, m), 2.38 (1H, m), 2.51 (1H, m), 
2.73 (1H, d, J =14.0 Hz) 3.06 (1H, d, J = 14.0 Hz), 4.05 (1H, t, J = 3.0 Hz), 7.21 (1H, m), 7.28-7.25 
(4H, m), 
13
C NMR (125 MHz, CDCl3) δ 220.5, 137.9, 130.4, 128.1, 126.2, 76.4, 54.8, 35.7, 33.7, 
28.2, 19.6; mp 88-90 °C. 
 
(2S,3S)-3-hydroxy-2-methyl-2-propylcyclohexan-1-one (6b)
69
: αD
20
= + 65 ° (c 0.57, CHCl3); 
1
H 
NMR (CDCl3, 300 MHz) δ 0.97 (3H, t, J = 7.5 Hz, CH3), 1.02 (1H, m), 1.18 (3H, s, CH3), 1.29 
(1H, m), 1.60 (4H, m), 1.70 (1H, m), 1.97 (2H, m), 2.37 (2H, m), 3.69 (1H, dd, J = 8.5,4 Hz); 
13
C 
NMR (CDCI3, 300 MHz) δ 14.9 (CH3), 16.7 (CH2), 19.0 (CH3), 20.7 (CH2), 28.8 (CH2), 33.8 
(CH2), 37.7 (CH2), 54.9 (C), 77.6 (CHOH), 215.4 (C=O); MS, m/e M
+ 
170. Anal. Calcd for 
CI0Hl8O2: C, 70.55; H, 10.66. Found: C, 70.67; H, 10.56.  
 
(2S,3S)-2-allyl-3-hydroxy-2-methylcyclohexan-1-one (7b)
69
: αD
20
= + 27.5 ° (c 0.42, CHCl3); 
1
H 
NMR (CDCl3, 300 MHz) δ 1.19 (3H, s, CH3), 1.72 (1H, m), 1.76 (1H, br s, OH), 1.90 (1H, m), 2.05 
(2H, m), 2.41 (4H, m), 3.81 (1H, m), 5.10 (2H, m), 5.78 (1H, m); 
13
C NMR (CDCl3, 300 MHz) δ 
20.0 (CH3), 20.6 (CH2), 28.5 (CH2), 36.9 (CH2), 37.7 (CH2), 54.0 (C), 76.7 (CHOH), 118.0(=CH2), 
134.2 (CH=), 214.4 (C=O); MS, m/e M
+
 168. Anal. Calcd for C10H1602: C, 71.39; H, 9.59. Found: 
C, 71.41; H, 9.45.  
 
(2S,3S)-2-benzyl-3-hydroxy-2-methylcyclohexan-1-one (8b)
77
: αD
20
= + 10.5 ° (c 1.2, CHCl3); 
1
H 
NMR (CDCl3, 300 MHz) δ 1.06 (3H, s, CH3), 1.72 (1H, m), 1.76 (1H, m, OH), 1.86 (1H, m), 2.05 
(1H, m), 2.12 (1H, m), 2.55 (2H, t, J = 6.9 Hz), 2.96 (1H, d, J = 13.7 Hz), 3.10 (1H, d, J = 13.7 Hz), 
3.75 (1H, m), 7.13-7.29 (5H, m). 
13
C NMR (CDCl3, 300 MHz) δ 20.5, 20.9, 28.7, 37.6, 38.0, 54.8, 
75.9, 126.6, 128.3, 130.7, 137.8, 214.4.  
 
General procedure for biotransformation with purified KRED1-Pglu enzyme 
 
A solution of the substrates (3a-8a) (14 mM) was prepared in 20 mL of buffer TRIS HCl 50mM pH 
8.0 containing 5% of DMSO. In the same solution were added glucose (40 mM), NADP
+
 (0.1 mM) 
and a tip of spatula of GDH from Pseudomonas sp (commercially available at Sigma Aldrich with > 
200 U/mg). 1 mg of lyophilized KRED1-Pglu was used as biocatalyst. After different times 
(according with Table 7, pag 89) the reactions were acidified, extracted with ethyl acetate (3 times) 
and the organic phases were dried with sodium sulphate. After removal of the solvent, a 
chromatographic column was performed to separate the mono-alcohols and the diols (8:2 
cyclohexane/ethyl acetate). Both were then confirmed with 
1
H NMR. The absolute configuration of 
products were assigned by comparison with reported NMR spectra and reported optical rotation 
values.
73,69,72
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Products characterization (3d-8d): 
 
(2R,3S)-3-hydroxy-2-methyl-2-propylcyclopentan-1-one (3d)
69
: αD
20
= -110 ° (c 1.5, CHC13,); 
1
H 
NMR (CDCl3, 300 MHz) δ 0.89 (3 H, t, J = 7.2 Hz, CH3), 1.00 (3 H, s, CH3), 1.20-1.40 (4H, m), 
1.93 (1H, m), 2.05-2.15 (2H, m), 2.42 (1H, m), 4.20 (1H, t, J = 6.0 Hz) Chiral GC retention time: 
26.072 minutes. 
 
(2R,3S)-2-allyl-3-hydroxy-2-methylcyclopentan-1-one (4d)
69
: αD
20
= - 73 ° (c 0.26, CHCl3); IR 
(neat) 3400 (br s), 3050 cm
-1
 (w), 1730 cm
-1
 (s); 
1
H NMR (CDCl3, 300 MHz) δ 1.02 (3H, s, CH3), 
1.69 (1H, br s OH), 1.87 (1H, m), 2.14-2.30 (4H, m), 2.48 (1H, m), 4.23 (1H, t, J = 6.4 Hz), 5.11 
(2H, m), 5.76 (1H, m); 
13
C NMR (CDCl3, 75 MHz) δ 15.0 (CH3), 27.5 (CH2), 34.9 (CH2), 39.8 
(CH2), 53.0 (C), 75.4 (CHOH), 118.7 (=CH2), 133.5 (C=), 219.9 (C=O); MS , m/ e M
+ 
154. Anal. 
Calcd for C9H14O2: C, 70.10; H, 9.15. Found: C, 70.06; H, 9.40. 
 
(2S,3S)-2-benzyl-3-hydroxy-2-methylcyclopentan-1-one (5b)
76
: αD
20
= + 74.88 ° (c 1.0, CHCl3); 
IR (film) 3503, 2975, 2954, 2905, 1725, 1636, 1558, 1458, 1069, 1027, 741, 703 cm-1; 
1
H NMR 
(300 MHz, CDCl3) δ 0.87 (3H, s), 1.93-1.85 (2H, m); 2.18 (1H, m), 2.38 (1H, m), 2.51 (1H, m), 
2.73 (1H, d, J =14.0 Hz) 3.06 (1H, d, J = 14.0 Hz), 4.05 (1H, t, J = 3.0 Hz), 7.21 (1H, m), 7.28-7.25 
(4H, m), 
13
C NMR (125 MHz, CDCl3) δ 220.5, 137.9, 130.4, 128.1, 126.2, 76.4, 54.8, 35.7, 33.7, 
28.2, 19.6; mp 88-90 °C. 
 
(2R,3S)-3-hydroxy-2-methyl-2-propylcyclohexan-1-one (6d)
69
: αD
20
= - 40.85 ° (c 0.54, CHCl3); 
1
H NMR (CDCl3, 300 MHz) δ 0.92 (3H, t, J = 7.5 Hz, CH3), 1.10 (1H, m), 1.12 (3H, s, CH3), 1.34 
(1H, m), 1.57 (3H, m), 1.80 (2H, m), 2.11 (2H, m), 2.34 (1H, m), 2.42 (1H, m), 3.91 (1H, dd, J = 
5.5, 2.5 Hz); 
13
C NMR (CDCI3, 75 MHz) δ 14.8 (CH3), 17.3 (CH2), 17.5 (CH3), 20.7 (CH2), 28.2 
(CH2), 37.9 (CH2), 38.6 (CH2), 54.5 (C), 76.4 (CHOH), 214.9 (C=O); MS, m/e M
+ 
170. Anal. Calcd 
for CI0Hl8O2: C, 70.55; H, 10.66. Found: C, 70.48; H, 10.71.  
 
(2R,3S)-2-allyl-3-hydroxy-2-methylcyclohexan-1-one (7d)
69
: αD
20
= - 9.4 ° (c 0.6, CHCl3); 
1
H 
NMR (CDCl3, 300 MHz) δ 1.17 (3H, s, CH3), 1.68 (2H, m), 1.88 (1H, m), 2.05 (2H, m), 2.20 (4H, 
m), 3.90 (1H, m), 5.10 (2H, m), 5.78 (1H, m); 
13
C NMR (CDCl3, 75 MHz) δ 17.6 (CH3), 20.4 
(CH2), 28.5 (CH2), 37.6 (CH2), 40.2 (CH2), 54.5 (C), 75.1 (CHOH), 118.0(=CH2), 134.0 (CH=), 
214.4 (C=O); MS, m/e M
+
 168. Anal. Calcd for C10H1602: C, 71.39; H, 9.59. Found: C, 71.43; H, 
9.48.  
 
(2S,3S)-2-benzyl-3-hydroxy-2-methylcyclohexan-1-one (8b)
77
: αD
20
= + 10.5 ° (c 1.2, CHCl3); 
1
H 
NMR (CDCl3, 300 MHz) δ 1.06 (3H, s, CH3), 1.72 (1H, m), 1.76 (1H, m, OH), 1.86 (1H, m), 2.05 
(1H, m), 2.12 (1H, m), 2.55 (2H, t, J = 6.9 Hz), 2.96 (1H, d, J = 13.7 Hz), 3.10 (1H, d, J = 13.7 Hz), 
3.75 (1H, m), 7.13-7.29 (5H, m). 
13
C NMR (CDCl3, 300 MHz) δ 20.5, 20.9, 28.7, 37.6, 38.0, 54.8, 
75.9, 126.6, 128.3, 130.7, 137.8, 214.4. 
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Diols characterization (3f-8f) 
 
2-methyl-2-propylcyclopentane-1,3-diol (3f): αD
20
= + 44.6 ° (c 2.0, CHCl3); 
1
H NMR (CDCl3, 
300 MHz) δ 0.92 (3H, s, CH3), 0.96 (3H, t, J = 7.2), 1.22-1.42 (4H, m), 1.42-1.59 (2H, m), 2.17 
(2H, m), 3.90 (1H, t, J = 4.5 Hz), 4.03 (1H, t, J = 6.0).  
 
2-allyl-2-methylcyclopentane-1,3-diol (4f): αD
20
= + 69.68 ° (c 2.5, CHCl3); 
1
H NMR (CDCl3, 300 
MHz) δ 0.89 (3H, s, CH3), 1.42-1.60 (2H, m), 2.09-2.22 (2H, m), 2.22-2.35 (2H, m), 3.90 (1H, dd, J 
= 4.3 Hz), 4.11 (1H, t, J = 6.4 Hz), 5.11 (2H, m), 5.95 (1H, m).  
 
2-benzyl-2-methylcyclopentane-1,3-diol (5f): αD
20
= + 91.00 ° (c 1.5, CHCl3); 
1
H NMR (300 
MHz, CDCl3) δ 0.80 (3H, s), 1.45-1.62 (3H, m); 2.10-2.36 (2H, m), 2.67 (1H, d, J = 14.0), 2.91 
(1H, d, J = 14.0), 3.89 (1H, dd, J = 1.5 Hz), 4.26 (1H, t, J = 3.0 Hz), 7.21 (1H, m), 7.28-7.25 (4H, 
m). 
 
2-methyl-2-propylcyclohexane-1,3-diol (6f): αD
20
= + 40.63 ° (c 0.95, CHCl3); 
1
H NMR (CDCl3, 
300 MHz) δ 0.92 (3H, s), 0.95 (3H, t, J = 7.5 Hz), 1.20-1.35 (2H, m), 1.35-1.45 (2H, m), 1.35-1.76 
(6H, m), 3.71 (1H, dd, J = 8.5,4 Hz), 3.77 (1H, dd, J = 5.5, 2.5 Hz).  
 
2-allyl-2-methylcyclohexane-1,3-diol (7f): αD
20
= + 42.0 ° (c 2.5, CHCl3); 
1
H NMR (CDCl3, 300 
MHz) δ 0.94 (3H, s, CH3), 1.44-1.57 (6H, m), 2.32 (2H, d, J = 4.8), 3.71 (1H, m), 3.78 (1H, m), 
5.11 (2H, m), 5.95 (1H, m).  
 
2-benzyl-2-methylcyclohexane-1,3-diol (8f): αD
20
= + 36.0 ° (c 3.5, CHCl3); 
1
H NMR (CDCl3, 300 
MHz) δ 0.86 (3H, s, CH3), 1.46-1.91 (6H, m), 2.84 (1H, d, J = 13.7 Hz), 2.99 (1H, d, J = 13.7 Hz), 
3.60 (1H, m), 3.88 (1H, dd, J = 3.0 Hz), 7.13-7.29 (5H, m). 
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Introduction 
 
Aromatic aldehydes are key intermediates in a number of synthetic processes and have a prominent 
role as flavor and fragrance components. Among other synthetic methods,
78
 they can be obtained 
from the corresponding primary aromatic amines, which are readily available substrates. Methods 
for the oxidation of amines to carbonyl compounds have received significant attention, but these 
approaches are often poorly sustainable, because they require drastic reaction conditions, produce 
waste and by-products difficult to recycle and often proceed with poor selectivity.
79
 Therefore, 
biocatalytic processes are interesting alternatives for amine oxidations under mild and benign 
conditions. For example, copper amine oxidases (CAOs) have been used to catalyze the oxidation 
of primary amines to aldehydes (while O2 is simultaneously reduced to H2O2).
80
 Vanillin has been 
prepared by oxidation of vanillylamine using an amine oxidase (AO) from Aspergillus niger.
81
 
Recently, selective oxidation of amines to aldehydes has been obtained using a laccase with 
TEMPO (2,2,6,6-tetramethylpiperidine N-oxide) as mediator and O2 as oxidant.
82
 Aromatic 
aldehydes can also be enzymatically prepared using other approaches, such as oxidation of primary 
alcohols
83,26,34
 and reduction of carboxylic acids.
84
  
Also, the preparation of enantiopure aromatic amines can be challenging with traditional synthesis. 
Indeed, three main strategies can be used: (1) the resolution of racemic β-amino acids derivatives, 
(2) the use of naturally occurring chiral α-amino acids as starting material, and (3) asymmetric 
synthesis. All these strategies have their limitations when applied in an industrial scale (i.e., 
resolutions of complex and time-consuming racemic mixtures, the limited chiral pool of natural α-
amino acids and the high costs of catalysts or chiral auxiliaries).
85
 Thus, biocatalytic paths are a 
promising alternative for the preparation of chiral β-amino acids and enantiopure amines and they 
are receiving increased attention in the last years for their application in the manufacture of 
pharmaceutical intermediates on a large scale.
86 
 
 
In this context, transaminases are a family of enzymes with high potential in biotechnological 
applications. They can be useful for the enantioselective production of a series of compounds with 
high pharmaceutical value such as chiral amines and enantiopure amino alcohols.
87
 Some 
transaminases displayed high stability, high turnover rate, broad substrate specificity and no 
requirement for external cofactors.
88
 Problems such as inability to accept larger molecules, 
unfavourable equilibrium constant, substrate and product inhibition and reduced stability at extreme 
pHs, temperature and organic solvents are often challenging but by protein engineering several 
aspects can be successfully addressed.  
Halophilic organisms and their enzymes have a remarkable tolerance towards organic solvents.
89
 
They are a type of extremophile organisms, that usually thrive in high salt concentrations, as for 
example in the Great Salt Lake in Utah and the Dead Sea, which have a salt concentration five 
times greater that the salt concentration in oceans. 
A moderate halophilic organism which evolved an organic-osmolyte strategy to overcome the high 
osmotic pressure of its natural environment is Halomonas elongata.
90
 In addition, H. elongata 
preserves an appropriate cytoplasm osmotic pressure by accumulation and/or biosynthesis of 
organic solute. Since H. elongata is a haloadapted bacterium, it allows for heterologous expression 
of its proteins inside a common mesophilic host like Escherichia coli, thus avoiding less 
conventional expression systems required for true halophilic proteins.
8 
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Results and discussion 
 
This project was developed with the group of Prof. Francesca Paradisi, School of Chemistry, 
University of Nottingham. 
The aim of this project was to perform biocatalyzed transamination using an immobilized form of 
ω-transaminase from Halomonas elongata in a flow chemistry reactor. The enzyme was isolated 
and immobilized by prof. Paradisi’s research group.86a/87a The versatility of this enzyme is that the 
reaction can be performed in both the directions: from aldehydes to amines and from amines to 
aldehydes. 
In order to study the biotrasformation and its adaptability in continuous flow reactors, we started 
from aromatic aldehydes as substrates, in order to obtain the corresponding enantiomerically pure 
amines (Scheme 1). 
 
 
  
Scheme 1. General representation of transamination reaction from aromatic aldehydes substrates to 
enantiomerically pure corresponding amines. 
  
As it is possible to see from Scheme 1, the transaminase used needs a second co-substrate in order 
to run the reaction. In this case, we used L-alanine which is transformed during the reaction in 
pyruvate. Also, the enzyme needs as co-factor the pyridossal phosphate (PLP), also known as 
vitamin B6. PLP acts as co-factor not only in transamination reactions, but also in some 
decarboxylation, deamination and racemization reactions of amino acids. The mechanism of 
transamination reaction is reported in Figure 1. 
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Figure 1. Mechanism of transamination reaction. 
 
The proposed mechanism is referred to amino acids, but it can be applied also for transamination 
reaction with amines and aldehydes, or amines and ketones. 
The process starts with the formation of the Shiff base between PLP and the ε-amino group of the 
active-site lysine residue. The amine group of the substrate displaces the ε-amino group of the 
enzyme with a process called transaldimination, and an aldimmine group is formed. After loss of 
one hydrogen, the aldimmine group becomes a ketimine and the carbonyl moiety is able to break 
off the amino group attached to PLP. In this way, the corresponding aldehyde is able to exit and the 
pyridoxal phosphate becomes pyridoxamine. Then, in order to re-convert pyridoxamine to 
pyridoxal phosphate a second substrate (an aldehyde) is necessary in order to take the amino group 
from the co-factor.  
 
The strategy used for the immobilization of ω-transaminase from Halomonas elongata exploits the 
poly-His-tag fused to the enzyme for a selective interaction with a metal derivatized epoxy-resin, in 
order to obtain a multi-covalent system of interactions
91
. Cobalt (II) resulted to be the best metal ion 
for complexation with the resin.
91
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The immobilized transaminase was used in a packed bed reactor to perform the desired 
biotransformation over three aromatic aldehydes, that are shown in Figure 2 (p-NO2-benzaldehyde, 
cinnamaldehyde and vanillin, respectively): 
 
 
Figure 2. Aromatic aldehydes used as substrates. 
 
The flow reactor configuration used for optimization of the reaction parameters (i.e., aldehyde 
concentration, L-alanine concentration, % of DMSO, residence time) is the following (Scheme 2): 
 
Scheme 2. Schematic representation of flow set-up used for the transamination reactions with 
substrates (1a-1c). 
 
Solution A is the solution of aldehyde (1a-1c) at different concentrations in phosphate buffer (50 
mM pH 8.0) with different percentages of DMSO. Solution B is a 500 mM solution of L-alanine 
containing 0.1 mM PLP. The two flow streams entered the column packed with immobilized 
enzymes, and the exiting flow was collected and analyzed by chiral HPLC. The bioreactor was 
maintained at 37 °C and atmospheric pressure. 
The results for each compound are the following
86a
: 
 p-NO2-benzaldehyde (1a): after different attempts, to completely solubilize this substrate, a 
10 mM substrate concentration in phosphate buffer containing 10% of DMSO was 
prepared. Indeed, it is really important to have a solution in flow if HPLC pumps are used, 
otherwise the pumps and the system can be blocked. Secondly, different reaction times 
were tried, obtaining a maximum of conversion (>99%) in only 2 minutes. In batch, the 
same conversion was achieved after 210 minutes of reaction; 
 Cinnamaldehyde (1b): the corresponding amine of this substrate represents an important 
intermediate in the synthesis of biologically active molecules.
92 
It was obtained using a 20 
mM solution of substrate 1b in a mixture phosphate buffer with 10% of DMSO. Different 
residence times were tested, obtaining 90% of molar conversion in 2 minutes. The same 
conversion in batch was achieved after 24 h. 
For the compounds 1a and 1b, an in-line purification procedure was developed to isolate the pure 
amines without any manipulation. Therefore, after the biotransformation, an in-line basification and 
103 
 
followed by an extraction with ethyl acetate were performed. The in-line extraction was performed 
using a commercially available Zaiput liquid-liquid separator.  
In details, since the exiting flow stream buffer has a pH of 8.0 that was too low to allow the 
extraction of the amines, we added an inlet of 1N NaOH to reach a pH of 10/11 and to extract the 
amine in the organic phase. The set-up used is depicted in Scheme 3:
86a
  
 
Scheme 3. Schematic representation of the flow set-up used for the transamination reaction, with 
in-line basification and extraction with ethyl acetate and purification with polymer supported 
benzylamine. 
 
After the in-line basification and extraction with ethyl acetate both the amine product and any un-
reacted aldehyde were collected in the organic phase (Scheme 3). Therefore, in order to obtain only 
the desired product amine in the organic phase, an in-line purification with polymer supported 
benzylamine was performed, that selectively links the un-reacted aldehyde, while the amine product 
remains in the flow stream. After the collection, only evaporation of the solvent under reduced 
pressure is required in order to obtain the pure amine. With this system, for compound 1a, the 
isolated yield was 95%, while for substrate 1b was 86%
86a 
  
 Vanillin (1c): this was the most challenging reaction. Indeed, in batch a conversion of only 
18% was achieved after 24 h of reaction time without significant improvement over  longer 
incubation times. In flow, the same conversion was obtained after 2 minutes of residence 
time, using a 20 mM substrate concentration in phosphate buffer containing 10% DMSO. 
Even if different reaction parameters were changed (e.g., concentration, residence time, 
temperature), it was not possible to increase the conversion. Therefore, a recycling system of 
un-reacted vanillin was tried, followed by a removal of the product exploiting an acidic resin 
(A15) (Scheme 4). In this way, a conversion of 50% was achieved after 5 cycles. Increasing 
the number of cycles did not further increase the conversion. The vanillylamine, an 
important building block for the synthesis of natural products, such as capsaicinoids,
93
 was 
recovered by flowing through the immobilized acidic resin a diluted HCl flow stream. The 
isolated yield was 46%.
86a
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Scheme 4. Solution A: 20 mM vanillin solution in phosphate buffer (50 mM, pH 8.0) and 10% 
DMSO containing 0.1 mM PLP. Solution B: 1 M alanine solution in phosphate buffer (50 mM, pH 
8.0). T = 37 °C, P = atm. The un-reacted vanillin is then recycled into the system after separation 
with A15 resin. 
A summarizing table is reported here below (Table 1): 
 
   Batch   Flow   
Entry Sub. (10 mM) Amino donor Time Conv. r(µmol 
min-1g-1)a 
Time Conv. r(µmol 
min-1g-1)a 
1 p-NO2-benzaldehyde L-alanine (500 mM) 3.5 h >99% 0.24 2 min >99% 1.9 
2 Cinnamaldehyde L-alanine (500mM) 24 h 92% 0.06 2 min 90% 3.5 
3 Vanillin L-alanine (500 mM) 24 h 18% 0.012 2 min 18% 0.7 
4 Vanillin L-alanine (500 mM) 24 h 18% 0.012 5∙2 min 50% 0.4 
 
Table 1. Residence times, conversions and specific reaction rates for substrates (1a-1c) for both 
batch and flow procedures are reported. For p-NO2-benzaldehyde the concentration used was 5 
mM. For all the reactions, 10% of DMSO was added to the substrate solution. The bioreactor was 
stable after several weeks of continuous work. 
a
Specific reaction rates for batch and flow calculated 
as reported in reference [94]. 
 
To prove the versatility of the bioreactor, we secondly tried to perform the opposite react ion, 
starting from benzylamine derivatives and obtaining aldehydes as products. In order to do so, 
pyruvate as second substrate was necessary, and it was transformed during the reaction in L-alanine 
(Scheme 5). 
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Scheme 5. Schematic representation of transamination reaction from benzylamine derivatives to 
aldehyde products. 
 
The selected substrates are reported in Figure 3. 
 
 
 
Figure 3. Benzylamine derivates used as substrates for the biotransformation. 
 
The corresponding aldehyde products are normally used as fragrance and flavor components in 
food, beverage, cosmetics and also pharmaceutical. For examples, among them, there are the bitter 
almond aroma (benzaldehyde, 4a), anice aroma (4c), cumin aroma (4f), vanillin (4h), woody 
aromas (4i and 4l) (Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Examples of the synthesized aromas. 
 
The flow set-up we used for the reaction is reported in Scheme 6: 
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Scheme 6. Schematic representation of flow set-up used for the transamination reaction from 
amines to aldehydes. Solution A: 20 mM solution of amines (3a-3l) in phosphate buffer (50 mM, 
pH 8.0) with 10% DMSO. Solution B: 20 mM solution of pyruvate containing 0.1 mM PLP. 
 
Solution A and solution B were pumped into the reactor, mixed in a T piece and the resulting flow 
stream was directed into an Omnifit glass column packed with the immobilized transaminase, 
maintained at 37 °C. Residence time was varied and the exiting flow stream was collected and 
analyzed. In all the cases, the reactions were completed in 15 minutes and therefore the residence 
time was decreased, in order to find the minimum time that allows us to obtain the higher 
conversion, as reported in Table 2: 
 
 
Entry 
Subs. Batch reaction 
time (min) 
M. c. 
(%) 
rbatch
a  
(µmol/min g) 
Flow residence 
time (min) 
M. c. 
(%) 
rflow
a  
(µmol/min g) 
1 3a 120 > 99 0.83 3 > 99 4.24 
2 3b 120 > 99 0.83 3 > 99 4.24 
3 3c 120 > 99 0.83 3 > 99 4.24 
4 3d 120 > 99 0.83 3 > 99 4.24 
5 3e 120 > 99 0.33 10 > 99 1.41 
6 3f 300 > 99 0.33 10 90 1.29 
7 3g 300 > 99 0.33 10 90 1.29 
8 3h 120 > 99 0.83 3 95 4.07 
9 3i 300 > 99 0.33 10 > 99
b 1.41 
10 3l 300 > 99 0.33 10 > 99
b 1.41 
 
Table 2. Reaction times, conversions and specific reaction rates for batch and flow procedures are 
reported. All the conversions were determined by HPLC. 
a
Specific reaction rates for batch and flow 
calculated as reported in reference [94] 
 
As it is possible to see in Table 2, we obtained conversions comparable to the batch ones with 
residence times between 3 and 10 minutes. Specific reaction rates (normalized to the amount of 
biocatalyst employed for the reaction) were higher in flow, compared to the batch procedures.   
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In order to exploit the advantages of flow chemistry and to avoid the traditional work-up 
procedures, the downstream process was automated, by performing an acidification of the exiting 
flow stream with 1N HCl and inserting an inlet of ethyl acetate for the extraction. Using a 
membrane separator the two phases were separated and, in this way, the pure aldehyde product was 
collected in the organic phase (Scheme 7). 
 
 
Scheme 7. Schematic representation of flow configuration for biotransformation and in-line product 
isolation. 
 
The protocol described above was used for the ten selected substrates (3a-3l). However, it was 
successful for the first eight compounds (3a-3h), while for the last two (3i and 3l) the formed 
aldehyde probably remained attached to the support used for the immobilization of the enzyme. In 
order to solve this problem, we thought about an inlet of an organic solvent before entering the 
column packed with the immobilized enzymes. In this way, a biphasic liquid-liquid biphasic system 
was obtained and this led to avoid the attachment of the product on the support. Different organic 
solvents were tried and, in the end, we selected toluene. Exploiting this strategy, the desired 
aldehydes 3i and 3l were obtained (Scheme 8). 
 
Scheme 8. Schematic representation of flow configuration used for substrates 3i and 3l. 
 
Again, an in-line acidification with 1M HCl and extraction with toluene was performed, and only 
the pure aldehyde was collected in the organic phase. After removal of the solvent under reduced 
pressure, we obtained the products. The residence times, conversions and specific reaction rates for 
these two substrates are reported in Table 2 (entries 9 and 10). In these cases, DMSO was not added 
to solution A.  
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Conclusions 
 
New biocatalytic method for the synthesis of aldehydes with extensive applications as components 
of flavours and fragrances was developed. This is the first example of a transaminase exploited in a 
flow chemistry reactor under highly favourable oxidizing conditions for the preparation of aromatic 
aldehydes, showing excellent adaptability and stability during the processes. The use of a flow-
based approach allowed for dramatic accelerations of the reactions, with all the reaction tested 
occurring with isolated yields above 80% and very short residence times (3-15 min) of the 
substrates. This system required in the majority of cases only one equivalent of pyruvate as the 
amino acceptor, generating alanine as by-product. A successful implementation was achieved with 
an in-line extraction step, which permitted the recovery of the desired pure aldehydes in the organic 
stream and alanine in the aqueous one, with an extremely simplified work-up procedure and almost 
no manipulation. Due to the high local concentration of the (bio)catalyst and to the enhanced heat 
and mass transfer,
95,7
 the combination between biocatalysis and flow chemistry reactors not only 
leads to significant reductions of reaction times and increased productivity, but it can be also 
considered a sustainable technology for the production of aldehydes commonly used in food, 
cosmetic, and pharmaceutical industry. 
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Materials and methods 
 
General 
 
All reagents and solvents were purchased from Sigma–Aldrich. The continuous flow reactions were 
performed using a commercial R2+/R4 flow reactor (Vapourtec, Bury St. Edmunds, Suffolk, UK) 
equipped with Omnifit glass columns (6.6 mm i.d. X 100 mm length). The R2+ unit is the pumping 
unit that contains two adapted Knauer pumps, which are able to pump highly concentrated and 
corrosive acids. R4 is the heating unit with four heating positions. The additional HPLC pumps 
necessary to perform the overall synthesis were provided by another R2+/R4 flow reactor 
(Vapourtec) and by two external pumps (ThalesNano). The temperature sensor sits on the wall of 
the PFA tubing. The pressure was controlled using BPRs with different psi values. In-line liquid–
liquid extractions were performed using a Zaiput separator. 
1
H NMR and 
13
C NMR spectra were 
recorded with a Varian Mercury 300 (300 MHz) spectrometer. Chemical shifts (δ) are expressed in 
ppm, and coupling constants (J) are expressed in Hz. The molar conversion of the biotransformation 
was determined by HPLC equipped with a Supelcosil LC-18-T column (250 mm x 4.6 mm, 5 µm 
particle size; Supelco, Sigma-Aldrich, Germany). The compounds were detected using an UV 
detector at 210 nm, 250 nm or 280 nm after an isocratic run with 25% acetonitrile/75% water with 
TFA 0.1% v/v at 25 °C with a flow rate of 1 mL/min.  
 
Expression, purification, and immobilization of HEWT in E. coli  
 
Protein expression and purification were performed following previously reported protocols in 
Cerioli et al.;
87a
 immobilization was carried out according to the procedure reported by 
Planchestainer et al.
86a 
 
 
Imm-HEWT catalysed batch reactions
86a
  
 
The batch reactions using the imm-HEWT were performed in 1.5 mL micro centrifuge tubes; 500 
µL reaction mixture in 50 mM phosphate buffer pH 8.0, containing 10 mM amino acceptor 
substrate, amino donor substrate (concentration reported in Tab 1), 0.1 mM PLP, and 50 mg of 
imm-HEWT (5 mg/g) was left under gentile shaking at 37 °C. For reactions starting from amine 
compounds, rections were performed using the same volumes and buffer as before, but adding10 
mM pyruvate, 10 mM amino donor substrate, 0.1 mM PLP, and 50 mg of imm-HEWT (5 mg/g). for 
both, 10 µL aliquots were quenched with trifluoroacetic acid (TFA) 0.2% every hour and then 
analysed by HPLC equipped with a Supelcosil LC-18-T column (250 mm x 4.6 mm, 5 µm particle 
size; Supelco, Sigma-Aldrich, Germany). The compounds were detected using an UV detector at 
210 nm, or 250 nm after an isocratic run with 25% acetonitrile/75% water with TFA 0.1% v/v at 25 
°C with a flow rate of 1 mL/min. The retention times in minutes are: p-nitrobenzaldehyde (12.2 
min), (p-nitrophenyl)methanamine (4.4 min), vanillin (5.7 min), vanillylamine (3.7 min), 
cinnamaldehyde (16.9 min), cinnamylamine (6.6 min), benzylamine (4.1 min), benzaldehyde (9.4 
min), p-methylbenzylmine (5.2 min), p-tolualdehyde (16.4 min), p-methoxylbenzylmine (4.4 min), 
p-anisaldehyde (10.3 min), p-ethylbenzylamine (5.0 min), p-ethylbenzaldehyde (16.5 min), p-
hydroxybenzykamine (3.8 min), p-hydroxybenzaldehyde (10.5 min), p-isopropylbenzylmine (10.0 
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min), cuminaldehyde (35.0 min), 2-(aminomethyl)-phenol (3.7 min), salicilaldehyde (10.3 min), 
veratrylamine (4.1 min), veratraldehyde (8.0 min), 4-(aminomethyl)-2,6-dimethoxyphenol (3.5 
min), syringaldehyde (5.4 min), confirmed by comparison with commercially available compounds. 
 
Imm-HEWT catalysed flow reactions, in-line purification and product isolation for 
compounds 2a and 2b
86a
  
 
The continuous flow biotransformations were performed using a R2+/R4 flow reactor commercially 
available from Vapourtec® equipped with an Omnifit® glass column (6.6 mm i.d × 100 mm 
length) filled with 1.0 g of imm-HEWT (5 mg/g). A 20 mM amino acceptor substrate solution 
(solution A, for p-NO2-benzaldehyde 10 mM solution, Scheme 2) in phosphate buffer (50 mM, pH 
8.0) containing 0.1 mM PLP and a 1 M amino donor solution (solution B, Scheme 2) were 
prepared. The percentage of cosolvent (i.e., DMSO) is reported in the text (Table 1). The two 
solutions were mixed in a T-piece and the resulting flow stream was directed into the column 
packed with the biocatalyst (packed bed reactor volume: 0.78 mL, Scheme 2). The flow rate was 
varied and optimised. The exiting flow stream was analysed by HPLC using the conditions reported 
in the paragraph above. 
An in-line basification to pH 11 was performed by using an inlet of 1N NaOH aqueous solution 
(flow rate: 0.20 mL/min) that was mixed to the exiting reaction flow stream using a T junction. The 
resulting aqueous phase was extracted in-line using a stream of EtOAc (flow rate: 0.59 mL/min) 
and a Zaiput liquid/liquid separator. The organic phase, containing the amine and possible traces of 
unreacted aldehyde, was passed through a column packed with a polymer supported benzylamine 
(PS-BZA) (Scheme 3). The organic solvent was evaporated to yield the desired amine. The purity 
of the amine was assessed by HPLC and 
1
H NMR, compared with the one found in literature. 
1
H 
NMR spectra were recorded with a Varian Mercury 300 (300 MHz) spectrometer. Chemical shifts 
(δ) are expressed in ppm, and coupling constants (J) are expressed in Hz. 
 
Characterization of products 2a and 2b: 
 
 (p-nitrophenyl) methanamine (2a)96: yellow oil; 1H NMR (300 MHz, CDCl3): 4.06 (2H, 
s), 7.55 (2H, d, J = 8.4), 8.20 (2H, d, J = 8.4) 
 (E)-3-phenylprop-2-en-1-amine (cinnamylamine) (2b)97: slightly yellow oil; 1H NMR 
(300 MHz, CDCl3): 3.48 (2H, d, J = 4.8), 6.25 (1H, dt, J = 4.8, 15.6), 6.52 (1H, d, J = 15.6), 
7.20–7.40 (5H, m) 
 
Flow synthesis and characterization of vanillylamine (2c)
86a
 
 
An Omnifit® glass column (6.6 mm i.d × 100 mm length) was packed with 1.0 g of imm-HEWT (5 
mg/g). A 20 mM vanillin solution (solution A, Scheme 2) in phosphate buffer (50 mM, pH 8.0) and 
10% DMSO containing 0.1 mM PLP and a 1 M alanine solution (solution B, Scheme 2) were 
prepared. The two solutions were mixed in a T-piece and the resulting flow stream was directed into 
the column packed with the biocatalyst (packed bed reactor volume: 0.78 mL, residence time: 2 
min, T = 37 °C). The exiting flow stream was directed into a column (10 mm i.d × 100 mm length) 
packed with A-15 resin (packed bed reactor volume: 3.8 mL) and then collected into a separated 
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flask from which was newly pumped through the imm-HEWT packed column after mixing with the 
amine donor solution. After 5 cycles a 50% conversion was achieved. The vanillylamine was then 
recovered as the salt from the A15 resin by flowing through the A-15 column 1N HCl. 
 
(4-hydroxy-3-methoxyphenyl) methanaminium chloride (vanillylamine hydrochloride, 2c)
98
: 
1
H NMR (300 MHz, DMSO-d6): 3.75 (s, 3H), 3.85 (m, 2H), 6.75 (1H, d, J = 8.1), 6.82 (1H, dd, J = 
1.9, 8.1), 7.10 (1H, d, J = 1.9), 8.20 (3H, bs), 9.18 (1H, s). 
 
Flow reactions with immobilized HEWT (compounds 4a-4h) 
 
Continuous flow biotransformations were performed using a R2+/R4 Vapourtec® flow reactor 
equipped with an Omnifit® glass column (0.3421 mm i.d × 100 mm length) filled with 0.7 g of 
imm-HEWT (5 mg/g). A 20 mM sodium pyruvate in phosphate buffer (50 mM, pH 8.0) containing 
0.1 mM PLP, and 20 mM amino donor (3a-3h, Figure 3) solution with 10% of DMSO were 
prepared. The two solutions were mixed in a T-piece and the resulting flow stream was directed into 
the column packed with the biocatalyst (packed bed reactor volume: 1.0 mL). The flow rate was 
varied and optimized. An in-line acidification was performed by using an inlet of 1N HCl aqueous 
solution (flow rate: 0.1 mL/min) that was mixed to the exiting reaction flow stream using a T-
junction. The resulting aqueous phase was extracted in-line using a stream of EtOAc (flow rate: 0.2 
mL/min) and a Zaiput liquid/liquid separator. Both the organic and aqueous phase were analyzed by 
HPLC using the above reported conditions. The amount of substrate and product was evaluated by 
exploiting a previously prepared calibration curve. For the optimization procedure, the reactions 
have been performed by injecting 250 µL of each starting solutions (volume of EtOAc used for the 
in-line extraction: 1 mL). To isolate the product, 10 mL of each starting solutions have been used 
(volume of EtOAc used for the in-line extraction: 40 mL). The organic phase, containing the 
aldehyde, was evaporated to yield the desired product. 
 
Flow reactions in two-liquid-phase systems with immobilized HEWT (compounds 4i and 4l) 
 
A 20, 40 or 100 mM pyruvate in phosphate buffer (50 mM, pH 8.0) containing 0.1 mM PLP, and 20 
mM amino donor (3i and 3l, Figure 3) solution were prepared. The two solution were mixed in a T-
piece. A second junction for additional supplement of toluene at the same flow rate was installed 
before the packed enzyme column. The resulting segmented flow stream was directed to the imm-
HEWT. The flow rate was varied and optimized. After an in-line acidification step, as previously 
reported, the exiting flow stream was separated by a Zaiput liquid/liquid separator, the organic and 
aqueous phases analyzed by HPLC exploiting a calibration curve (see conditions above) and the 
toluene, containing the desired product, was evaporated to yield the aldehydes. 
 
Characterization of products (4a-4h) 
 
The purity of aldehydes was assessed by HPLC and 
1
H NMR. 
1
H NMR spectra were recorded with 
a Varian Mercury 300 (300 MHz) spectrometer. Chemical shifts (δ) are expressed in ppm, and 
coupling constants (J) are expressed in Hz: 
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 Benzaldehyde (4a): colourless oil; yield 95%; 1H NMR (CDCl3) δ 10.00 (s, 1H), 8.15-8.12 
(m, 2H), 7.67-7.51 (m, 3H) ppm. 
 p-Tolualdehyde (4b): yellow oil; yield 96%; 1H NMR (CDCl3) δ 9.95 (s, 1H), 7.74 (d, J = 
7.5 Hz, 2H), 7.32 (d, J = 7.5 Hz, 2H), 2.40 (s, 3H) ppm. 
 p-Anisaldehyde (4c): colourless oil; yield 94%; 1H NMR (CDCl3) δ 9.85 (s, 1H), 7.80 (d, J 
= 8.0 Hz, 2H), 6.96 (d, J = 8.0 Hz, 2H), 3.90 (s, 3H) ppm. 
 p-Ethyl benzaldhyde (4d): yellow oil; yield 94%; 1H NMR (CDCl3) δ 9.98 (s, 1H), 7.81 (d, 
J = 8.1 Hz, 2H), 7.36 (d, J = 8.1 Hz, 2H), 2.74 (q, J = 7.5 Hz, 2H), 1.27 (t, J = 7.5 Hz, 3H) 
ppm. 
 p-Hydroxybenzaldehyde (4e): yellow solid; yield 92%; 1H NMR (CDCl3): δ 9.61 (s, 1 H), 
7.60 (d, J = 8.3 Hz, 2 H), 6.73 (d, J = 8.3 Hz, 2 H) ppm. 
 Cuminaldehyde (4f): colourless oil; yield 84%; 1H NMR (CDCl3) δ 9.98 (s, 1H), 7.84 (d, J 
= 8.4 Hz, 2H), 7.40 (d, J = 8.4 Hz, 2H), 3.00 (septet, J = 6.9 Hz, 1H), 1.30 (d, J = 6.9 Hz, 
6H) ppm. 
 Salicilaldehyde (4g): yellow oil; yield 82%; 1H NMR (CDCl3) δ 11.00 (bs, 1H, OH), 9.85 
(s, 1H), 7.46-7.54 (m, 2H), 6.94-7.00 (m, 2H) ppm. 
 Vanillin (4h): white solid; yield 90%; 1H NMR (CDCl3) δ 9.78 (s, 1H), 7.37–7.40 (m, 2H), 
7.02 (d, J = 8.5 Hz, 1H), 6.72 (bs, 1H, OH), 3.90 (s, 3H) ppm. 
 Veratrylaldehyde (4i): yellow solid; yield 96%; 1H NMR (CDCl3)  9.85 (s, 1H), 6.70-7.65 
(m, 3H), 3.98 (s, 3H), 3.95 (s, 3H) ppm. 
 Syringaldehyde (4j): yellow solid; yield 94%; 1H NMR (CDCl3) δ 9.83 (s, 1H), 7.15 (s, 
2H), 6.10 (s, 1H), 3.98 (s, 6H) ppm.  
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GENERAL CONCLUSIONS AND PERSPECTIVES 
 
The present thesis had the aim to develop innovative, robust and versatile protocols for performing 
biocatalyzed redox reactions using a combination of biocatalysis and flow-reactor technology for 
the obtainment of high value chemicals of pharmaceutical interest. This goal crossed all the projects 
presented in this PhD work, and for all interesting results were achieved, underlining the importance 
of flow chemistry, as a novel chemical methodology, and of biochemistry, as an alternative way to 
perform reactions in a more environmental friendly way. The possibility to apply this combination 
to the pharmaceutical chemistry can be a new perspective for also the industrial point of view, if 
processes demonstrate to have advantages in terms of productivity, costs, waste produced. For this 
reason, during my thesis I tried to optimize the flow processes keeping in mind this corollary aim, 
even if sometimes it was hard to find more adavantageous processes, compared to the ones already 
existent. I think that, in the future, both flow chemistry and biocatalysis will be more and more 
present in the industrial reality, and that, maybe, there will be a cooperation between these systems 
and the traditional chemistry. Indeed, some synthesis can benefit if a flow processes is applied, 
while for others is better to remain with “batch” processes, when disadvantages can be higher that 
advantages. In any case, is mandatory for companies (pharmaceutical and others) to keep in mind 
the environmental problems of our world. This thesis wants to remember this, since “green” 
chemical solutions are used. 
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A Valerio, con il quale ho collaborato per buona parte del mio dottorato. Ci siamo trovati subito in 
sintonia, fin dal mio periodo di tesi, e da te ho imparato tanto. Grazie per la pazienza, i consigli, il 
lavoro di squadra fruttuoso e determinante.  
A Martina, sei stata per me una guida molto importante,e anche con te mi sono trovata molto bene 
fin da subito. Grazie per i consigli preziosi, gli interminabili aiuti, la pazienza, il reciproco rapporto 
di aiuto e di stima, che è fondamentale sempre. 
Ad Imma, è stato un piacere lavorare e collaborare con te. Grazie per l’accoglienza e per gli 
insegnamenti. 
A Otto, Francesco, Giulia e tutti gli altri ragazzi che ho incontrato in questi anni ai piani alti.  
A tutti voi auguro il meglio!! 
 
As last but not least, I would like to thank Prof. Dörte Rother and her group, that hosted me for six 
months at the Forschungszentrum Jülich, in Germany.  
To Dörte, thanks for the warm welcome, for hosting me in a splendid way, I never had the sensation 
of being just a guest, but I always felt as a collegue of yours. You teached me a lot, about science 
and about other personal things. Thank you for your honesty and continuous helpfulness. 
To Reinhard, Johannes, Julia, Ramona, Kevin, Selina, Tim, Céline, Lisa, Lilia, Ursula, Ilona, Doris, 
Heike, Anna and Prof. Martina Pohl, because despite the cultural differences and language barriers 
you always helped me, in everything, and you made me feel like I was at home, even if I was far 
away from my real one. I will forever keep in my heart and in my mind very nice memories of 
laughs, joks and work together, side by side. I think it’s not easy to be able to be yourself when you 
are far away from home, but I was to able to feel like that, thanks to you all. 
Ritorno all’italiano, perchè ci tengo a scrivere queste parole in modo che vengano capite da tutti. 
Chi mi conosce sa benissimo quanto mi sia costato prendere la decisione di partire e di stare via per 
mesi, lonatana da casa, mollare tutte le persone a me care e tutte le mie attività, alle quali sono 
molto legata. E’ vero, è stato uno sforzo difficilissimo. Il momento della partenza me lo ricordo  
bene, così come ricordo i primi giorni là. Non lo nascondo, sono stati proprio una sofferenza. Ma 
piano piano, giorno per giorno, ho preso confidenza con la mia nuova vita e, credo, con la nuova 
parte di me, al punto che, quando ho dovuto salutare tutti là, avevo un groppo in gola, che mai avrei 
pensato di poter provare. E’ stata una esperienza importantissima, che mi ha dato più 
consapevolezza di me, dei miei limiti e delle mie potenzialità, mi ha dato più fiducia e un’apertura 
mentale che prima non avevo. Devo ringraziare le persone che hanno insistito con me affinchè io 
partissi, perché se non fossi partita me ne sarei sicuramente pentita. Esperienze così ti fanno venire 
voglia di sperimentare ancora, vedere altri posti e conoscere altre culture, con meno barriere nella 
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mente e nel cuore, ed è bellissimo quando capisci che, in ogni angolo della terra, siamo in realtà 
tutti uguali. 
 
Ora guardo con fiducia al futuro, con la speranza che ci possano essere altre bellissime avventure da 
affrontare, sempre col sorriso. 
 
 
 
